

Index

Note: Page number followed by f and t indicates figure and table only.

A

- abamectin, 1102, 1103f
- Abbreviated New Animal Drug Applications (ANADAs), 1407, 1409, 1420
- ABCG2 (drug transporter), 1337
- ABON algorithm, 1453
- abortion
 - prostaglandins analogs for, 681
 - reproductive hormonal drugs for, 686–687
- absorption and clearance processes (AME), 48
- absorption, distribution, metabolism, and elimination (ADME processes), 8, 9f, 48, 90
- absorption, drug
 - aminoglycosides, 882
 - benzimidazoles, 1037–1038, 1038f
 - bioavailability
 - absolute systemic availability, 22
 - relative systemic availability, 22
 - cephalosporins, 842
 - chloramphenicol, 904–905
 - clindamycin, 928–929
 - florfenicol, 909
 - fluoroquinolones, 965–966
 - gastrointestinal, 12–17
 - disintegration, dissolution, and diffusion, 14–15
 - enterohepatic recycling, 15–16
 - first-pass metabolism, 16–17
 - formulation factors, 17
 - species effects, 16
 - lincomycin, 926
 - of lipophilic compounds, 9–10
 - macrolide antibiotics, 918–920
 - penicillins, 830, 833
 - peritoneal, 22
 - pharmaceutical factors affecting, 17t
 - pharmacogenetics of, 1334–1335, 1335f
 - pH-dependent, 11
 - respiratory, 20–21
 - aerosols and particulates, 21
 - vapors and gases, 20–21
 - rifampin, 932
 - sulfonamides, 800
 - systemic, 22
 - tetracyclines, 860–861, 861t
 - topical and percutaneous, 17–20
 - dermis and appendages, 18
 - drug delivery system and definition of dose, 18–19
 - factors modulating, 19–20
 - mechanisms in skin, 17–18, 18f
 - pathways for, 19
 - stratum corneum barrier, 18
 - variations in species and body region, 19
- absorption spectroscopy detection methods, 1442
- acarbose, 770–771
- acceptable daily intake (ADI), 1359, 1470
- acepromazine, 179, 325, 328, 1245, 1246t
- acepromazine maleate, 326, 327f
- acetaminophen, 481
- acetylcholine (ACh), 151, 174, 194, 422, 1181
 - muscarinic and nicotinic effects of, 156f
 - pharmacological mechanisms and effects, 154–155
 - target organ effects of, 155
- acetylcholinesterase (AChE), 174, 196, 1181
- acetyl coenzyme A (acetyl CoA), 174
- acetylcysteine, 1315
- acid-base metabolism
 - anesthetics and, 588–589
 - in cattle, 588
 - disorders of, 573–577
 - characteristics of, 574t
 - metabolic acidosis, 574–576, 575f, 578t
 - metabolic alkalosis, 576
 - mixed disturbances, 577, 578t
 - respiratory acidosis, 576–577, 576t, 578t
 - respiratory alkalosis, 577, 577t
 - fluid therapy and, 578–580
 - in horses, 588
 - principles of, 569–573
 - anion gap, 571–572
 - disturbance assessments, 571
 - homeostasis, 569–570
 - hydrogen ion, carbon dioxide, and bicarbonate regulation, 570–571, 570t, 571f
 - nontraditional analysis, 572–573, 573t
- acid citrate dextrose (ACD), 629
- acidosis
 - metabolic, 574–576, 575f
 - respiratory, 576–577, 576t
- ACTH. *see* adrenocorticotropic hormone
- actinomycin D, 1206, 1207f
- activated partial thromboplastin time (aPTT), 628
- active pharmaceutical ingredient (API), 87–88, 88f, 1431
- chemical properties
 - apparent solubility, 93
 - buffer composition, 94
 - common ion effect, 94
 - geometrical configuration, 93
 - ionic strength of a solution, 94

- active pharmaceutical ingredient (API)
(*Continued*)
 optic rotation, 93
 permeability, 95
 pH of solvent, 94
 saturation concentration, 93
 solubility, 93–95
 stability, 92
 stereochemistry, 93
 temperature effects, 95
 dosage form considerations, 99–105
 biomass products, 103–104
 bolus, 102
 capsules, 103
 chewable tablets, 102–103
 common veterinary forms, 99f
 considerations when formulating, 100f
 controlled internal drug release system (CIDR), 104
 cream, 101
 delayed release, 101–102
 emulsions, 100
 extended release (ER) tablets, 101
 gels, 101
 granules, 103
 immediate release (IR) tablets, 101
 implants, 102
 liquid suspension, 99–100
 lotions, 101
 medicated feed, 103
 modified release (MR) tablets, 101
 ointment, 101
 parenteral products, 104–105
 pastes, 101
 powders, 103
 solutions, 99
 suspoemulsion (SE), 101
 tablets, 101
 topical products, 105
 transdermal drug delivery, 105
 formulation elements, 95–99
 manufacturing process
 direct compression, 106
 extrusion, 106
 factors influencing product
 dissolution, 106–107
 roller compaction, 106
 slugging, 106
 tableting processes, 106
 wet/dry granulation, 105–106
 physical properties
 crystalline form, 88–89
 dissociation constants/pKa, 90–91
 Log P and D, 91
 melting point, 91–92
 particle geometry, 89–90
 partition coefficients, 91
 rheology, 92
 product quality control, 107
 Activyl Tick Plus, 1179
 acute renal failure (ARF), mannitol in, 604–605
 acyclovir, 1010–1012
 adverse effects, 1012
 clinical use, 1011–1012
 pharmacokinetics, 1011
 spectrum of activity, 1011
 ADAA. *see* Animal Drug Availability Act
 ADE. *see* adverse drug experience
 adefovir. *see* PMEAs
 adenine dinucleotides, 177
 adenosine, 177
 adenosine diphosphate, 627
 ADE reports, 1424–1425. *see also* adverse drug experience (ADE)
 aditoprim, pharmacokinetics of, 804t
 adrenal insufficiency, in foals, 655
 adrenal reserve testing,
 glucocorticoids, 747
 adrenal steroidogenesis, 730f
 adrenal steroidogenic enzymes, 730t
 adrenergic agonists, classification of, 131, 132f, 133t
 adrenergic receptors, 123–126,
 132–134
 agonists, clinical applications of, 137–142
 beta-adrenergic receptor (β AA), 141
 blood pressure regulation and, 138–139
 in food production, 141–142
 for improved respiratory effort, 137–138, 138f
 in ophthalmology, 140–141
 sedative and analgesic effects, 140
 treatment of urinary
 incontinence, 139–140
 vasoconstriction, 140
 antagonists, clinical applications of
 alpha-adrenoceptor antagonists, 142–144
 beta-adrenoceptor antagonists, 144–148
 pharmacodynamic characteristics of, 145t
 and cell signaling, 132–134
 selectivity and tissue distribution, 134–137
 types and subtypes, 133t
 adrenocorticotrophic hormone (ACTH), 561, 651–655, 654t, 662t
 biosynthesis of, 651–652, 652f
 dosage protocols for, 654t
 function of, 653–654
 negative-feedback systems, 653
 preparations of, 654
 secretion regulation of, 653
 stimulation test, 654–655, 747
 structure of, 652–653, 652f
 adrenolytic drugs, 751–755
 hyperadrenocorticism treatment
 with, 751–752
 ketoconazole, 754
 L-deprenyl, 754–755
 mitotane, 752–753
 structures of, 752f
 trilostane, 753
 adriamycin. *see* doxorubicin
 adverse drug experience (ADE), 1449
 definition of, 1449
 reporting of, 1449–1453, 1450f
 animal devices, 1450–1451
 approved *versus* unapproved drugs, 1450
 medication errors, 1451–1452
 pesticide products/vaccines, 1453
 pet food adverse event and product problem reporting, 1452
 product defect, 1451
 AeroHippus[®] mask, 1313
Aeromonas salmonicida, 1380–1381, 1382t, 1383t–1384t
 affinity, of drugs, 69–70, 69f, 70f
 constant of, 69
 afoxolaner, 1174–1175
 agar and broth dilution susceptibility tests, 1379
 agmatine, 177
 airway irritation, 225
 aklomide, 1145, 1145f
 albendazole, 1036f, 1039, 1045, 1048, 1137–1138, 1137f. *see also* benzimidazoles
 albuterol, 1305, 1306–1307
 alcohol-based handrubs, 789
 alcohols, use of, 782–783
 alcuronium (Alloferin), 202
 aldehyde disinfectants, 784–785
 aletplase, 641
 alfaxalone, 174, 188, 267f

- chemistry, 267
 history, 267
 metabolism, 269
 pharmacokinetics, 268, 268t
 physiological/pharmacodynamic effects, 268
 preparation of, 267
 species differences, 269
 Alfaxan[®], 267
 alfentanil, 303
 alfuzosin, 143
 alkaloids, as antiprotozoan drugs, 1146
 alkalosis
 metabolic, 576
 respiratory, 577, 577t
 alkeran. *see* melphalan
 allele, 1333
 allethrin, 1179
 allometric relationship, 62
 allometric scaling, 1353–1354
 allometry, 62
 in zoo medicine, 1400–1401
 allyltrenbolone, 683
 alpaca, alfaxalone effects on, 269
 alpha-2-adrenergic antagonists,
 142–144
 adverse effects/contraindications,
 353–354
 atipamezole, 350, 350t
 classification, 349
 clinical applications of
 cardiovascular effects, 142–143
 for hypertension, 143
 noncardiovascular effects, 143
 for restoration of physiological
 responses, 143
 reversal of sedative effects, 144
 for urethral relaxation, 144
 drug interactions, 354
 indications, 349
 overdose/acute toxicity, 354
 pharmacodynamic effects
 cardiovascular effects, 353
 CNS effects, 353
 muscular effects, 353
 pharmacokinetics, 352t
 in preanesthetic period, 187
 species differences, 354
 tolazoline, 351–353, 351f, 353t
 yohimbine, 350–351, 351t
 alpha-2-adrenergic receptor agonists
 adverse effects/contraindications,
 349
 chemistry, 339
 classification, 338
 detomidine hydrochloride, 345f,
 346–347, 346t
 dexmedetomidine, 345f, 348, 348t
 doses for sedation, 343
 drug interactions, 349
 indications, 339
 mechanism of action, 339
 medetomidine, 345f, 347, 348t
 overdose/acute toxicity, 349
 pharmacokinetics properties, 343,
 344t
 physiological effects
 analgesic activity, 343
 cardiovascular effects, 340–341
 CNS effects, 339–340
 equine recovery, 342
 gastrointestinal effects, 341
 on glucose homeostasis, 342
 musculoskeletal effects, 341
 neuroendocrine stress response,
 342
 platelet activation, 342
 renal effects, 341
 reproductive effects, 342
 respiratory effects, 341
 thermoregulation of body, 342
 preparation, 339
 ratio of drug selectivity and
 imidazoline receptor activity,
 339t
 romifidine, 345f, 347, 347t
 species differences, 348
 xylazine hydrochloride, 343–346,
 345f
 alpha-chloralose
 chemistry, 269–270
 degree of CNS depression, 270
 dose, 270t
 drug availability, 270
 history, 269
 indication for use, 270
 mechanism of action, 270
 physiology, 270
 preparation, 270
 regulatory information, 270
 alphadolone, 267
 alpha interferon, 1017, 1020
 alternate-day therapy, glucocorticoids,
 746–747
 altrenogest, 678t, 683
 alveolar partial pressure (P_A) of
 anesthetic, 219–220
 alveolar ventilation, 220
 alvimopan, 1254
 amantadine, 1016–1017
 AMDUCA. *see* Animal Medicinal
 Drug Use Clarification Act
 American Academy of Veterinary
 Pharmacology and Therapeutics
 (AAVPT), 5, 1466
 American Board of Anesthesiologists
 (ABA), 180
 American Board of Clinical
 Pharmacology (ABCP), 5
 American College of Veterinary
 Anesthesiologists, 180
 American College of Veterinary
 Clinical Pharmacology
 (ACVCP), 5
 American Feed Industry Association
 (AFIA), 1462
*American Society of Pharmacology and
 Experimental Therapeutics*, 4
 American Veterinary Medical
 Association (AVMA), 1373,
 1462, 1466
 amicarbalide, 1157f, 1158
 amikacin, 877, 888–889
 once-daily dosages for, 880t
 pharmacokinetic data for, 888t, 889t
 structure of, 879f
 amiloride, 611–612
 amines, as neurotransmitters, 174–176
 acetylcholine, 174
 dopamine, 174–175
 histamine, 175
 5-hydroxytryptamine, 175–176
 norepinephrine and epinephrine,
 175
 aminoacetonitrile derivatives (AADs),
 1069, 1071
 amino acids, as neurotransmitters,
 172–174, 173t
 GABA, 172, 174
 glutamate, 172
 glycine, 172
 aminoglycosides, 198, 877, 1433
 activity of, factors effecting
 cations, 880
 cellular debris, 879–880
 other drugs, 880
 oxygen tension, 880
 pH effect, 879
 amikacin, 888–889
 as antiprotozoan drugs, 1138–1139
 apramycin, 890
 dihydrostreptomycin and
 streptomycin, 890–891
 gentamicin, 886–888
 kanamycin, 889–890

1484 | Index

- aminoglycosides (*Continued*)
 local administration, 881–882
 neomycin, 890
 for ocular infections, 1327
 paromomycin, 891
 pharmacokinetic–
 pharmacodynamic properties, 880
 pharmacokinetics of, 882–884
 absorption, 882
 distribution, 882–883
 general, 882
 metabolism and excretion, 883
 in nonmammals, 883–884
 pharmacology of, 877–882
 clinical uses, 880–882
 general properties, 877
 mechanism of action, 877–878
 spectrum of activity, 878–880
 regulatory status, 882
 resistance mechanisms, 880
 single daily dose administration, 881
 susceptibility testing guidelines for, 881t
 tobramycin, 890
 toxicity, 884–885, 884t
 cats, 885–886
 dogs, 885
 horses, 886
- aminopentamide, 1264, 1264t
 4-aminoquinolines, 1156
 5-aminosalicylic acid, 1268, 1268f
 aminosteroid neuromuscular blocking agents, 199
 pancuronium, 200
 rocuronium bromide, 201
 vecuronium, 200–201
 aminosteroids, 199, 749
 amiodarone, 549–550
 amitraz, 1182–1183
 efficacy, 1182
 safety/toxicity, 1182–1183
 amitriptyline, 176, 430
 amnestic effects of inhaled anesthetics, 223
 amoxicillin–clavulanate, 837
 amoxicillin, in aquatic animals, 1386
 amphibian, drugs for, 1396
 amphotericin B, 990–993
 adverse effects, 991, 993
 clinical use, 991
 combination therapy with, 990
 dosing protocols for, 992t
 formulations of, 990
 mechanism of action, 990
 for ocular infections, 1328
 pharmacokinetics, 991
 spectrum of activity, 990–991
 structure of, 990f
 amprolium, 1144, 1144f
 anabolic steroids, 684–685
 anabolic steroids, use of, in racing horses, 1445–1446
 ANADAs. *see* Abbreviated New Animal Drug Applications
 analgesia
 barbiturates, 252
 butyrophenone and, 329
 dissociative anesthetics, 262
 etomidate, 265
 flumazenil and, 337
 guaifenesin and, 355
 meperidine, 312–313
 morphine, 312–313
 neurosteroid anesthetics, 268
 nitrous oxide, 224
 opioids, 281, 285–286
 phenothiazines, 326
 xenon, 224
 anandamide, 177
 anemia, sulfonamides and, 806
 anesthesia, 180, 183
 anesthetic protocol and drug, selection of, 185, 186t
 classification of, 183–185, 183t
 depth of, 189
 general, 184–185
 immediate postanesthetic period, drugs in, 188–189
 local and regional, 183–184, 183t
 perianesthetic period, drugs in, 188, 188t
 preanesthetic medication, 186
 α_2 -adrenergic drugs, 187
 dissociative drugs, 187
 drug classes for, 186t
 drug combinations, 187
 goals for, 186t
 hypnotic-sedatives, 187
 opioids, 187
 parasympatholytic (anticholinergic) drugs, 187–188
 tranquilizer-sedatives, 186–187
 response to, evaluation of, 189–191, 190f
 route of administration, 183t
 anesthesiology
 anesthetic use, 181t
 immobility, 183
 perception of noxious stimulus, 181–183
 definition of, 180
 anesthetic recovery period, 188–189, 189t
 anesthetics
 and acid-base metabolism, 588–589
 for food animals, 1369–1370
 inhalation (*see* inhalation anesthetics)
 injectable (*see* injectable anesthetics)
 local (*see* local anesthetics)
 anesthetist, role of, 180
 angiotensin converting enzyme (ACE), 65, 66, 84
 angiotensin-converting enzyme inhibitors (ACEIs), 558, 615–617
 absorption and elimination of, 616
 adverse effects, 518, 616–617
 chemistry/formulations of, 615
 in chronic kidney disease, 520
 drug interactions, 520, 616–617
 efficacy, 518–520
 mechanisms and sites of action, 517–518, 615–616
 therapeutic uses, 617
 toxicity, 616–617
 in use, 520
 angiotensin I, 558
 angiotensin II, 558
 effects on renal functions, 597–599
 angiotensin receptor antagonists, 615–617
 angiotensin receptor blockers (ARBs), 615, 616–617
 angular limb deformities in foals, tetracyclines for, 870
 Animal and Plant Health Inspection Service, 1408
 Animal Drug Availability Act (ADAA), 1410–1411
 Animal Drug User Fee Act (ADUFA), 1361
 Animal Health Institute (AHI) website, 1412
 Animal Medicinal Drug Use Clarification Act (AMDUCA), 41, 882, 1185, 1346–1348, 1358, 1373, 1395, 1410, 1472
 anion gap (AG), 571–572
Anoplocephala perfoliata infections, 1081
 ANP. *see* atrial natriuretic peptide
 antacids, 1255–1256

- adverse effects, 1255
- dose recommendations, 1255–1256
- formulations, 1255
- anterior uveitis, 1232
- anthelmintics, 1369
- anthraquinone, 1270
- antiandrogens, 678t
- antiarrhythmic agents
 - amiodarone, 549–550
 - atenolol, 546
 - beta-blockers, 545
 - calcium channel blocking drugs, 545
 - classification, 542–543, 542t–543t
 - digoxin, 544–545
 - esmolol, 546
 - heart rhythmicity
 - arrhythmogenic mechanism
 - classification, 540–542, 540f–541f
 - cardiac cell electrophysiologic properties, 537–540, 538f–539f
 - isoproterenol, 544
 - lidocaine, 548–549
 - mexiletine, 549
 - procainamide, 547
 - propranolol bromide, 543–544
 - quinidine, 547–548
 - sotalol, 546, 550
- antibacterial agents, for ocular infections, 1326–1328
- antibiotic-impregnated polymethylmethacrylate (AIPMMA), 881
- antibiotic-responsive enteropathy, 1265
- antibiotic use, in food animals, 1361–1365, 1362t–1363t
- anticestodal drugs, 1081
 - bunamidine, 1081–1082, 1082f
 - epsiprantel, 1085, 1085f
 - niclosamide, 1082, 1082f
 - praziquantel, 1082–1085, 1082f
- anticholinergics, 188, 1310
 - adverse effects, 1310
 - for diarrhea, 1263–1264, 1264t
 - in horses, 1310
 - for inflammatory bowel diseases, 1268
- anticoagulants
 - for blood and blood component transfusions, 629
 - natural, in hemostasis, 628
 - new drugs, 636t
- anticoagulants, 1365, 1366t
- anticonvulsant drugs
 - bromide, 409–411
 - clonazepam, 404
 - clorazepate, 404–405
 - diazepam, 402–404
 - felbamate, 405
 - gabapentin, 405–406
 - imepitoin, 401–402
 - levetiracetam, 407–408
 - midazolam, 404
 - phenobarbital, 395–399
 - phenytoin, 400–401
 - pregabalin, 406–407
 - primidone, 399–400
 - used in veterinary medicine, 396t
 - valproic acid, 401
 - zonisamide, 408–409
- antidiuretic hormone (ADH), 558, 600, 665–667
 - absorption, metabolism, and excretion of, 665
 - for diagnosis of diabetes insipidus, 666
 - mechanism of action, 665, 666t
 - preparation of, 665
 - stimulus for release, 665
 - structure of, 665
 - therapeutic uses, 666–667
 - toxicity of, 667
- antiemetic drugs, 1245–1250, 1246t
- antihistamines, 1246
- antimuscarinic drugs, 1245–1246
- cannabinoids, 1247–1248
- glucocorticoids, 1247
- metoclopramide, 1247
- mirtazapine, 1249–1250
- NK-1 receptor antagonists, 1248–1249
- phenothiazine tranquilizers, 1245
- serotonin antagonists, 1247
- antiepileptic potassium bromide, 702
- antifibrinolytic drugs, 641–642
- antifungal drugs, 988
 - amphotericin B, 990–993
 - azole, 993–1006
 - drug–drug interactions, 995t
 - flucytosine, 1008
 - griseofulvin, 988–990
 - lufenuron, 1007–1008
 - for ocular infections, 1328
 - sites of action, 989f
 - sodium or potassium iodide, 1008
 - terbinafine, 1006–1007
 - topical
 - clotrimazole, 1009
 - enilconazole, 1008–1009
 - mefenoxam, 1009–1010
 - miconazole, 1009
 - natamycin, 1010
 - nystatin, 1010
- antihistamines, 1246, 1246t
 - chemistry, 456–457
 - development, 456
 - H₁ receptor antagonists, 456, 457t
 - H₂ receptor antagonists, 460
 - pharmacological effects, 457
 - side effects and interactions, 459–460
 - therapeutic uses, 457–459
 - therapeutic uses of, 459
- antiinflammatories use, in food animal, 1365–1368, 1366t
- antiinflammatory and antiallergic therapy, glucocorticoids, 745
- antimetabolites, 1206–1210
 - cytosine arabinoside, 1207–1208, 1208f
 - 5-fluorouracil, 1209–1210, 1209f
 - gemcitabine, 1208–1209, 1209f
 - methotrexate, 1206–1207, 1207f, 1208f
- antimicrobials, for diarrhea, 1264t, 1265–1267
- antimicrobial susceptibility testing (AST), 1378, 1379
- antimicrotubule agents, 1210–1211
 - vinca alkaloids, 1210–1211, 1210f
- antimuscarinic drugs, 1245–1246, 1246t
- antinematodal drugs, 1035
 - benzimidazoles and
 - pro-benzimidazoles, 1035–1054
 - administration routes, 1050
 - anthelmintic spectrum, 1047–1049
 - chemistry of, 1035–1037, 1036f
 - disposition kinetics and efficacy of, 1050–1053
 - drug transfer into target parasites, 1046–1047
 - formulations of, 1050, 1053
 - pharmacodynamics, 1037
 - pharmacokinetics, 1037–1046
 - structures of, 1035, 1036f
 - withdrawal times, safety, and toxicity, 1053–1054
- drug combinations, use of, 1067–1069
- heartworm adulticides, 1064
- heterocyclic compounds, 1062–1064

1486 | Index

- antiparasitic drugs (*Continued*)
 diethylcarbamazine, 1063–1064, 1063f
 phenothiazine, 1062
 piperazine, 1062–1063, 1063f
 imidazothiazoles, 1054–1058
 novel drugs, 1069–1072
 organophosphate compounds, 1061–1062
 resistance to, 1065–1067
 tetrahydropyrimidines, 1058–1061
- antinuclear antibodies (ANA), 717
- antiplatelet drugs, 638–640
 aspirin, 638–639
 clopidogrel, 639–640
 ticlopidine, 640
- antiprostaglandins, 178
- antiprotozoan drugs, 1128, 1129t–1131t
 alkaloids, 1146
 halofuginone, 1146, 1146f
 aminoglycosides, 1138
 paromomycin, 1138–1139, 1138f
 4-aminoquinolines, 1156
 chloroquine, 1156
 arsenicals, 1137
 azalides, 1156
 azithromycin, 1156
 benzimidazoles, 1137, 1137f
 albendazole, 1137–1138
 febantel, 1138
 fenbendazole, 1138
 for coccidiosis, 1132t–1133t
 diamidine derivatives, 1157, 1157f
 amicarbalide, 1158
 diminazene diacetate, 1157–1158
 imidocarb dipropionate, 1158–1159
 pentamidine isethionate, 1158
 phenamidine isethionate, 1158
 dihydrofolate reductase/thymidylate synthase inhibitors, 1152, 1153f
 ormetoprim, 1153f, 1154
 pyrimethamine, 1153f, 1154–1155
 trimethoprim, 1152–1154, 1153f
 guanidine derivatives, 1143
 robenidine, 1143–1144, 1143f
 hydroxyquinolones and naphthoquinones, 1141, 1141f
 atovaquone, 1141f, 1142–1143
 buparvaquone, 1141f, 1143
 decoquinone, 1141–1142, 1141f
 parvaquone, 1141f, 1143
- lincosamides, 1155, 1155f
 clindamycin, 1155–1156, 1155f
 nicarbazin, 1145–1146, 1145f
 nitrobenzamides, 1144–1145, 1145f
 aklomid, 1145, 1145f
 dinitolmide, 1145, 1145f
 nitrofurans, 1139
 nifurtimox, 1139–1140, 1140f
 nitroimidazoles, 1128, 1134f
 benznidazole, 1135
 metronidazole, 1128, 1131, 1133–1134
 ronidazole, 1135
 secnidazole, 1135
 tinidazole, 1134–1135
 nitrothiazole derivatives, 1159
 nitazoxanide, 1159
 pentavalent antimonials, 1135–1136, 1136f
 meglumine antimonate, 1136
 sodium stibogluconate, 1136, 1136f
 polyether ionophores, 1146–1147, 1147f
 lasalocid, 1147–1148, 1147f
 maduramicin, 1147f, 1148
 monensin, 1147f, 1148
 narasin, 1147f, 1148
 salinomycin, 1149
 semduramicin, 1147f, 1148–1149
 pyridinols, 1143
 clopidol, 1143, 1143f
 sulfonamides, 1151, 1152f
 tetracyclines, 1140
 thiamine analogues, 1144
 amprolium, 1144, 1144f
 triazine derivatives, 1149, 1149f
 diclazuril, 1149–1150, 1149f
 ponazuril, 1150–1151
 toltrazuril, 1149f, 1150
- antipseudomonas penicillins, 835–836
- antiseptics, 781
 alcohols as, 782–783
 biguanides as, 784
 definition of, 782
 and disinfectants, 781
 factors affecting efficacy of, 786
 biofilms, 788
 concentration, 786
 contamination, 787
 exposure time, 787
 organism types, 787
 pH, 787
 temperature, 787
 halogens as, 783–784
- ideal, 782
 oxidizing agents as, 785
 phenol as, 785–786
 resistance to, 788–789
 use of, examples of, 782, 789
 open wounds, treatment of, 790
 presurgical skin cleansers, 789
- antithrombin, 628
- antithyroid drugs, 715–719, 715f, 716t
 carbimazole, 718
 goitrogens, 715
 methimazole, 715, 716–718, 716t
 propylthiouracil, 716, 716t
 thioureylenes, 715–719, 715f
- antitrematodal drugs, 1085–1087, 1087t
 benzenesulfonamides, 1087
 clorsulon, 1092–1093
 benzimidazoles, 1087, 1093
 triclabendazole, 1093–1097
 nitrophenolic compounds, 1087
 nitroxylnil, 1087–1088, 1087f
 phenoxyalkanes, 1087
 diamphenetide, 1097–1098
 salicylanilides, 1087, 1088
 closantel, 1088–1091
 oxyclozanide, 1091
 rafoxanide, 1091
- antitumor antibiotics, 1204–1206
 actinomycin D, 1206, 1207f
 doxorubicin, 1204–1205, 1204f
 mitoxantrone, 1205–1206, 1206f
- antitussive drugs, 1302
 butorphanol, 1303
 codeine, 1302–1303
 cough reflex, 1302
 dextromethorphan, 1303
 hydrocodone, 1303
 mechanism of action of, 1302
 morphine, 1302
 tramadol, 1304
- antiviral therapy, 1010
 acyclovir and valacyclovir, 1010–1012
 amantadine and rimantadine, 1016–1017
 and antibacterial therapy, difference between, 1010
 cidofovir, ganciclovir, and valganciclovir, 1013
 cytarabine and vidarabine, 1014
 idoxuridine and trifluridine, 1013–1014
 interferon, 1017–1020
 L-lysine, 1020

- for ocular infections, 1328–1329
- oseltamivir, 1015–1016
- penciclovir and famciclovir, 1012–1013
- ribavirin, 1014
- zidovudine, PMEA, and lamivudine, 1014–1015
- Anypril, 751
- API. *see* active pharmaceutical ingredient (API)
- apixaban, 636–637, 636t
- apomorphine, 304
- apomorphine hydrochloride, 304
- apoptosis, 1194
- appendages of the skin, 18
- apramycin, 890
- aprepitant, 1248
- aprotinin, 642
- aquaretics, 614–615
- aquatic animals, antimicrobial for use in, 1373
- administration routes in fish, 1375
- antimicrobial dosages, 1376t–1377t
- dipping treatments, 1378
- immersion baths, 1377–1378
- injections, 1377
- oral treatment, 1378
- antimicrobials prohibited from extralabel use, 1375
- beta-lactams, 1386
- clinical approaches, 1378–1381
- antimicrobial susceptibility testing and interpretive criteria, 1379–1381, 1380t
- salinity effects, 1381
- temperature effects, 1381
- timing of treatment, 1381
- ELU in food-producing animal, 1375
- florfenicol, 1385, 1388–1389
- general conditions for ELU, 1375
- legal considerations, 1373
- valid veterinarian–client–patient relationship (VCPR), 1373, 1375
- oxytetracycline, 1381, 1384, 1386–1397
- pharmacokinetics of, 1386–1389
- in poikilothermic food species, 1374t
- quinolones, 1385–1386
- sulfadimethoxine–ormetoprim, 1384–1385, 1387–1388
- aqueous humor (AH), 1321
- arachidonic acid (AA), 467, 471f
- 2-arachidonylglycerol (2-AG), 177
- Archiv für experimentelle Pathologie und Pharmakologie*, 4
- arecoline, 157, 1081
- argon, 389
- arsenicals, 1137
- arterial oxygen tension (P_aO_2)
- effects of volatile inhalation
- anesthetics, 224, 225f
- in spontaneously breathing, 225f
- arthritis, tetracyclines for, 870
- Ascaris suum*, 1046
- aspirin, 11, 471f, 638–639
- for food animal, 1365
- Association of Racing Commissioner's International (ARCI), 1440
- astrocytes, 178
- asymmetric mixed-onium chlorofumarates, 201
- atenolol, 145–146, 147, 546
- atipamezole, 144, 350, 350t, 351f, 354
- atopic dermatitis, 1294–1297
- cyclosporine for, 1229
- atovaquone, 1141f, 1142–1143
- ATP-binding cassette (ABC) transporters, 179, 1105, 1196
- atracurium, 196, 197, 199–200
- characteristics of, 199t
- atrial natriuretic peptide (ANP), 561
- Atropa belladonna*, 159
- atropine, 159–160, 174, 1263–1264, 1264t
- as bronchodilator, 1310
- in preanesthetic period, 187
- aurothioglucose, 1238–1239. *see also* gold therapy
- automaticity, with cardiac glycosides and digitalis, 507–508
- autonomic ganglionic blocking drugs, 162, 162t
- autonomic nervous system (ANS), 113, 114f
- anatomy of, 119–121
- enteric nervous system, 121
- nonadrenergic–noncholinergic neurons, 121
- parasympathetic nervous system (PSNS), 120–121
- sympathetic nervous system (SNS), 119–120
- neurohumoral transmission
- ACh synthesis, 122–123
- adrenergic, 123–126, 132–134
- catecholamine synthesis, 123–124, 125f
- cholinergic, 122–123, 123f
- enzyme choline acetyltransferase (ChAT) synthesis, 122
- exocytic process of, 125
- postganglionic sympathetic nervous system, site of, 126f
- synaptic, 125
- vesicle synthesis, 122
- physiology of function and regulation
- neurotransmitter synthesis, storage, release, and inactivation, 122–126
- peripheral nerve activity and transmission of action potentials, 122
- receptor types, typical anatomical locations, and their primary mechanisms of action, 124t
- autonomic receptors, 126–129
- adrenergic receptors, 128–129
- cholinergic receptors, 127–128, 151
- G protein-coupled receptors (GPCRs), 128, 151
- muscarinic receptors, 128, 151
- nicotinic receptors, 127–128, 151
- autoreceptors, 171
- avermectins, 1102, 1103f, 1109, 1175. *see also* macrocyclic lactones (MLs)
- avian influenza, 791–792
- avian medicine, 1397
- AVMA. *see* American Veterinary Medical Association
- azalides, 1156
- azaperone, 329f
- adverse effects/contraindications, 330
- analgesic activity, 329
- cardiovascular effects, 329
- CNS effects, 329
- dose, 330t
- drug interactions, 330
- dysphoric effects, 330
- indications, 329
- musculoskeletal effects, 329
- overdose/acute toxicity, 330
- paraphimosis and, 330
- preparation, 330
- regulatory information, 330
- respiratory effects, 329
- thermoregulation effects, 330
- veterinary approved products, 330
- azapirones, behavioral responses of, 427

1488 | Index

- azathioprine, 1235–1237
 adverse effects, 1236
 clinical use, 1236
 for inflammatory bowel disease, 1269
 mechanism of action, 1235
 metabolism of, 1235, 1235f
 toxicity, 1236–1237
- azithromycin, 912t, 924–925, 1156
 chemical structures of, 914f
 clinical use of, 925
 pharmacokinetics of, 917t
 safety of, 925
- azole antifungal drugs, 993–1006, 993f, 993t
 drug–drug interactions, 994, 995t
 fluconazole, 997–998
 imidazoles, 993
 itraconazole, 998, 1000–1003
 ketoconazole, 994, 996–997
 mechanism of action, 993–994
 for ocular infections, 1328
 physicochemical properties and in vitro activity of, 993t
 posaconazole, 1005–1006
 triazoles, 993
 voriconazole, 1003–1005
- AZT. *see* zidovudine
- B**
- babesiosis, drugs for, 1129t
- bacampicillin, 835
- bacitracin, 930
- balanced anesthesia, 184
- barbiturate acid, 248, 249f
- barbiturates, 248–255, 249f, 390
 adverse effects/contraindications, 253
 analgesic effects of, 252
 chemical structure of, 248
 chemistry, 248
 classification, 248, 249t
 CNS depressant effects, 248
 dose, 253–254, 254t
 drug interactions, 255
 duration of action, 254
 history, 248
 indications, 249
 mechanism of, 248–249
 metabolism, 253
 methohexital, 248, 249f, 249t, 250–251
 overdose/acute toxicity, 255
 pentobarbital, 248, 249f, 249t
 pharmacokinetics of, 252–253
- phenobarbital, 248, 249f, 249t, 250
 physiological effects
 arterial pressure changes, 251
 cardiovascular effects, 251
 CNS effects, 251
 dose-dependent effects, 251
 on gastrointestinal tract, 252
 on kidney, 252
 muscular effects, 252
 respiratory effects, 251–252
- in preanesthetic period, 187
 preparation of, 248
 on reticular activating system (RAS), 249
 species differences, 254–255
 thiamylal (Surital), 250
 thiopental, 248, 249–250, 249f, 249t
 tolerance level of, 253
- basal metabolic rate (BMR), 62
- base excess (BE), 571
- behavior drugs
 drug classes
 alpha-2-agonists, 438
 anticonvulsant drugs, 436–437
 antidepressants, 428–436
 antipsychotics, 422–423
 anxiolytics, 423–427
 beta-blockers, 438
 hormonal therapy, 437–438
 nonbenzodiazepine hypnotics, 427–428
 nutraceuticals, 439
 opiates, 437
 selective serotonin reuptake inhibitors (SSRIs), 431–436
 tramadol, 438–439
- drug combinations, 439
- neurotransmitters, 419–422
 acetylcholine (ACh), 422
 dopamine, 421
 gamma amino butyric acid (GABA), 422
 norepinephrine (NE), 421
 serotonin, 421
- pharmacokinetics of, 416–419, 418t
 treatment success with, 440
- Beiträge zur Arzneimittellehre*, 4
- benign prostatic hypertrophy (BPH)
 reproductive hormonal drugs for, 687
 treatment options for, 685f
- benzathine penicillin G, 834
- benzimidazoles, 1035–1054, 1066, 1087, 1093–1097
 administration routes, 1050
- albendazole, 1036f, 1045, 1048
 anthelmintic spectrum, 1047–1049
 as antiprotozoan drugs, 1137–1138, 1137f
 albendazole, 1137–1138
 febantel, 1138
 fenbendazole, 1138
 chemistry of, 1035–1037, 1036f
 disposition kinetics and efficacy of, 1050–1053
 GI transit time and, 1051, 1052f
 nutritional status and parasite infection and, 1051, 1053
 ruminant esophageal groove closure and, 1050–1051
 types of diets and, 1051
- distribution to parasite location, 1042–1044, 1043f, 1044f
 drug transfer into target parasites, 1046–1047
- fenbendazole, 1036f, 1048–1049
 flubendazole, 1036f, 1049
 formulations of, 1050, 1053
 GI tract, reductive metabolism in, 1042
 hepatic and extrahepatic oxidative metabolism, 1039–1042, 1040f, 1041f
- mebendazole, 1036f, 1049
 oxfendazole, 1036f, 1049
 oxibendazole, 1049
 pharmacodynamics, 1037
 pharmacokinetics
 in nonruminant species, 1044–1046
 in ruminant species, 1037–1044, 1038f
- ricobendazole, 1048
 structures of, 1035, 1036f
 thiabendazole, 1048
 withdrawal times, safety, and toxicity, 1053–1054
- benznidazole, 1135
- benzocaine, 384
 gel, 392, 393
 hydrochloride, 392
- benzodiazepine antagonists
 classification, 336
 flumazenil, 337–338
 history, 336
- benzodiazepines (BZDs)
 adverse effects/contraindications, 336
 behavioral responses of, 423–425, 424f

- cerebral uptake of, 335–336
 chemistry, 331
 classification, 331
 drug interactions, 336
 history, 330
 indications, 331
 mechanism of action, 331
 metabolism of, 336
 overdose/acute toxicity, 336
 pharmacodynamic effects
 cardiovascular effects, 331
 CNS effects, 331
 musculoskeletal effects, 331–332
 respiratory effects, 331
 pharmacokinetics in various species, 333t, 424
 safety margin of, 424–425
 sedation by, 187
- benzylisoquinoliniums, 199–200
 atracurium, 199–200
 doxacurium, 200
 mivacurium, 200
- beta-adrenoceptor antagonists, clinical
 applications of
 for cardiovascular regulation, 145
 metabolic and endocrine effects, 146
 for obstructive pulmonary disease, 145
 for reducing dynamic LVOT obstruction, 147
 for reducing intraocular pressure, 146, 148
 for supraventricular and ventricular tachyarrhythmias, 148
- β-adrenergic receptor agonists. *see* bronchodilators
- β agonists, nebulized, 1306–1307
- β-lactam antibiotics, 826
 in aquatic animals, 1386
 binding sites for, 826
 carbapenems, 848–849
 ertapenem, 849
 imipenem, 849
 meropenem, 849
 cephalosporins, 838
 adverse reactions, 847–848
 classification, 839–840, 839t
 first-generation, 843–844
 fourth-generation, 847
 general pharmacology, 838–839
 mechanism of action, 840
 pharmacokinetics, 840–843, 841t
 second-generation, 844
 special species considerations, 848
 third-generation, 844–847
 mechanism of action of, 826–827
 microbial resistance to, 827
 β-lactamases, 827–828
 binding sites, reduced access to, 828
 penicillins
 adverse effects, 836
 aminopenicillins, 834–835
 antimicrobial activity, 829–830
 antistaphylococcal, 835
 β-lactamase inhibitors, 836–838
 extended-spectrum, 835–836
 general pharmacology, 828–829
 natural, 834
 pharmacokinetics, 830, 833–834
 special species considerations, 836
 pharmacokinetic–
 pharmacodynamic (PK-PD)
 properties, 827
- β-lactamase inhibitors, 836–838
 examples and clinical use
 amoxicillin–clavulanate, 837
 new combinations, 838
 piperacillin–tazobactam, 838
 sulbactam–ampicillin, 838
 ticarcillin–clavulanic acid, 838
 mechanism of action, 837
 pharmacokinetics, 837
 structure of, 837, 837f
- β-lactamases, 827–828
 gram-negative, 828
 staphylococcal, 828
- beta-blockers, 438, 545
 for glaucoma, 1323
- betamethasone, 740t, 741f
- bethanechol, 156–157, 1252
- bethanecol, 156
- beyond-use dating (BUD), 1435
- 11-β-hydroxysteroid dehydrogenase system (11-β-HSD), 730–731
- bile acids, 1271
- biliary drug elimination, 36
- biliary drug transport, 37–38, 38t
- biodegradable gels, 1460
- bioequivalence studies, 1420
- biofilms, formations of, 788
- biologically effective dose (BED), 1192
- biological spaces, 9
- birds
 fluoroquinolones for, 971
 herpesviral infections in, 1012
 opioid effects on, 312
 propofol effect on, 258–259
 pyrimethamine for, 1154
 voriconazole in, 1005
- bismuth subsalicylate, 1263
- the bispectral index (BIS), 191
- bleeding disorders, cephalosporins
 and, –848
- bleomycin, 1213
- blood–brain barrier (BBB), 178–180, 179f
- blood coagulation factors, 627t
- blood/gas solubility of anesthetics, 219
- blood pressure, 113, 116f
 adrenergic receptor agonists and, 135–137
 adrenergic receptor antagonists and, 142–143
 antagonism of β-adrenergic receptors, 145
 with cardiac glycosides and digitalis, 507
 PK/PD modeling approach and, 80
 sympathomimetics and, 138–139
- blood samples, 1441
- blood substitutes, 585–588
 hemoglobin-based oxygen carriers, 586–588
 adverse effects of, 587–588
 osmolality of, 586
 perfluorochemicals, 585–586
- blood volumes, in animals, 556t
- Blue Book, 1470
- body fluids
 anesthetics and, 588–589
 cations and anions in,
 concentrations of, 557t
 compartments, 555–556, 556t
 composition and distribution of,
 555–558
 fluid and electrolyte distribution,
 556–558
 units of measure, 555, 556t
 drug distribution and
 extracellular fluid, 556
 fluid therapy and, 578–580
 intracellular fluid, 556
 potassium, 565–569
 disorders of balance, 566–569
 homeostasis, 565–566
 renal regulation of excretion of,
 566
 total body water, 556
 transcellular fluid, 556
 water, sodium, and chloride,
 558–565

1490 | Index

- body fluids (*Continued*)
 disorders of balance, 561–565
 homeostasis, 558–559, 559f
 renal regulation of excretion of, 559–561, 560f
- boldenone, 685
- botulinum toxin, 171, 198
- bovine leukemia virus, 1015
- bovine respiratory disease (BRD), 1313
- bovine serum encephalopathy (BSE), 96
- bovine somatotropin, 1368
- bradyarrhythmias, antiarrhythmic agents for, 543–544
- braking phenomenon, 76
- breast cancer resistance protein (BCRP), 1335
- British Pharmacopeia*, 4
- bromide, 409–411
 adverse effects, 411
 clinical use, 410
 dose, 410
 drug interactions, 411
 effect on diet, 410
 pharmacokinetics, 410
 therapeutic monitoring, 411
- bromosdalans, 1088
- bromosulfophtalein (BSP), 37
- bronchodilators, 1304
 adverse effects from, 1307
 clinical use, 1304
 inhalant formulations, 1306–1307
 longer-acting, 1305–1306
 albuterol, 1305
 clenbuterol, 1305–1306
 metaproterenol, 1305
 salmeterol and formoterol, 1306
 terbutaline, 1305
 mechanism of action, 1304
 short-acting, 1304–1305
 epinephrine, 1304
 isoproterenol, 1305
 tolerance with chronic use, 1307
- broth dilution susceptibility testing of aquatic bacterial pathogens, 1379, 1380t
- budesonide, 1269
- bulk drug substances, 1431
- bulk flow, 11
- bulk laxatives, 1270–1271, 1271t
- bunamidine, 1081–1082, 1082f
- buparvaquone, 1141f, 1143
- bupivacaine, 382–383
- physical–chemical properties and pharmacological properties of, 376t
- buprenorphine, 292, 293, 304–306, 306t, 312
 administration of, 305
 bioavailability of, 306
 cardiovascular safety of, 305
 dose, 306t
 duration of pain control in animals, 305
 lipophilicity of, 305
 oral bioavailability of, 305
- buspirone, 427
- butorphanol, 179, 293, 307, 312, 313
 as antitussive, 307, 1303
 cardiovascular effects, 307
 dose, 307
 onset of effects, 307
 sedative effects of, 307
- butoxypolypropylene glycol, 1184
- butyrophenone, 328–330
 adverse effects/contraindications, 330
 chemistry, 329
 mechanism of action, 329
 pharmacodynamic effects
 analgesic activity, 329
 cardiovascular effects, 329
 CNS effects, 329
 musculoskeletal effects, 329
 respiratory effects, 329
 pharmacokinetics properties, 329–330
- butyrophenones, 187
- BZD. *see* benzimidazoles
- C**
- Caenorhabditis elegans*, 74
- CAIs. *see* carbonic anhydrase inhibitors
- calcium channel blocking drugs, 523–524, 545
- Calf Antibiotic and Sulfa Test (CAST), 1472
- calf diarrhea, antimicrobials for, 1266
- calorigenesis, thyroid hormones and, 705
- Campylobacter* enteritis, 1266
- cancer, 1191
 adjuvant therapy, 1192
 biology, 1192–1193
 cancer cell, chemotherapy of, 1194–1197
 drug toxicity, 1197–1199
 pharmacodynamic response, 1197
 cure, 1191
 drugs for
 alkylating agents, 1199–1200, 1203–1204
 antimetabolites, 1206–1210
 antimicrotubule agents, 1210–1211
 antitumor antibiotics, 1204–1206
 bleomycin, 1213
 corticosteroids, 1214
 cyclooxygenase inhibitors, 1213
 L-asparaginase, 1212–1213
 nitrogen mustard, 1200–1202
 nitrosoureas, 1202
 platinum containing agents, 1211–1212
 rabacfosadine, 1215–1216
 taxanes, 1211
 tyrosine kinase inhibitors, 1214–1215
 immunotherapy, 1191
 induction therapy, 1192
 maintenance therapy, 1192
 neoadjuvant/primary therapy, 1192
 palliation, 1191
 related terminology and treatment perspectives, 1191–1192
 salvage therapy, 1192
- Canine Cancer Clinic, 1191
- canine influenza virus (CIV), 1016
- canine transmissible venereal tumor (CTVT), 1211
- cannabinoid receptors (CB1-2), 177
- cannabinoids, 1247–1248
- canrenone, 612, 613
- capsaicin, 168
- carbachol, 156
- carbadox, 936
- carbamates, 1182
- carbamazepine, 667
- carbapenem-resistant Enterobacteriaceae* (CRE), 828
- carbapenems, 826, 827, 848–849
 ertapenem, 849
 imipenem, 849
 meropenem, 849
- carbaryl, 1169t
- carbimazole, 716t, 718
- carbolic acid, 785–786
- carbomycin, 913
- carbon dioxide, 388–389

- carbonic anhydrase inhibitors (CAIs),
601–603
absorption and elimination, 602
chemistry/formulations of, 601
contraindications, 602
drug interactions, 602
for glaucoma, 1323–1324
mechanisms and sites of action
extrarenal actions, 602
renal mechanisms, 601–602
therapeutic uses of, 602–603
toxicity, adverse effects, 602
- carbon monoxide, 389
- carboplatin, 1212, 1212f
- carboxypenicillins, 836
- cardiogenic edema, furosemide for,
608–609
- cardiorespiratory effects, of
glucocorticoids, 738–739
- cardiovascular effects, of thyroid
hormones, 707
- cardiovascular system (CVS)
alpha-2-adrenergic antagonists,
effects of, 353
basic aspects
cellular concepts, 504–505,
505f
intrinsic regulation, 503
nervous system regulation,
503–504
drugs, effects of
acetylcholine (ACh), 155
adrenergic receptor agonists,
135–137
β-adrenergic receptor antagonists,
145
alpha-adrenoceptor antagonists,
142–144
barbiturate, 251
benzodiazepine derivatives, 331
buprenorphine, 305
butorphanol, 307
butyrophenone, 329
choline esters, 156
desflurane, 229
digitalis and cardiac glycoside, 505
dissociative anesthetics, 261
ephedrine, 139
etomidate, 265
flumazenil, 337
guaifenesin, 355
halothane, 230
inhalation anesthetics, 225–226
isoflurane, 228
ketamine, 261
muscarinic receptor antagonists,
160
neurosteroid anesthetics, 268
nitrous oxide, 232
opioids, 287–288
pentobarbital, 250
phenothiazine, 325
physostigmine, 158
propofol, 256–257
sevoflurane, 230
thiopental, 251
management of cardiovascular
disease, 528
- carfentanil, 303–304
- carprofen, 471f
- carriers, 66
- carvedilol, 146, 527, 546
- castor oil, 1271
- catechol, 131
- catecholamines, 131–132
arrhythmogenic effects of, 226
chemical structures of, 132f
classification of, 132f
- cats
absorption of buprenorphine, 306
aminoglycosides toxicity in,
885–886
amprolium for, 1144
antiherpetic therapy for, 1011
apixaban for, 636–637
aspirin dose for, 639
atovaquone for, 1143
azathioprine in, 1236, 1237
azithromycin for, 1156
benzodiazepine derivatives in, 333t
bromide in, 411
butorphanol in, 307
cisapride in, 1252
clindamycin for, 1155–1156
clopidogrel dose for, 640
corticosteroids in, 1311, 1312t
cyclosporine in, 1229
diabetes in, insulin for treatment of,
767–768
diazepam hydrochloride in, 335,
403–404
digitalis in, 510–513, 512t
diminazene for, 1158
doxorubicin in, 1205
etomidate in, 266
febantel for, 1138
fenbendazole for, 1138
florfenicol for, 911
fluconazole for, 998
fluoroquinolones for, 968–970
griseofulvin for, 989
imidocarb for, 1159
itraconazole for, 1002
ketamine in, 262t
levothyroxine dosages for, 712
macrocyclic lactones for, 1113
maropitant in, 1249
metronidazole for, 1133
mineralocorticoid receptor blockers
and, 521–522
morphine in, 295
oclacitinib in, 1233
paromomycin for, 1139
parvaquone and buparvaquone for,
1143
pimobendan in, 515
ponazuril for, 1151
propofol in, 258
proton pump inhibitors in,
1259–1260
psychotropic agents used in, 420t
primethamine for, 1154
rivaroxaban for, 637
ronidazole for, 1135
streptokinase for, 641
sulfonamides for, 1151
theophylline in, 1309
thyroid hormone and iodide kinetics
in, 700t
thyroxine kinetics in, 701t
tinidazole for, 1134–1135
tissue-type plasminogen activator
for, 641
toltrazuril for, 1150
topical antifungal products for,
1006t
tramadol in, 310
TRH for diagnosis of
hypothyroidism in, 657
triiodothyronine suppression test in,
713
trimethoprim for, 1154
vitamin K₁ dose for, 638
voriconazole in, 1005
- cat scratch disease, 1166
- cattles
acid-base metabolism in, 588
albendazole for, 1138
amprolium for, 1144
azithromycin for, 1156
chloral hydrate in, 357
decoquinatate for, 1142
diminazene for, 1157
fenbendazole for, 1138
florfenicol for, 911

1492 | Index

- cattles (*Continued*)
- griseofulvin for, 989
 - guaifenesin in, 356
 - halofuginone for, 1146
 - imidocarb for, 1158
 - ketosis in, insulin for treatment of, 768
 - lasalocid for, 1148
 - maduramicin for, 1148
 - metronidazole for, 1134
 - monensin for, 1148
 - oxytetracycline for, 1140
 - paromomycin for, 1139
 - parvaquone and buparvaquone for, 1143
 - pentamidine for, 1158
 - ponazuril for, 1151
 - sulfadimethoxine–ormetoprim for, 816
 - sulfonamides for, 1151
 - theophylline in, 1310
 - trimethoprim–sulfadiazine for, 815
 - vitamin K₁ dose for, 638
- cefadroxil, 843
- cefazolin, 844
- cefepime, 840, 847
- cefovecin, 840, 846–847
- cefoxitin, 844
- cefpodoxime proxetil, 847
- cefquinome, 840, 847
- ceftazidime, 846
- ceftazidime–avibactam, 838
- ceftiofur, 840, 845–846, 845t
- Centaura™ Insect Repellent, 1184
- Center for Drug Evaluation and Research (CDER), 1451
- Center for Food Safety and Applied Nutrition (CFSAN), 1448
- Center for Veterinary Medicine (CVM), 1346, 1407, 1409, 1411, 1448, 1461. *see also* regulation of animal drugs
- ADE reports, evaluation of
- review process, 1453
 - signal detection, 1453–1455
- adverse drug experience (ADE), reporting of, 1449–1453, 1450f
- animal devices, 1450–1451
- approved *versus* unapproved drugs, 1450
- medication errors, 1451–1452
- pesticide products/vaccines, 1453
- pet food adverse event and product problem reporting, 1452
- product defect, 1451
- case series, 1454
- Division of Veterinary Product Safety (DVPS), 1448
- drug safety information, communication of, 1455
- international pharmacovigilance activities, 1456
- Office of Surveillance and Compliance (OS&C), 1448
- pharmacovigilance, 1449–1453
- safety measures beyond labeling, 1455
- central analgesic drugs, 309–311, 310t
- central nervous system (CNS), 167
- alpha-2-adrenergic antagonists, effects of, 353
 - alpha-chloralose and, 270
 - barbiturates and, 251
 - benzodiazepine derivatives, effects of, 331
 - blood–brain barrier, 178–180, 179f
 - butyrophenone and, 329
 - chloral hydrate and, 357
 - depressant effects of barbiturates, 248
 - depression, 223, 247
 - desflurane and, 228–229
 - dissociative anesthetic and, 260–261
 - enflurane and, 231
 - epidural barrier, 180, 180f, 181f
 - etomidate and, 265
 - flumazenil and, 337
 - glucocorticoids and, 742–743, 742t
 - guaifenesin and, 355
 - injectable anesthetics in, 247
 - isoflurane and, 228
 - ketamine and, 261
 - neuroanatomy and neurophysiology, 167–168
 - neurosteroid anesthetics in, 268
 - neurotransmitters and receptors, 171–172
 - agmatine, 177
 - amines, 174–176
 - amino acids, 172–174
 - endocannabinoids, 177
 - peptides, 176–177
 - purines, 177
 - neurotransmitter systems, interactions between, 178
 - nitrous oxide and, 231–232
 - nonneuronal cells, role of, 177–178
 - opioids and, 286
 - partial pressure of anesthetic, 219–220
 - phenothiazines and, 324–325
 - postsynaptic processes, 171
 - presynaptic processes, 168, 170–171, 170f
 - propofol and, 256
 - sevoflurane and, 229–230
 - transduction, 168, 169f
- cephalexin, 843–844
- cephalosporins, 826, 838
- adverse reactions, 847–848
 - bleeding disorders, 848
 - blood disorders, 848
 - gastrointestinal, 848
 - glycosuria, 848
 - hypersensitivity reactions, 847–848
 - classification, 839–840, 839t
 - first-generation, 839, 839t, 843–844
 - cefadroxil, 843
 - cefazolin, 844
 - cephalexin, 843–844
 - cephapirin, 844
 - fourth-generation, 840, 847
 - general pharmacology, 838–839
 - mechanism of action, 840
 - pharmacokinetics, 840–843, 841t
 - elimination, 843
 - metabolism, 843
 - oral absorption, 842
 - pharmacokinetics–pharmacodynamics, 840–841
 - susceptibility testing, 841, 842t
 - tissue concentrations and protein binding, 841–842
 - second-generation, 839, 839t, 844
 - special species considerations, 848
 - third-generation, 839–840, 839t, 844–847
 - cefovecin, 846–847
 - cefpodoxime proxetil, 847
 - ceftazidime, 846
 - ceftiofur, 845–846, 845t
- Cephalosporium acremonium*, 826
- cephapirin, 844
- cerebral ischemia, 224
- cerebral perfusion pressure, 224
- certification of analysis (COA), 96
- cetirizine, 458
- Charm Tests, 1472
- chemical residues, in tissues of food animals, 1469
- concern over, 1469–1471
 - drugs prohibited from extralabel use, 1476

- pharmacokinetics and, 1473–1476
- prevention of, 1476–1477
- regulation of, 1471–1473
- chemical sterilization, 782
- chemoreceptor trigger zone (CTZ), 178, 1245
- chemotherapy
 - of cancer cell, 1194–1199
 - combination chemotherapy, 1196–1197
 - tumor cell resistance, 1194–1196
 - tumor cell sensitivity, 1194
- definition of, 1191
- drugs
 - actinomycin D, 1206, 1207f
 - alkylating agents, 1199–1200
 - bleomycin, 1213
 - cell cycle and, 1192, 1193f
 - chlorambucil, 1201–1202, 1201f
 - corticosteroids, 1214
 - COX-2 inhibitors, 1213
 - cyclohexylchloroethylnitrosurea, 1202, 1202f
 - cyclophosphamide, 1200, 1200f
 - cytosine arabinoside, 1207–1208, 1208f
 - dacarbazine, 1203, 1203f
 - dosing of, 1192
 - doxorubicin, 1204–1205, 1204f
 - 5-fluorouracil, 1209–1210, 1209f
 - gemcitabine, 1208–1209, 1209f
 - ifosfamide, 1200–1201, 1200f
 - L-asparaginase, 1212–1213
 - masitinib, 1215
 - maximum tolerated dose (MTD), 1191
 - mechlorethamine, 1201, 1201f
 - melphalan, 1202, 1202f
 - methotrexate, 1206–1207, 1207f, 1208f
 - mitoxantrone, 1205–1206, 1206f
 - paclitaxel, 1211, 1211f
 - platinum containing agents, 1211–1212
 - procarbazine, 1203–1204, 1204f
 - rabacfosadine, 1215–1216
 - temozolomide, 1203, 1203f
 - toceranib, 1214–1215, 1214f
 - vinca alkaloids, 1210–1211, 1210f
- fractional kill hypothesis, 1193
- metronomic, 1193
- resistance to, 1194–1196, 1195t
- chickens
 - amprolium for, 1144
 - decoquinate for, 1142
- diclazuril for, 1150
- dinitolmide for, 1145
- halofuginone for, 1146
- lasalocid for, 1148
- monensin for, 1148
- narasin for, 1148
- nicarbazin for, 1146
- ormetoprim for, 1154
- robenidine for, 1144
- semduramicin for, 1149
- sulfonamides for, 1151
- chloral hydrate, 357–358, 357f
- in preanesthetic period, 187
- chloralose, 269–270, 270f
- chlorambucil, 1201–1202, 1201f, 1234–1235
 - adverse effects, 1234
 - clinical use, 1235
 - for inflammatory bowel disease, 1269
- chloramine-T, 790
- chloramphenicol, 254, 903, 1470
 - adverse effects and precautions, 905, 907
 - aplastic anemia, 907
 - bone marrow suppression, 905, 907
 - GI disturbances in dog, 907
 - peripheral neuropathy, 907
 - toxicity in cats, 907
- chemical features, 903
- clinical uses, 907–908
- derivatives, 908
 - florfenicol, 909–912
 - thiamphenicol, 908–909
- drug interactions, 907
- formulations, 903–904
- mechanism of action, 904
- for ocular infections, 1327–1328
- pharmacokinetics, 904–905, 905t, 906t
 - absorption and distribution, 904–905
 - metabolism and excretion, 905
 - resistance to, 904
 - spectrum of activity, 904
 - structure of, 904f
- chlorhexidine (Chx), 784, 790
- chlorine-containing solutions, 783–784
- chloroquine, 1156
- chlorpheniramine, 459
- chlorpromazine, 1245, 1246t
- chlorpromazine hydrochloride, 327, 327f, 328
- chlorpropamide, 667
- chlorpyrifos, 1181
- chlortetracycline, 859f, 859t, 861t, 866–867, 1140
- choline, 174
- choline esters, 153
 - cholinergic receptor activating properties of, 154t
 - clinical uses, 156–157
 - molecular structures of primary, 154f
 - pharmacological mechanisms and effects, 156
 - target organ effects, 156
- cholinesterase inhibitors, 66, 198–199
 - pharmacological mechanisms and effects, 157
 - reversible, 158–159
 - structure–activity relationships, 158
- cholinomimetic alkaloids, 154f, 157
- Chondrodendron tomentosum*, 198
- choroid plexus, 178
- chronic lymphocytic leukemia (CLL), 1201
- chronic palliative therapy, glucocorticoids, 746
- Chrorulon, 678t
- chrysotherapy. *see* gold therapy
- chukar partridges, lasalocid for, 1148
- cidofovir, 1013
- cimetidine, 1256–1257, 1256t
- cimicoxib, 470, 471f
- ciprofloxacin, 953, 954t, 955f
 - for dogs and cats, 969–970
- circumventricular organs (CVOs), 178
- cisapride, 1251–1252
 - clinical use, 1252
 - formulations, 1252
 - mechanism of action, 1251
 - pharmacokinetics, 1251–1252
 - side effects and interactions, 1252
- cisatracurium, 198, 199–200
 - characteristics of, 199t
- cisplatin, 1212, 1212f
- citalopram, 434
- citrate-phosphate-dextrose-adenine (CPDA-1), 629
- clarithromycin, 1262
- clathrins, 171
- cleansers, 781
 - types of, 781
- clemastine, 458, 459

1494 | Index

- clenbuterol, 138, 1305–1306, 1368
in food-producing animals, 1306
in horses, 1306
unapproved use of, 1306
- Client Information Sheet (CIS), 1455
- clindamycin, 927–930, 1155–1156, 1155f
absorption and distribution, 928–929
adverse effects and precautions, 929–930
chemical structures of, 925f
clinical use, 930
mechanism of action, 928
metabolism and excretion, 929
pharmacokinetics –
pharmacodynamics, 928–929
resistance to, 928
source and chemistry, 927
spectrum of activity, 928
- Clinical and Laboratory Standards Institute (CLSI), 1379
- clinical anesthesia, 185–189
- clinical breakpoint, 1381
- clomipramine, 431
- clonazepam, 404
- clopidogrel, 639–640, 1261
- clopidol, 1143, 1143f
- cloprostenol, 678t
- clorazepate, 404–405
behavioral responses of, 426
- clorsulon, 1092–1093
chemical structure of, 1092f
dosage, 1092
elimination of, 1093
with ivermectin, 1092
pharmacokinetic behavior of, 1093
safety and toxicity, 1093
- closantel, 1088–1091, 1089f, 1092f
and ivermectin, 1089
mechanism of action, 1089
pharmacokinetic behavior of, 1089–1090, 1090f
toxicity, 1091
- Clostridium* spp., 198, 1265
- clotrimazole, 1009
- cloxacillin, 835
- coagulopathies, agents for treatment of, 638
- cocaine, 175
- coccidiosis, drugs for, 1131t, 1132t–1133t
- codeine, as antitussive, 1302–1303
- Code of Federal Regulations (CFR), 1408
- Codex Alimentarius*, 1426
- Codex Committee on Residues of Veterinary Drugs in Foods (CCRVDF), 1426
- colitis-X, 865
- colloid osmotic pressure (COP), 583–584
- colloid therapy, 583–584
- column chromatography, 1441
- common ion effect, 94
- comparative pharmacokinetics, 1351–1353
- comparative pharmacology, 6
- Compliance Policy Guide (CPG), 1348–1349, 1358, 1431
- compounded drugs, 1430
current status of, 1430–1432
potential problems from, 1432–1434
signs of drug instability, 1432t
transdermal medications for pets, 1434–1435
veterinarians and veterinary pharmacists, guidelines for, 1435
- compounding of drugs, 1359. *see also* compounded drugs
- concentration gradient, 10
- congestive heart failure (CHF), 601
ancillary therapy in, 527
digitalis for, 510
- conivaptan, 614–615
- constant flow treatments, 1377
- constant-rate infusion (CRI), 607
- Consumer Complaint Coordinator, FDA, 1452
- Controlled Internal Drug Release (CIDR), 104, 683–684, 684f
- controlled-release dosage formulations, 1460
- controlled substances, 1430
inventory records, 1436
medical record, 1436
prescribing, 1436
prescription for, 1437t
storage and security, 1436
- coprophagy, 15–16
- corticosteroids
in cancer chemotherapy, 1214
in cats, 1311, 1312t
in dogs, 1311
in horses, 1312
inhaled, 1312–1313
as metered-dose inhalers, 1312t
for ocular inflammation, 1325–1326, 1325t
- corticotropin-releasing hormone (CRH), 649–651, 650t, 651t
dosage protocols for, 654t
stimulation test, 654
- cortisol, 732, 741f
- cortisone, 740t, 741f
- cosolvent, 94
- cotransmission, 420
- cotrimoxazole, 815
- cough reflex, 1302
- coumaphos, 1061
- coumarin derivatives, 632–638
- COX-inhibiting nitric oxide donors (CINODs), 472
- Crempophore-free paclitaxel, 1211
- cresols, 786
- cromolyn, 1307
- crufomate, 1061
- cryptorchidism
in dogs, hCG for, 679
reproductive hormonal drugs for, 687
- cryptosporidiosis, drugs for, 1130t
- crystalline penicillin, 834
- crystalloid therapy, 582–583
- crystalluria, sulfonamides and, 805
- CTBP. *see* cytosolic thyroid hormone-binding proteins
- CTX. *see* cyclophosphamide
- curare alkaloids, 194
- cutaneous metabolism, 19
- CVM. *see* Center for Veterinary Medicine
- cyclodextrin molecule, 268f
- cyclohexanones, 185
- cyclohexylchloroethylnitrosourea (CCNU), 1202, 1202f
- cyclooxygenase (COX), 467
cyclooxygenase-1 (COX-1)
characteristics, actions, and roles of, 469t
cyclooxygenase-2 (COX-2), 1213
characteristics, actions, and roles of, 469t
inhibition of, 477–478, 478t
efficacy, potency, and sensitivity of, 478–480
in vivo and ex vivo determination of, 480
- cyclophosphamide, 1200, 1200f, 1233–1234
adverse effects, 1234
clinical use, 1234
mechanism of action, 1234
cycloplegics, 1330

- cyclosporine, 1227–1232
 administration, 1230
 adverse effects and precautions, 1231–1232, 1231t
 clinical use
 in cats, 1229
 in dogs, 1228–1229
 drug interactions, 1232
 formulations and pharmacokinetics, 1229–1230
 for inflammatory bowel disease, 1270
 mechanism of action, 1228, 1228f
 monitoring, 1230–1231, 1231f
 for ocular disease, 1329
 ophthalmic use
 anterior uveitis, 1232
 keratoconjunctivitis sicca, 1232
 structure of, 1228f
 cyfluthrin, 1179
 Cyklokapron, 642
 cyclooxygenase (COX), 600
 CYP2D6, 1337–1338
 cypermethrin, 1179
 cystic ovaries therapy, gonadorelin for, 676
 Cystorelin, 676, 678t
 cytarabine, 1014. *see also* cytosine arabinoside (Ara-C)
 cytauxzoonosis, drugs for, 1130t
 cytosine arabinoside (Ara-C), 1207–1208, 1208f
 cytosolic binding proteins, thyroid hormones and, 704
 cytosolic glucocorticoid receptor (cGR), genomic effects by, 732–733
 cytosolic thyroid hormone-binding proteins (CTBP), 698
 cytotoxic drugs, 1194
- D**
 dabigatran etexilate, 635, 636t
 dacarbazine (DTIC), 1203, 1203f
 dactinomycin (DACT). *see* actinomycin D
 dalbavancin, 936
 dalteparin (Fragmin), 631–632
 danofloxacin, 954t, 973
 dapson, 1239–1240
 adverse effects, 1240
 clinical use, 1239–1240
 mechanism of action, 1239
 pharmacokinetics, 1239
Datura stramonium, 159
 dazamide, 601
 Dear Doctor Letters, 1455
 decamethonium, 197
 decongestants, 1315
 for incontinence, 1316
 systemic, 1315–1316
 topical, 1315
 decoquinat, 1141–1142, 1141f
 dehydration
 physical findings in, 562t
 types of, 561–562
 dehydrocholic acid, 1271
 deiodinase enzymes, regulation of, 695–698
 Delvo tests, 1472
 demulcents, 1315
 deoxycorticosterone (DOC), 730
 depot preparations, 1460
 deracoxib, 470, 471f
 dermatological effects
 of glucocorticoids, 743
 of thyroid hormones, 706
 dermis of the skin, 18
 derquantel, 1069
 DERs. *see* Drug Experiencing Reports
 desflurane, 228–229
 biotransformation, 228
 cardiovascular actions of, 229
 CNS, effect on, 228–229
 CO₂ absorbent stability, 228
 convulsive activity of, 224
 respiratory system, effect on, 229
 rubber or plastic/gas partition coefficient of, 219t
 solubility of, 218t
 vapor pressure of, 228, 228t
 desmopressin acetate (DDAVP), 638, 665, 666–667
 desoxycorticosterone acetate (DOCA), 751
 desoxycorticosterone pivalate (DOCP), 751
 detomidine hydrochloride, 345f, 346–347, 346t
 dexamethasone, 740, 740t, 741f, 1214, 1247
 in food animal, 1365, 1368
 in horses, 1312
 dexmedetomidine, 345f, 348, 348t
 in preanesthetic period, 187
 dexrazoxane, 1205
 Dextran 40, 582t
 Dextran 70, 582t
 dextromethorphan, 1303
 diabetes insipidus (DI)
 ADH for diagnosis of, 666
 central, chlorpropamide for treatment of, 667
 nephrogenic, treatment of, 667
 Diabinese, 667
 diamidine derivatives, 1157, 1157f
 amicarbalide, 1158
 diminazene diaceturate, 1157–1158
 imidocarb dipropionate, 1158–1159
 pentamidine isethionate, 1158
 phenamidine isethionate, 1158
 diaminopyrimidines, 796
 Diamox, 601
 diamphenetide, 1097–1098
 chemical structure and metabolic fate, 1097, 1097f
 mechanism of action, 1098
 safety, 1098
 diarrhea, sulfonamides and, 807
 diarrhea, treatment for, 1262
 antimicrobials, 1265–1267
 motility modifiers, 1263–1264
 mucosal protectants and adsorbents, 1262–1263
 opioids, 1264–1265
 diazepam, 402–404
 adverse reactions and tolerance, 402
 behavioral responses of, 425–426
 in cats, 403
 clinical use, 403
 induced eating in anorexic cats, 404
 mechanism of action, 402
 pharmacokinetics, 402–403
 routes of administration, 403
 rectal administration, 403
 as skeletal muscle relaxant, 404
 in treatment for anxiety, 404
 diazepam hydrochloride, 331–334
 chemical name, 331–332
 dose, 333t
 molecular formula, 331
 regulatory information, 333–334
 diazoxide, 773
 dichlorvos, 1061
 diclazuril, 1149–1150, 1149f
 diethylcarbamazine, 1063–1064, 1063f
 diethylenediamine. *see* piperazine
 diethyl-m-toluamide (DEET), 1184
 diethylstilbestrol (DES), 683
 diffusional coefficient of drug, 10
 difloxacin, 954t
 diflubenzuron, 1183

- digitalis, 505–513
cardiac energy metabolism with, 507
cardiac output with, 506, 507f
cardiovascular effects of, 505
in cats, 510–513, 512t
cellular mechanisms, 505–506
chemistry and sources, 505
combined effects during atrial fibrillation and flutter, 508
electrophysiological effects, 508
excitability and automaticity, 507–508
impulse conduction and refractory periods, 508
kidneys and diuresis with, 508–509
myocardial contractility, 505
neuroendocrine effects, 507
pharmacokinetics, 509–510
preparations, 513
therapeutic indications for, 510
toxicity
clinical signs, 509
electrolyte involvement, 509–510
plasma concentrations, 509
- digoxin, 544–545
- dihydrofolate reductase/thymidylate synthase inhibitors, 1152, 1153f
ormetoprim, 1153f, 1154
pyrimethamine, 1153f, 1154–1155
trimethoprim, 1152–1154, 1153f
- dihydropyrimidine dehydrogenase (DPD), 1195
- dihydrostreptomycin and streptomycin, 890–891
- dimenhydrinate, 1246, 1246t
- diminazene diaceturate, 1157–1158, 1157f
- dinitolmide, 1145, 1145f
- dinoprost, 678t, 681
- dinotefuran, 1174
- di-npropyl isocinchomerone (MGK 326), 1184
- dioctyl calcium sulfosuccinate, 1271
- dioctyl sodium sulfosuccinate (DSS), 1271
- dipeptidyl peptidase 4 inhibitors, 772
- diphemanil, 1264, 1264t
- diphenhydramine, 1245, 1246, 1246t
- diphenoxylate, 1264
- diphenylmethane, 1270
- diprenorphine, 309
- dip treatments, 1378
- direct-acting parasympathomimetic agonists
acetylcholine, 154–155
choline esters, 156–157
cholinomimetic alkaloids, 157
effects of, 153t
general characteristics, 153
structure–activity relationships, 153–154
- direct compression technique, 106
- direct stimulants, 1314
- disinfectant footbaths, 791
- disinfectants, 781, 782
alcohols as, 782–783
aldehyde, 784–785
factors affecting efficacy of, 786
biofilms, 788
concentration, 786
contamination, 787
exposure time, 787
organism types, 787
pH, 787
temperature, 787
gas, 786
ideal characteristics of, 781
oxidizing agents as, 785
Q₁₀ coefficient, 787, 787t
resistance to, 788–789
use of, examples of, 790–791
avian influenza, 791–792
Salmonella species, 791
- disinfection, 782
high-level, 782
intermediate-level, 782
low-level, 782
- disk diffusion susceptibility tests, 1379
- disophenol, 1087, 1088
- Dispensatorium*, 3
- displacement, with plasma protein binding, 25
- dissociation constant of ligand, 69
- dissociative anesthetics, 259–264
adverse effects/ contraindications, 263
chemistry, 260
classification, 260
dose, 263
drug availability, 264
drug interactions, 264
history, 259–260
indications, 260
mechanism of action, 260
metabolism, 262–263
overdosage/acute toxicity, 264
pharmacokinetics, 262
physiological/pharmacodynamic effects, 260–262
analgesic effects, 262
cardiovascular effects, 261
CNS effects of, 260–261
effects on ICP, 260–261
muscular effects, 262
norepinephrine affects, 261
respiratory effects, 261–262
preparation, 260
regulatory information, 264
- dissociative drugs, 187
- distal convoluted tubule (DCT), 595, 596, 599f
- distribution, drug
aminoglycosides, 882–883
chloramphenicol, 904–905
clindamycin, 928–929
extent of tissue binding, 25–26
factors affecting, 22–23, 25–26
florfenicol, 909–910
fluoroquinolones, 967
lincomycin, 926
of lipophilic compounds, 9–10
macrolide antibiotics, 918–920
penicillins, 833–834
physiological determinants of, 23
plasma protein binding, 24–25
sulfonamides, 800, 802, 804
tetracyclines, 861–864, 861t–863t
tissue barriers to, 23–24
volume of, 26
- diuretics
aquaretics, 614–615
carbonic anhydrase inhibitors, 601–603
dopamine receptor agonists, 615
edema formation, 601
effect on water and electrolyte elimination, 601t
loop/high-ceiling, 605–610
mineralocorticoid receptor antagonists, 612–614
neutral endopeptidase inhibitors, 615
osmotic, 603–605
principles of, 600–601
renal epithelial sodium channel inhibitors, 611–612
renal physiology, 593–600, 594f, 596f
epithelial transport and secretion, 600
nephron function, 593–597, 595f, 596f
thiazide and thiazidelike, 610–611
d-limonene, 1182
dobutamine, 513

- dogs
- absorption of buprenorphine in, 306
 - acepromazine in, 328
 - acquired cardiac disease in,
 - treatment of, 146–147
 - albendazole for, 1137–1138
 - alfaxalone in, 269
 - aminoglycosides toxicity in, 885
 - amprolium for, 1144
 - apomorphine dosage for, 304
 - aspirin dose for, 639
 - atovaquone for, 1142–1143
 - azithromycin for, 1156
 - barbiturate in, 254–255
 - benzodiazepine derivatives in, 333t, 425
 - bromide in, 410
 - butorphanol in, 307
 - carvedilol in, 147
 - chloramphenicol for, 904, 907–908
 - cisapride in, 1252
 - clindamycin for, 1155–1156
 - clopidogrel dose for, 640
 - colloids in, indications, dosages and administration of, 582t
 - cyclophosphamide in, 1200
 - cyclosporine in, 1228–1229
 - decoquinatate for, 1142
 - diabetes in, insulin for treatment of, 767–768
 - digitalis in, 509
 - diminazene for, 1157
 - doxorubicin in, 1205
 - doxycycline for, 1140
 - etomidate in, 267
 - febantel for, 1138
 - fenbendazole for, 1138
 - fluconazole for, 998
 - fluoroquinolones for, 968–970
 - griseofulvin for, 989
 - guaifenesin in, 356
 - heparin dose for, 630
 - imepitoin in, 401–402
 - imidocarb for, 1158–1159
 - with immune-mediated hemolytic anemia, 625
 - itraconazole for, 1002
 - ketamine in, 262t
 - leflunomide in, 1238
 - levothyroxine dosages for, 711–712
 - macrocyclic lactones for, 1113
 - maropitant in, 1249
 - mechlorethamine in, 1201
 - meglumine antimonate for, 1136
 - metoclopramide in, 1250
 - metronidazole for, 1133
 - morphine in, 294–295
 - nifurtimox for, 1140
 - ocloacitinib in, 1233
 - ormetoprim for, 1154
 - paromomycin for, 1139
 - pentamidine for, 1158
 - phenamidine for, 1158
 - pimobendan in, 514, 514t
 - ponazuril for, 1151
 - propofol in, 258
 - proton pump inhibitors in, 1259–1260
 - pyrimethamine for, 1154
 - rivaroxaban and apixaban for, 636–637
 - ronidazole for, 1135
 - selective serotonin reuptake inhibitors (SSRIs) in, 432
 - skin reactions in, 806
 - sodium stibogluconate for, 1136
 - sterile hemorrhagic cystitis in, 1200
 - streptokinase for, 641
 - subaortic stenosis (SAS) in, 147
 - sulfonamides for, 1151
 - theophylline in, 1309
 - thyroid hormone and iodide kinetics in, 700t
 - thyroxine kinetics in, 701t
 - tinidazole for, 1135
 - tissue-type plasminogen activator for, 641
 - toltrazuril for, 1150
 - topical antifungal products for, 1006t
 - tramadol in, 309–310
 - TRH for diagnosis of hypothyroidism in, 656–657
 - trimethoprim for, 1153–1154
 - ulcerative colitis in, 1266
 - vitamin K₁ dose for, 638
 - warfarin dose for, 635
 - domperidone, 680, 1251
 - dopamine, 124, 129, 138, 421, 513, 679, 1245
 - as neurotransmitters, 174–175
 - receptors, 175
 - termination of action of, 175
 - dopamine receptor agonists, 615
 - doping control, 1439
 - doramectin, 1102, 1103f, 1116, 1175, 1177
 - dosage form considerations, 99–105, 1459
 - biomass products, 103–104
 - bolus, 102
 - capsules, 103
 - chewable tablets, 102–103
 - common veterinary forms, 99f
 - considerations when formulating, 100f
 - controlled internal drug release system (CIDR), 104
 - cream, 101
 - delayed release, 101–102
 - different types, use of, 1459
 - ease of drug administration, 1461
 - emulsions, 100
 - extended release (ER) tablets, 101
 - feed additives, 1461–1463, 1463f
 - gels, 101
 - granules, 103
 - immediate release (IR) tablets, 101
 - implants, 102
 - liquid suspension, 99–100
 - lotions, 101
 - medicated feed, 103
 - modified release (MR) tablets, 101
 - ointment, 101
 - parenteral products, 104–105
 - pastes, 101
 - pharmacokinetic considerations and controlled-drug delivery, 1459–1461, 1460f
 - powders, 103
 - site-directed therapy, 1463
 - solutions, 99
 - suspension (SE), 101
 - tablets, 101
 - topical products, 105
 - transdermal drug delivery, 105
 - dosage regimens, 57–62
 - adjusting for disease, 60–62, 61f
 - constant-dose, interval-extension method (IE), 61, 61f
 - constant-interval, dose-reduction (DR), 61
 - determination of an effective and safe, 77
 - dosage rate, 59
 - efficacy and safety, 60
 - factors important in designing, 59
 - instantaneous dose rate, 59
 - loading dose, 58–59
 - maintenance dose, 58
 - plasma concentration vs time profile, 58f
 - for quinolone, 82, 83
 - relative dosage interval, 59
 - selection of dose, 81–83

1498 | Index

dosages

alpha-chloralose, 270t
 apomorphine, 304
 atipamezole, 350t
 azaperone, 330t
 barbiturates, 253–254, 254t
 bromide, 410
 buprenorphine, 306t
 butorphanol, 307
 chloral hydrate, 357
 clorsulon, 1092
 detomidine hydrochloride, 346t
 diazepam hydrochloride, 333t
 dissociative anesthetics, 263
 dose–effect relationship vs PK/PD modeling, 66f
 etomidate, 266
 etorphine in animals for immobilization, 303t
 gentamicin, 880t
 glucocorticoids, 1227
 guaifenesin, 355–356
 hydromorphone, 297t
 ketamine, 263
 levamisole, 1057
 metomidate, 272
 midazolam maleate, 334
 opioids, 312t
 pimobendan, 516
 piperazine, 1062–1063
 praziquantel, 1083
 propofol, 259, 259t
 romifidine, 347t
 species differences, 269
 telazol, 263
 tetracycline antibiotics, 866t
 tetrahydropyrimidines, 1060
 tolazoline, 353t
 tribromoethanol, 272–273
 trimethoprim–sulfadiazine, 814
 urethane, 271
 xylazine hydrochloride, 345t
 yohimbine, 351t
 dose-limiting toxicity (DLT), 1198
 dose titration trial, 78–79, 78f, 79f
 down-regulation, 76
 doxacurium, 200
 characteristics of, 199t
 doxapram, 1316
 doxazosin, 143
 doxil, 1205
 doxorubicin, 1204–1205, 1204f
 doxycycline, 859f, 859t, 864–865, 868–869, 1140
 pharmacokinetic parameters of, 863t

dronabinol, 1248
 droperidol, 328
 drug administration, routes of
 intra-peritoneal injection, 22
 parenteral dosage forms, 21
 subcutaneous (SC or SQ) and intramuscular (IM) route, 21
 drug approval process, for minor food-producing animals, 1345–1346
 Drug Enforcement Authority (DEA), 1436
 Drug Experiencing Reports (DERs), 1423–1424
 drug receptor theories, 74–76, 75f
 drugs, 3
 absorption of (*see* absorption, drug)
 affinity, efficacy, and potency of, 69–70, 69f, 70f
 as agonist or antagonist, 67–69
 binding of, and chemical forces, 72
 disposition of, 8–10
 distribution of
 factors affecting, 22–23, 25–26
 physiological determinants of, 23
 plasma protein binding, 24–25
 tissue barriers to, 23–24
 hepatic disposition, 32–38
 hepatic clearance, 34–35
 metabolism impact, 34
 metabolism induction and inhibition, 35–38
 phase I and phase II reactions, 33–34, 33t
 mechanism of action, 67f
 partial agonist vs full agonist, 74
 receptors, 72–74
 renal elimination, 26–32
 clearance, 30–31
 mechanism of, 27–30
 physiology relevant to, 26–27
 tubular secretion and reabsorption, 31–32
 specificity and selectivity of, 70–72
 drug targets, types of, 65–67, 66f
 drug transporters, 1334
d-tubocurarine, 197, 198, 200
 histamine release by, 207
 neuromuscular blocking effect of, 204–205, 204f, 205f
 Dyrenium, 611
 dysautonomia, 118

E

ear tags, 1167
Eat this Bug, 1395
 Eazi-Breed CIDR, 678t, 684, 684f
Ebers Papyrus, 3
Echinococcus granulosus, 1081
 ectoparasiticides, 1166
 amitraz, 1170t, 1182–1183
 approval and registration in US, 1184–1185, 1184t
 carbamates, 1182
 chemical structures and physicochemical properties of, 1169t–1170t
 d-limonene and linalool, 1182
 fipronil, 1170–1172, 1170t
 ideal, 1166
 indoxacarb, 1180
 insect growth regulators, 1170t, 1183
 insect development inhibitors, 1183
 juvenile-hormone analogs, 1183
 macrocyclic lactones, 1175–1177
 mechanisms of action, 1168, 1170t
 neonicotinoids
 dinotefuran, 1174
 imidacloprid, 1172–1173
 isoxazoline, 1174–1175
 nitenpyram, 1173
 spinosad, 1174
 organophosphates, 1170t, 1180–1182
 pyrethrins and pyrethroids, 1170t, 1178–1180
 resistance to, 1168, 1170
 routes of dermal absorption, 1167–1168, 1167f
 synergists and repellents, 1170t, 1183–1184
 topical formulations, 1167
 transdermal delivery, 1167
 edema formation, diuretics and, 601
Edinburgh Pharmacopoeia, 3
 edrophonium, 158–159
 for reversal of neuromuscular blockade, 210
 effect compartment model, 79
 efficacy of drugs, 69–70, 69f, 70f
 clinical, 69
 intrinsic, 69
 eicosanoids, 467–468, 485, 600
 eicosapentanoic acid, for colitis, 1269–1270

- EIPH. *see* exercise-induced pulmonary hemorrhage
- electrocardiogram, cardiac glycosides and digitalis effects on, 508
- Electronic Submissions Gateway (ESG), FDA, 1453
- Electronic Submissions System (ESS), 1453
- elimination, drug
- of aminoglycosides, 883
 - of angiotensin-converting enzyme inhibitors, 616
 - of carbonic anhydrase inhibitors, 602
 - of cephalosporins, 843
 - of florfenicol, 910
 - of loop diuretics, 607
 - of mannitol, 603–604
 - of mineralocorticoid receptor antagonists, 613
 - of osmotic diuretics, 603–604
 - of penicillins, 833
 - of tetracyclines, 861t–863t, 864
- elimination half-life, 1474
- emodepside, 1069, 1070, 1070f
- endectocides, 1369
- endocannabinoids, 177
- endocrine effects
- of glucocorticoids, 742, 742t
 - of thyroid hormones, 708
- endometritis, persistent
- oxytocin for, 681
 - prostaglandins analogs and, 681
- endothelial NO synthase (eNOS), 121
- energy metabolism, glucocorticoids and, 737
- enflurane, 228
- CNS, effects of, 231
 - pharmacokinetics, 231
 - rubber or plastic/gas partition coefficient of, 219t
 - solubility of, 218t
 - tonic-clonic muscle activity, 224
 - undesirable features of, 231
 - vapor pressure of, 228t
- enilconazole, 1008–1009
- enoxaparin (Lovenox), 632
- enrofloxacin, 953, 954t, 955f, 969t, 1337, 1433
- enteric nervous system, 121
- enterohepatic recycling, 15–16
- concentration vs time profile, 16f
- Environmental Protection Agency (EPA), 781, 1408, 1453, 1470
- enzyme-linked immunoassay (ELISA), 1443, 1472
- eosinophilic colitis, 1269
- epidural barrier, 180, 180f, 181f
- epinephrine, 136, 175, 1304, 1304t
- eplerenone, 614
- eprinomectin, 1102, 1103f, 1108, 1116, 1175, 1176, 1460
- pour-on formulation, 1177
- epsiprantel, 1085, 1085f, 1086f
- Equidone, 680
- equine chorionic gonadotropin (eCG), 678t, 679
- equine herpesvirus type-1 (EHV-1), 1011
- equine, propofol effect on, 258
- equine protozoal myelitis, drugs for, 1130t
- equine protozoal myeloencephalitis (EPM), 799, 1142, 1149
- Equipoise, 685
- ertapenem, 849
- erythromycin, 11, 912t, 920–921, 1253
- chemical structures of, 913f
 - clinical use of, 921
 - formulations, 920
 - for ocular infections, 1328
 - pharmacokinetic parameters of, 919t
 - regulatory considerations, 921
- erythropoietin, 1446
- escitalopram, 434
- esmolol, 546
- esters, 742
- estradiol, 682
- estradiol benzoate, 682–683
- estrogens, 682–683
- estrous cycle, 674–675, 675f
- estrous synchronization, 681
- Estrumate, 678t
- estrus synchronization, 676
- E-test, 1379
- ethyl alcohol, 782–783
- ethylenediamine dihydroiodide (EDDI), 1008, 1314
- ethylenediaminetetra acetic acid (EDTA), 628
- ethylene oxide, 786
- etofenprox, 1179
- etomidate
- adverse effects/ contraindications, 266
 - chemistry, 264, 264f
 - classification, 264–265
 - compatibility of, 267
 - dose, 266
- drug availability, 267
- drug interactions, 267
- history, 264
- indications, 265
- mechanism of action, 265
- metabolism, 266
- overdosage/acute toxicity, 267
- pharmacokinetics, 265–266
- physiological effects, 265, 266f
- analgesic effects, 265
 - cardiovascular effects, 265
 - CNS effects, 265
 - endocrine system, 265
 - muscular effects, 265
 - respiratory system, 265
- preparation, 264–265
- regulatory information, 267
- species differences, 266–267
- stability of, 267
- storage of, 267
- etorphine, 303–304
- eucalyptus oil, 1314
- European Association for Veterinary Pharmacology and Toxicology (EAVPT), 5
- European Medicines Agency (EMA), 1453
- European Union (EU), 1425
- euthanasia, 388
- euthanizing agents
- in animals, 393
 - immersion agents, 391–392
 - benzocaine hydrochloride, 392
 - 2-phenoxyethanol, 392
 - quinaldine sulfate, 392
 - tricaine methane sulfonate, 392
- inhaled agents, 388–390
- anesthetic overdose, 390
 - argon, 389
 - carbon dioxide, 388–389
 - carbon monoxide, 389
 - nitrogen, 389–390
- injected agents
- barbiturate, 390
 - carfentanil citrate, 391
 - dissociative agents, 391
 - embutramide, 391
 - etorphine hydrochloride, 391
 - potassium chloride, 391
 - tributame, 390–391
- miscellaneous considerations, 392–393
- opioids, 391
- evidence-based pharmacology, 4

1500 | Index

- Evidence-Based Veterinary Medical Association (EBVMA), 1466
- evidence-based veterinary medicine (EBVM), 1465–1467
- clinical decision making, 1465
 - definition of, 1465
 - evidence hierarchy, 1466, 1467f
 - evidence rating system, 1467, 1467f
- excitatory amino acid transporters (EAATs) neurotransmitters, 172
- excretion
- chloramphenicol, 905
 - clindamycin, 929
 - fluoroquinolones, 967
 - macrolide antibiotics, 920
 - pharmacogenetics of, 1339–1340
 - sulfonamides, 805
- exercise-induced pulmonary hemorrhage (EIPH), 609–610, 1445
- exocytosis, 171
- exogenous glucocorticoids, 701–702
- exotic animals, antifungal drugs for, 998, 999t–1000t
- expectorants and mucolytics, 1314
- acetylcysteine, 1315
 - demulcents, 1315
 - direct stimulants, 1314
 - guaifenesin, 1315
 - saline expectorants, 1314
- extended-spectrum β -lactamases (ESBLs), 828
- extracellular fluid (ECF), 556
- cations in, 557–558
 - osmolality, 557
- extralabel use (ELU), 1358–1359, 1375, 1410
- definition of, 1472
 - drugs prohibited for, 1429t, 1473t
 - regulatory discretion for, 1427
 - requirements for, 1429t
 - veterinarian and, 1472–1473
- extrusion processes, 106
- F**
- factor Xa inhibitors, 636–637
- Factrel, 676, 678t
- famciclovir, 1012–1013
- adverse effects, 1013
 - clinical use, 1013
 - pharmacokinetics, 1012–1013
- famotidine, 1256–1257, 1256t
- famphur, 1181
- FARAD. *see* Food Animal Residue Avoidance Databank (FARAD)
- Fasciola hepatica*, 1046, 1053, 1085–1087, 1087t
- fasciolosis, 1085–1086. *see also* antitrematodal drugs
- febantel, 1039, 1048, 1138
- Federal Food Drug and Cosmetic Act (FFDCA), 1407, 1408, 1425
- Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), 1408
- Federation Equestre Internationale (FEI), 1440
- felbamate, 405
- feline herpesvirus type-1 (FHV-1), 1011, 1013
- fenbendazole, 1036f, 1048–1049, 1137f, 1138. *see also* benzimidazoles
- fenleuton, 1314
- fentanyl, 178, 1398–1399
- fenthion, 1169t, 1181
- fenvalerate, 1179
- fescue toxicosis, 1251
- FFDCA. *see* Federal Food Drug and Cosmetic Act
- fibrinolytic agents, 640–641
- Fick's law of diffusion, 10, 31
- field-block anesthesia, 370
- finasteride, 678t, 685
- fipronil, 1166, 1170–1172, 1170t
- chemistry, 1171
 - efficacy, 1171
 - formulations, 1170–1171
 - mechanism of action, 1171
 - pharmacokinetics, 1171
 - safety/toxicity, 1171–1172
- firocoxib, 471f, 475t
- fish
- florfenicol for, 911–912
 - fluoroquinolones for, 971–972
 - morphine and, 296
 - propofol and, 259
- flea allergy dermatitis, 1166
- flip-flop phenomenon, 47
- florfenicol, 909–912, 1361
- adverse effects, 912
 - in aquatic animals, 1385, 1388–1389
 - clinical use, 911–912
 - cattle and pigs, 911
 - fish, 911–912
 - horses, 912
 - other species, 912
 - small animals, 911
 - topical forms, 911
 - pharmacokinetics of, 909–911, 910t
 - absorption, 909
 - distribution, 909–910
 - metabolism and elimination, 910
 - pharmacokinetic–pharmacodynamic properties, 911
 - regulatory information, 912
 - structure of, 909
- flubendazole, 1036f, 1049. *see also* benzimidazoles
- fluconazole, 993t, 997–998
- adverse effects, 998
 - clinical use
 - exotic animals, 998, 999t–1000t
 - large animals, 998
 - small animals, 997–998 - interactions, 998
 - pharmacokinetics, 997
 - spectrum of activity, 997
 - structure of, 1004f
- flucytosine, 1008
- fluid therapy, 577–588
- diagnosis and monitoring for, 577–578, 579t
 - fluid volume and type for, 578–580
 - products for, 582–588
 - blood substitutes, 585–588
 - colloids, 583–584
 - crystalloids, 582–583
 - hypertonic solutions, 584–585 - rates and routes of administration, 580–582
 - solutions, composition of, 579t
 - units of measure and conversions used in, 556t
- flumazenil
- adverse effects/contraindications, 337
 - analgesic activity of, 337
 - cardiovascular effects, 337
 - CNS depressant effects, 337
 - doses, 338
 - indications, 337
 - mechanism of action, 337
 - molecular formula, 337
 - musculoskeletal effects, 337
 - pharmacokinetics properties, 338
 - regulatory information, 338
 - respiratory effects, 337
- flumequine, 1385–1386
- flumethasone, 740t, 741f
- flunixin, 1475–1476
- flunixin meglumine, 1313
- fluoroquinolone-induced retinal toxicity, 1337

- fluoroquinolones, 953, 1265
 advantages of, 953
 antibacterial spectrum, 956–957, 956t
 chemical features, 953–955
 clinical use
 birds, 971
 dogs and cats, 968–970
 fish, 971–972
 horses, 972–973
 nursing animals, 974
 pigs, 973–974
 pregnant animals, 974
 reptiles, 971
 ruminants, 973
 small mammals, 970–971
 young animals, 974–975
 dose guidelines, 968, 969t
 drug interactions, 977
 formulations, 977–978
 mechanism of action, 955–956
 for ocular infections, 1327
 pharmacokinetics, 958, 959t–964t, 965–987
 excretion, 967
 intramuscular and subcutaneous injection, 966
 metabolism, 966
 oral absorption, 965–966
 protein binding, 965t, 967
 tissue distribution, 967
 pharmacokinetics–
 pharmacodynamics, 967–968
 resistance to, 957–958
 clinical, 957–958
 human health risks of, 958
 safety of, 975–976
 blindness in cats, 975–976
 CNS effects, 975
 problems in young animals, 976
 structure–activity relationships, 954–955
 susceptibility testing, 954t, 957
 third-generation, 953, 955
 used in veterinary medicine, 954t
 5-fluorouracil (5-FU), 1008, 1209–1210, 1209f
 fluoxetine, 176, 432–433
 fluralaner, 1174–1175
 flush treatments, 1377
 fluticasone, 1312–1313
 fluvoxamine, 434
 FMRFamide-related peptides (FaRPs), 1070–1071
 foals, antimicrobials for diarrhea in, 1267
 follicle-stimulating hormone (FSH), 649, 651f, 675f, 678t, 679
 Follitropin, 678t
 Follutein, 678t
 Food and Agriculture Organization (FAO), 1426, 1476
 Food and Drug Administration (FDA), 6, 96, 1407–1409, 1409t, 1431, 1448, 1470–1471. *see also* regulation of animal drugs
 postapproval surveillance program, 1448
 Food and Drug Administration Amendments Act (FDAAA), 1452
 Food Animal Residue Avoidance Databank (FARAD), 816, 882, 1348, 1351, 1352, 1469, 1477
 food animals, use of drugs in, 1358
 anesthetics and analgesics, 1369–1370
 antibiotics, 1361–1365, 1362t–1363t
 anticoccidials, 1365, 1366t
 antiinflammatories, 1365–1368, 1366t
 antiparasitics, 1367t, 1369
 extralabel use, 1358–1359
 hormones for reproductive use, 1367t, 1369
 miscellaneous drugs, 1370
 production enhancement drugs, 1366t, 1368–1369
 residues and withdrawal times, 1359–1361
 food code, 1426
 food-producing animals
 major, 1345
 minor, 1345
 Food Safety and Inspection Service (FSIS), USDA, 1470–1472
 formaldehyde, 784–785, 791
 formulation elements, 95–99
 function of excipients, 95
 International Conference on Harmonization (ICH) guidelines, 96
 in liquid and semisolid formulations
 antimicrobial agents, 98
 antioxidants, 98
 buffering agents, 97
 bulking agents, 97
 chelating agents, 98
 coloring agents, 99
 complexing and dispersing agents, 98
 flavors, 99
 flocculating/suspending agents, 98
 humectants, 99
 preservatives, 98
 solubilizing agents, 98
 thickening agents, 98–99
 tonicity agents, 98
 wetting agents, 98
 for modified release formulations
 coated tablets, 97
 matrix tablets, 97
 natural ingredients, 95
 semisynthetic ingredients, 95–96
 for solid dosage forms
 binders, 97
 coating agents, 97
 disintegrants, 97
 fillers (diluent), 96–97
 glidants, 97
 lubricants, 97
 synthetic ingredients, 96
 Freedom of Information (FOI) summaries, 1407
 free hormone hypothesis, 698–699
 frog
 metomidate in, 272
 opioid in, 312, 312t
 Frontline Plus, 1166, 1170
 furazolidone, 934–935
 furosemide, 605–610, 1234, 1444–1445
G
 GABA, as neurotransmitters, 172, 173t, 174
 gabapentin, 405–406
 adverse effects, 406
 clinical use, 406
 pharmacokinetics, 406
 GABA receptors, 174, 174f
 GADPTRA. *see* Generic Animal Drug and Patent Term Restoration Act
 gallamine (Flaxedil), 201–202
 γ -hydroxybutyric acid (GHB), 174
 γ -amino butyric acid (GABA), 731
 gamithromycin, 912t, 923
 chemical structures of, 914f
 pharmacokinetics of, 917t
 gamma amino butyric acid (GABA), 422
 ganciclovir, 1013

1502 | Index

- gantacurium, 198, 201
characteristics of, 199t
- gas chromatography (GC), 1441–1442
- gas disinfectants, 786
- GastroGard[®], 1260
- gastrointestinal effects, of
glucocorticoids, 742t, 743
- gastrointestinal function, drugs
affecting
acetylcholine (ACh), 155
alpha-2-adrenergic receptor
agonists, 341
barbiturates, 252
bethanecol, 156
carbachol, 156
choline esters, 156
inhalation anesthetics, 226
muscarinic receptor antagonists,
160
nonsteroidal antiinflammatory
drugs (NSAIDs), 482–484
opioids, 288–289
- gastrointestinal stasis, 188
- gastrointestinal tract, thyroid hormone
effect on, 707
- gastrointestinal ulcers, drugs for, 1254,
1254t, 1255f
antacids, 1255–1256
Helicobacter gastritis and, 1262
histamine H₂-receptor antagonists,
1256–1257
proton pump inhibitors, 1258–1261,
1258t
sucralfate, 1257–1258, 1257f
synthetic prostaglandins, 1261–1262
- gatifloxacin, 953
- GC-induced leucine zipper (*GILZ*)
gene, 738
- gemcitabine, 1208–1209, 1209f
- general anesthesia, 184–185
injectable agents for, 188, 188t
mechanism of action, 185
stages of, 184, 184f
techniques of, 184–185
balanced anesthesia, 184
single-agent technique, 184
- general visceral afferent (GVA) system,
118
- general visceral efferent (GVE) system,
113
- Generic Animal Drug and Patent Term
Restoration Act (GADPTRA),
1409, 1420
- generic product application, 1421
- gentamicin, 877, 886–888
- chemical structure of, 877, 878f
- disposition of
age on, effect of, 886
body condition and disease on,
effect of, 886, 888
once-daily dosages for, 880t
pharmacokinetic data for, 887t–888t
- ghrelin, 661
- giardiasis, drugs for, 1129t
- glaucoma, 1323–1325
pharmacological therapy, 1323
beta-blockers, 1323
carbonic anhydrase inhibitors,
1323–1324
hyperosmotic agents, 1324–1325
parasympathomimetics, 1325
prostaglandin analogues, 1324
physiology of, 1323
- glial cells, 177–178
- glomerular filtration, 27–28, 28f
- glomerular net filtration pressure, 596f
- glomerulus, anatomy of, 598f
- glucagon, 771–772
- glucagon-like peptide 1, 772
- glucocorticoids, 729–750
adverse effects, 1227
cellular effects, 1226–1227
chemistry of, 740–742, 740t, 741f
esters, 742
source, 740
steroid base, 741–742
structure–activity relationships,
740, 740t, 741f
choice of drugs, 1227
classes of therapy with, 744–750
adrenal reserve testing, 747
alternate-day therapy, 746–747
antiinflammatory and antiallergic
therapy, 745
chronic palliative therapy, 746
immunosuppressive therapy,
745–746
intensive short-term and shock
therapy, 745
intraarticular administration,
748–749
neurologic applications, 749
ophthalmic applications, 749
physiological replacement
therapy, 744–745
stress supplementation, 747–748
topical and intralesional usage,
748
clinical dosing and cellular actions
of, relationship of, 734t
- clinical use, 1311–1312
- dosage, 1227
- every-other-day (EOD) therapy,
1227
- exogenous, 701–702
- fatal sequela in dog, 743
- genomic mechanisms of action,
732–736, 733f
- genomic effects via cGCR,
732–733
- lipocortin induction and
phospholipase A2 inhibition,
734, 735f
- posttranslational modifications,
736
- steroid receptor isoforms,
735–736
- hypoadrenocorticism management,
729
- for immune-mediated diseases,
1226–1227
- immunosuppressive effects,
1227
- for inflammatory bowel diseases,
1268–1269
- laminitis in horse, 743, 749
- mechanism of action, 1311
- mechanism of action of, 734, 734f
- molecular mechanisms of action,
732
- newer preparations of, 749–750
- nonadrenal disorder management,
729
- nongenomic effects of, 736–737
and NSAIDs, 735f, 748
- pharmacologic effects of, 737–740
cardiorespiratory, 738–739
CNS, 739, 742–743, 742t
endocrine, 739, 742, 742t
energy metabolism, 737
gastrointestinal, 739–740, 742t,
743
growth and development, 737
immune and hematologic effects,
738
water and electrolyte balance,
737–738
- physiological effects of, 737
- physiology and, 729–737
hypothalamic–pituitary–adrenal
axis, 731–732, 731f
negative feedback, cellular
mechanisms of, 732
steroids biosynthesis, 729–731,
730f

- plasma binding, metabolism, and excretion of, 732
- principles of rational therapy, 743–744
- for respiratory diseases, 1311–1313
- thyroid function and, 701–702
- toxicity of, 742–743, 742t
- for vomiting, 1247
- withdrawal from, 747
- glucoreceptor (GR), 71
- glucose effect, 252
- glucose metabolism
- diazoxide, 773
- dipeptidyl peptidase 4 inhibitors, 772
- glucagon, 771–772
- glucagon-like peptide 1, 772
- hypoglycemic agents, oral, 768–771
- acarbose, 770–771
- metformin, 770
- sodium–glucose cotransporters, 771
- sulfonylureas, 768–770
- thiazolidinediones, 770
- insulin, 763–768
- adverse effects of
- chemistry and biosynthesis of, 763–764
- history of, 763
- mechanism of action, 765
- metabolism of, 765–766
- preparations and properties of, 766–767, 766t
- secretion of, 764–765
- therapeutic uses of, 767–768, 768t
- somatostatin, 772–773
- toceranib phosphate, 773
- glutamate, as neurotransmitters, 172, 173t
- glutamate-gated chloride channels (GluCl), macrocyclic lactones and, 1104–1105
- glutamic acid decarboxylase (GAD), 172
- glutaraldehyde (GLT), 785, 791
- glycine, as neurotransmitters, 172, 173t
- glycine xylidide (GX), 381
- glycopeptides, 936–937
- glycopyrrolate, 161, 1310
- goats
- amprolium for, 1144
- decoquinatate for, 1142
- monensin for, 1148
- paromomycin for, 1139
- vitamin K₁ dose for, 638
- goitrogens, 715
- gold therapy, 1238–1239
- adverse effects, 1239
- clinical use, 1239
- dosage, 1239
- formulations for, 1239
- gonadorelin, 675t, 676–677
- clinical use of, 676–677
- dosage of, 678t
- gonadotropin-releasing hormone (GnRH), 676
- gonadotropins, 677–679, 678t
- human chorionic, 677–679
- mechanism of, 677
- secretion and function of, 677
- therapeutic uses of, 677
- Good Manufacturing Practices (cGMPs), 1451
- G-protein, 655
- G protein-coupled receptors (GPCRs), 72, 73f, 168
- granisetron, 176
- Green Book, 1409
- griseofulvin, 988–990
- clinical use
- adverse effects, 990
- large animals, 989–990
- small animals, 989
- mechanism of action, 988
- microsized formulations, 988
- pharmacokinetics, 988–989
- spectrum of activity, 988
- ultramicrosized formulations, 988
- growth hormone–releasing hormone (GHRH), 661
- guaiacol, 1315
- guaifenesin, 354f, 1315
- adverse effects/contraindications, 355
- classification, 354
- dose, 355–356
- drug interactions, 356
- indications, 355
- mechanism of action, 355
- metabolism, 355
- overdosage/acute toxicity, 356
- pharmacokinetics, 355
- physiological effects, 355
- regulatory information, 356
- species differences, 356
- guanidine derivatives, as
- antiprotozoan drugs, 1143–1144
- H**
- Haemonchus contortus*, 1046
- Hageman factor, 627t
- half-life of drug, 1474
- halofuginone, 1146, 1146f
- haloperidol, 328
- halothane, 228
- advantages, 230
- biotransformation, 229, 230
- cardiovascular actions of, 230
- CO₂ absorbent stability, 230
- complete respiratory arrest, 230
- declining use and availability, 230–231
- hepatic injury related with, 230–231
- pharmacokinetics, 230
- rubber or plastic/gas partition
- coefficient of, 219t
- solubility of, 218t
- vapor pressure of, 228t
- halothane hepatitis, 231
- haloxon, 1061
- hCG. *see* human chorionic gonadotropin
- heartworm adulticides, 1064
- Helicobacter* gastritis, 1262
- hemicholinium, 198
- hemoglobin-based oxygen carriers (HBOCs), 586–588
- adverse effects of, 587–588
- osmolality of, 586
- Hemopure, 587
- hemorrhagic cystitis, 1234
- Hemospan, 587
- hemostasis, 625–629
- coagulation phase in, 627–628
- calcium involvement, 627t, 628
- fibrin formation, 626f
- fibrinolysis phase in, 628
- natural anticoagulants in, 628
- vascular and platelet phases in, 626–627, 627f
- in vitro anticoagulants and clotting tests, 628–629
- Henderson–Hasselbalch equation, 10, 27, 29, 570f
- heparin, 629–632
- adverse effects of, 630
- for IMHA, 630
- indications and clinical uses, 629–630
- low-molecular-weight, 629, 630–632
- pharmacological properties of, 633t
- reversing agent for, 632
- unfractionated, 629

1504 | Index

- hepatic disposition of drugs, 32–38
bile formation, 36–37
biliary drug elimination, 36
cytochrome (Cyt) P450-dependent
mixed-function oxidation, 33,
34t
hepatic clearance, 34–35
metabolism impact, 34
metabolism induction and
inhibition, 35–38
phase I and phase II reactions,
33–34, 33t
hepatic necrosis, sulfonamides and,
806
hepatozoonosis, drugs for, 1130t
Hetastarch, 582t
high-ceiling diuretics. *see* loop
diuretics
high ceiling effect, 69
highly effective antiretroviral therapy
(HAART), 1015
Hill model, 80
Hippocrates, 3
histamine, 175
antihistamines
chemistry, 456–457
development, 456
H₁ receptor antagonists, 456, 457t
H₂ receptor antagonists, 460
pharmacological effects, 457
side effects and interactions,
459–460
therapeutic uses, 457–459
therapeutic uses of, 459
pharmacological effects, 455–456
receptors, 453–455, 454t
release, 452–453
serotonin
agonists and antagonists, 463
metabolism, 460–461
neuronal uptake of, 461–462
pharmacological effects, 462–463
physiological and pathological
processes, 463
side effects and interactions, 463
sources, 460–461
subtypes, 462
sources, 451–452
synthesis, 451–452
histamine H₂-receptor antagonists,
1256–1257
adverse effects, 1256
antiallergic effects, 1257
clinical use, 1256
immunological effects, 1257
mechanism of action, 1256
potency of, 1256t
smooth muscle activity, effects on,
1257
HIV-1 protease inhibitors, 1337
Hofmann elimination reaction, 199
homeostasis
of potassium, 565–566
of water, sodium, and chloride,
558–559, 559f
hormesis, 74
hormone implants, 1368
hormone response elements (HRE),
682
hormones
adrenocorticotrophic hormone,
651–655, 654t, 662t
antidiuretic hormone, 662t, 665–667
corticotropin-releasing hormone,
649–651
follicle-stimulating hormone, 649,
651f, 675f, 678t, 679
hypothalamic hormones, 649–668,
650t, 651t
luteinizing hormone, 649, 651f, 675
pituitary hormones, 649–668
anterior, 649–665
posterior, 665–668
reproductive hormones, 674–687,
675t
thyrotropin-releasing hormone,
655–657
hormones for reproductive use, 1367t,
1369
horses
acepromazine in, 327–328
airway diseases in, 1305
alfaxalone in, 269
aminoglycosides toxicity in, 886
anticholinergic drugs in, 1310
antiherpetic therapy for, 1011–1012
azathioprine in, 1236
benzodiazepine derivatives in, 333t
butorphanol in, 307
chloral hydrate in, 357
chloramphenicol for, 908
cisapride in, 1252
corticosteroids in, 1312
decoquinatone for, 1142
diazepam hydrochloride in, 335
diclazuril for, 1149–1150
digitalis in, 509
diminazene for, 1157
dissociative anesthetics in, 263
domperidone in, 1251
florfenicol for, 912
fluoroquinolones for, 972–973
guaifenesin in, 356
heparin dose for, 630
imidocarb for, 1158
intraarticular glucocorticoid usage
in, 748–749
itraconazole for, 1002
ketamine in, 262t
levothyroxine dosages for, 712
macrocyclic lactones for, 1112
metoclopramide in, 1250
metronidazole for, 1133
misoprostol in, 1262
morphine in, 295–296
phenytoin in, 401
ponazuril for, 1150–1151
proton pump inhibitors in, 1260
pyrimethamine for, 1154–1155
rifampin use in, 933
tetracyclines for, 1140
tetracyclines in, effects of, 865
theophylline in, 1309–1310
thiopental in, 255
tinidazole in, 1135
toltrazuril for, 1150
tramadol in, 311
TRH for diagnosis of
hypothyroidism in, 657
trimethoprim–sulfadiazine for,
814
vitamin K₁ dose for, 638
warfarin dose for, 635
HSS. *see* hypertonic saline
HSS plus dextran (HSD), 585
human chorionic gonadotropin (hCG),
677–679, 678t
adverse reactions and side effects,
679
dosage of, 678t
therapeutic uses of, 677–679
Human Genome Project, 1332
humidity, 92
hyaloideocapsular ligament, 1322
Hydodan[®], 1303
hydralazine hydrochloride, 522–523
hydrochlorothiazide, 667
hydrocodone, 1303
hydrocortisone, 740t
hydrogen peroxide, 785
gas plasma, 786
hydrolysis, 92
hydromorphone, 296–297
dosages, 297t
4-hydroxycoumarin, structure of, 633f

- hydroxyquinolones and
 naphthoquinones, 1141, 1141f
 atovaquone, 1141f, 1142–1143
 buparvaquone, 1141f, 1143
 decoquinone, 1141–1142, 1141f
 parvaquone, 1141f, 1143
5-hydroxytryptamine, 175–176
Hyoscyamus niger, 159
hyperadrenocorticism, adrenolytic
 drugs for, 751–752
hyperbolar agonist–effect
 relationships, 74
hypercapnia, 224
hyperchloremia, 565
hyperkalemia, 567–568
 causes of, 567, 567t
 management of, 568t
hypernatremia, 562–563, 563f
hyperosmotic agents, for glaucoma,
 1324–1325
hyperosmotic cathartics, 1270
hypersensitivity reactions
 cephalosporins and, 847–848
 sulfonamides and, 805–806
hyperthyroidism, 691
hypertonic saline (HSS), 584–585,
 790
hypervolemia, 563
hypnotic-sedatives, in preanesthetic
 period, 187
hypoadrenocorticism management,
 glucocorticoids for, 729
hypochloremia, 565
hypochlorites as disinfectants,
 783–784
hypoglycemic agents, oral, 768–771
 acarbose, 770–771
 metformin, 770
 sodium–glucose cotransporters, 771
 sulfonylureas, 768–770
 thiazolidinediones, 770
hypokalemia, 568–569
 causes of, 568t
 potassium supplementation in, 569t
hyponatremia, 563–565, 564f
hypothalamic–pituitary–adrenal axis,
 731–732, 731f
hypothalamic–pituitary–thyroid axis,
 694–695, 695f
hypothyroidism, 691
 therapeutic trial for diagnosis of,
 713
 thyroid replacement therapy of, 710f
hypotonic fluid loss, 561, 563
hysteresis loop, 79
- I**
I-653. *see* desflurane
ibafloxacin, 954t
idiosyncratic reactions, 1340
idoxuridine, 1013–1014
ifosfamide, 1200–1201, 1200f
imazalil, 1008
imepitoin, 401–402
 adverse effects, 402
 clinical use in dogs, 402
 drug interactions, 402
 pharmacokinetics, 402
IMHA. *see* immune-mediated
 hemolytic anemia
imidacloprid, 1166, 1170t, 1172–1173
 chemistry, 1172
 efficacy, 1172–1173
 mechanism of action, 1172
 pharmacokinetics, 1172
 products, 1172
 safety/toxicity, 1173
imidazothiazoles, 1054–1058. *see also*
 levamisole
imidocarb dipropionate, 1157f,
 1158–1159
imipenem, 849
imipramine, 430–431
immersion disinfection, 782
immune-mediated hemolytic anemia
 (IMHA), 625, 1226, 1227
immunoblotting, 1354–1355
immunological effects, of
 glucocorticoids, 743
immunosuppressive drugs, 1226
 azathioprine, 1235–1237, 1235f
 chlorambucil, 1234–1235
 cyclophosphamide, 1233–1234
 cyclosporine, 1227–1232
 dapsone, 1239–1240
 glucocorticoids, 745–746,
 1226–1227
 gold therapy, 1238–1239
 for inflammatory bowel diseases,
 1269
 leflunomide, 1238
 mycophenolate mofetil, 1237–1238
 oclacitinib, 1233
 pimecrolimus, 1232
 sirolimus, 1232–1233
 tacrolimus, 1232
inamrinone, 516–517
Increlex, 664
infections, ocular
 antibacterial agents
 aminoglycosides, 1327
 chloramphenicol, 1327–1328
 double antibiotic/triple antibiotic
 preparations, 1326–1327
 erythromycin, 1328
 fluoroquinolones, 1327
 tetracyclines, 1327
antibacterial agents for, 1326–1328
antifungal agents
 azoles, 1328
 polyenes, 1328
antifungal agents for, 1328
antimicrobial therapy for,
 1326–1329
antiviral agents for, 1328–1329
 purine analogues, 1329
 pyrimidine analogues, 1328–1329
infertility therapy
 gonadorelin for, 676
 hCG for, 677
inflammation, ocular, 1325
 and antiinflammatory therapy,
 1325–1326
 corticosteroids for, 1325–1326,
 1325t
 nonsteroidal antiinflammatory
 agents for, 1326, 1326t
inflammatory bowel disease (IBD),
 drugs for, 1267
 anticholinergics, 1268
 glucocorticoids, 1268–1269
 immunosuppressive drugs, 1269
 sulfasalazine, 1267–1268
inhalation anesthetics
 as cerebral vasodilators, 224
 drug kinetics properties, 218–219
 methods of characterization, 217
 pharmacodynamics of, 222–232
 cardiovascular system effects,
 225–226
 central nervous system effects,
 223–224
 desflurane, 228–229
 effects of volatile anesthetics on
 arterial oxygen tension (P_aO_2),
 224, 225f
 enflurane, 231
 gastrointestine, 226
 halothane, 230–231
 isoflurane, 227–228
 kidneys, 226–227
 liver, 226
 methoxyflurane, 231
 nitrous oxide, 231–232
 respiratory system effects,
 224–225

- inhalation anesthetics (*Continued*)
sevoflurane, 229–230
skeletal muscle, 227
pharmacokinetics
 blood flow characteristics in
 different tissue groups, 221t
 delivery to alveoli, 220
 dosage, 222
 factors contributing to anesthetic
 elimination, 222
 factors promoting rapid changes,
 220t
 minimum alveolar concentration
 (MAC), 222, 222t
 movement, 219f
 oil/gas partition coefficients vs
 potency (MAC), 223f
 partial pressure between alveoli
 and venous blood, 221
 recovery from, 221–222
 removal from alveoli, 220–221
 standard index of potency for,
 222
 upper limit of inspired
 concentration, 220
 uptake and elimination, 219–222
physicochemical characteristics of,
 216–218
 chemical, 216–217
 forms, gas vs vapor, 217
 physical, 217
 of volatile anesthetics, 218t
postanesthetic cognitive dysfunction
 and, 224
preconditioning effects, 224
solubility characteristics of
 in blood and tissues, 220
 blood/gas solubility, 219
 high agent solubility, 219
 oil/gas partition coefficient,
 219
 rubber or plastic/gas partition
 coefficients, 219t
 for tissues, 219
trace concentrations of, 232
inhaled corticosteroids, 1312–1313
injectable anesthetics
 barbiturates, 248–255, 254t
 CNS activity in seizing patients, 247
 disadvantages of, 247
 dissociative anesthetics, 259–264
 etomidate, 264–267
 indications for, 247
 intramuscular, 247
 neurosteroids, 267–269
 properties of ideal, 248
 pharmacological, 248
 physiological, 248
 propofol, 255–259, 255f, 259t
Innovar-Vet, 328
inodilators, 513–516
inodoxcarb, 1179
inosine monophosphate
 dehydrogenate (IMPDH), 1237
inotropic agents, 516–517
inotropic effect, 506
insect development inhibitors (IDIs),
 1183
insect growth regulators (IGRs), 1183
inspired concentration, of inhalation
 anesthetics, 220, 231
Institute for Safe Medication Practices
 (ISMP), 1451
insulin, 763–768
 chemistry and biosynthesis of,
 763–764
 history of, 763
 mechanism of action, 765
 metabolism of, 765–766
 preparations and properties of,
 766–767, 766t
 secretion of, 764–765
 therapeutic uses of, 767–768, 768t
intact animals, gonadorelin for, 677
interferons, 1017
 administration of, 1017
 adverse reactions, 1020
 alpha, 1017, 1020
 clinical and experimental uses of,
 1018t–1019t
 omega, 1020
 types of, 1017
International Conference on
 Harmonization of Technical
 Requirements for Registration of
 Pharmaceuticals for Human Use
 (ICH), 1425
International Federation of
 Horseracing Authorities (IFA),
 1440
interspecies extrapolations, 62–63, 62f
intraarticular administration, of
 glucocorticoids, 748–749
intracranial pressure (ICP), diuretics
 to reduce, 605
intramuscular (IM) injection of
 anesthetics, 247
intraocular pressure (IOP), 1321,
 1323
intraosseous fluids, 581
intravenous regional nerve block
 (IVRA or Bier block), 370
intrinsic sympathetic activity (ISA),
 145
iodinated radiocontrast agents, 719,
 719f
iodine, as antiseptic/disinfectant, 783
iodine metabolism, 691–693
iodophors, 783
ion channels, 66
ionic strength of a solution, 94
ionotropic receptors, 72, 171
ion trapping, 10, 11f
iopanoic acid, 716t
ischemia–reperfusion injury,
 associated with HBOCs, 587
isoflurane, 227
 anticonvulsant effects of, 228
 biotransformation, 227–228
 cardiovascular actions of, 228
 CNS, effect on, 228
 CO₂ absorbent stability, 227
 immobilizing effects of, 224
 respiratory system, effect on, 228
 rubber or plastic/gas partition
 coefficient of, 219t
 solubility of, 218t
 vapor pressure of, 228, 228t
isophosphamide. *see* ifosfamide
isopropamide, 1264, 1264t, 1310
isopropyl alcohol, 782–783
isoproterenol, 137, 138, 544, 1305
isosorbide dinitrate, 524–526
isoxazolines, 1174–1175
 efficacy, 1175
 mechanism of action, 1175
 pharmacokinetics, 1174–1175
 safety/toxicity, 1175
itraconazole, 993t, 998, 1000–1003
 adverse effects, 1002–1003
 clinical use, 1001–1002
 cats, 1002
 dogs, 1002
 large animals, 1002
 formulations, 998, 1000
 pharmacokinetics, 1001
 spectrum of activity, 1000–1001
 structure of, 1004f
ivermectin, 1102, 1103f, 1104f, 1111f,
 1115–1116, 1168, 1169t, 1175,
 1176. *see also* macrocyclic
 lactones (MLs)
 pour-on products, 1167
 sustained release device, 1115–1116
 toxicity, 179

J

Januvia, 772
 Joint Expert Committee on Food Additives (JECFA), 1476
Journal of Biological Chemistry, 4
Journal of Pharmacology and Experimental Therapeutics, 4
Journal of the American Veterinary Medical Association, 1476
Journal of Veterinary Pharmacology and Therapeutics (JVPT), 5
 juvenile-hormone analogs (JHAs), 1183
 juxtaglomerular cells, anatomy of, 598f

K

K9 Advantix™, 1173
Kahun Papyrus, 3
 kanamycin, 889–890
 structure of, 879f
 kaolin–pectin, 1262–1263
 keratinization, 1279
 keratoconjunctivitis sicca (KCS), 1232
 sulfonamides and, 805
 keratomycosis, in horses, 1328
 ketamine, 187, 260f, 263
 adverse effects/contraindications, 263
 bronchodilating properties of, 261
 cardiovascular effects, 261
 chemistry, 260
 CNS effects of, 261
 in different species, 262t
 dose, 263
 history, 259–260
 metabolism, 262
 pharmacokinetics, 262
 preparation, 260
 salivation stimulation of, 261
 species differences, 264
 ketoacidosis, 575–576
 ketoconazole, 752f, 754, 993t, 994, 996–997
 adverse effects, 996
 clinical use, 996
 interactions, 997
 pharmacokinetics, 994, 996
 spectrum of activity, 994
 structure of, 1004f
 ketoprofen, 471f, 1368
 kidneys
 cardiac glycosides and digitalis with, 508–509
 factors regulating function of, 597–600

antidiuretic hormone, 600
 cyclooxygenase, 600
 renin–angiotensin–aldosterone system, 597–600, 599f
 sympathetic nervous system, 600
 physiology of, 593–600, 594f, 596f
 epithelial transport and secretion, 600
 nephron function, 593–597, 595f, 596f
 kinesis, 170
Klebsiella pneumoniae carbapenemase (KPC), 828

L

labeling error, 1451
 labor induction, oxytocin for, 681
 lacrimogenics, for ocular disease, 1329
 lactic acidosis, 575
 lamivudine, 1014–1015
 clinical use, 1015
 pharmacokinetics, 1015
 larval development assay (LDA), 1109
 lasalocid, 1147–1148, 1147f
 L-asparaginase, 1212–1213
 laudanosine, 200
 law of mass action, 24
Lawsonia intracellularis, 1267
 laxatives and cathartics, 1270, 1270t
 bulk laxatives, 1270–1271, 1271t
 lubricant laxatives, 1271
 saline cathartics, 1270
 stimulants, 1270
 stool softeners, 1271
 lazaroids, 749
 L-deprenyl, 752f, 754–755
 leflunomide, 1238
 adverse effects, 1238
 indications and clinical uses, 1238
 leishmaniasis, drugs for, 1130t
 leucovorin, 1207
 leukeran. *see* chlorambucil
 leukotriene inhibitors, 1314
 leukotriene receptor blockers, 1314
 levamisole, 1055–1058, 1066
 anthelmintic spectrum, 1057
 dosages, 1057
 formulations, 1057
 immunomodulatory effects, 1057–1058
 metabolic pathways of, 1055f
 mode of action, 1055–1056
 pharmacokinetics, 1056–1057
 routes of administration, 1057
 safety and toxicity, 1058

levetiracetam, 407–408
 adverse effects, 408
 clinical use, 407–408
 pharmacokinetics, 407
 levobupivacaine, 383
 levofloxacin, 953
 levothyroxine, 708–712, 709t
 dosage considerations for, 710–711
 dosages
 for cats, 712
 for dogs, 711–712
 for horses, 712
 quality control of, 710
 LFRs (Livestock Food Reports), 1452
 lidocaine, 250, 251, 381–382, 548–549, 1253
 behavioral changes attributed to, 382
 in food animals, 1369–1370
 pharmacokinetics of, 381
 pharmacological and nonpharmacological features, 381
 physical–chemical properties and pharmacological properties of, 376t
 uses, 382
 ligand-gated ion channels, 67
 lincomycin, 926–927
 absorption and distribution, 926
 adverse effects and precautions, 926–927
 chemical structures of, 925f
 clinical use, 927
 formulations, 926
 mechanism of action and spectrum, 926
 metabolism and excretion, 926
 regulatory considerations, 927
 source and chemistry, 926
 lincomycin methyl, 1155f
 lincomycin–spectinomycin, 927
 lincosamides, 925–926, 1155–1156, 1155f
 clindamycin, 925f, 927–930
 lincomycin, 925f, 926–927
 lindane, 1470
 linezolid, 940
 lipid and carbohydrate metabolism, thyroid hormones influence on, 706
 lipid-soluble drugs, 12
 lipid : water partition coefficient, 10
 lipocortin, 734
 lipooxygenase inhibitor, 1314

1508 | Index

- liquid chromatography (LC), 1442, 1443
- liquid–liquid extraction (LLE), 1441
- liquid petrolatum, 1271
- liver
- bile secretion in lobule of, 37f
 - drug localization and
 - biotransformation in, 32
 - relationship between blood flow and hepatic clearance, 35, 35f
 - liver fluke, 1085–1086. *see also* antitrematodal drugs
- L-lysine, 1020
- lobendazole, 1039
- local anesthetics, 183–184
- activity-dependent blockade, 371
 - chemical properties
 - amino-ester vs amino-amide classes, 373
 - effect of local pH, 373–375
 - stability and formulations, 375–376
 - stereoisomerism, 375
 - clinical uses in veterinary medicine, 369–370
 - differential effects on nerve fibers, 371–373
 - drug interactions, 378
 - general ADME considerations, 377–378
 - major classes of, 373f
 - mechanism for, 371–373
 - metabolic degradation of, 378
 - model for sodium channel blockade by, 372f
 - for ocular disease, 1330–1331
 - onset and duration of action, 376–377
 - physical–chemical properties and pharmacological properties of, 376t
 - regulatory issues of, 380–381
 - topical use of, 370
 - toxicity of
 - cardiovascular system, 380
 - central nervous system, 379–380
- logit, 81
- lomustine. *see* cyclohexylchloroethylnitrosurea (CCNU)
- long-acting rodenticides, 635
- loop diuretics
- absorption and elimination of, 607
 - chemistry/formulations of, 605–606
 - mechanisms and sites of action, 606
 - therapeutic uses, 608–610
 - toxicity, adverse effects, contraindications, and interactions, 607–608
- loop of Henle, 27, 595–596, 595f, 598f
- loperamide, 1114, 1264–1265
- lorazepam
- behavioral responses of, 426–427
 - chemical name, 334–335
 - molecular formula, 334
 - regulatory information, 335
- low-molecularweight heparin (LMWH), 629, 630–632
- dalteparin (Fragmin), 631–632
- enoxaparin, 632
- L-triiodothyronine, synthetic, 709t, 712–713
- lubricant laxatives, 1271
- lufenuron, 1007–1008, 1183
- Lutalyse, 678t
- lymphocytic–plasmacytic colitis, 1269
- lysergic acid diethylamide (LSD), 1398
- M**
- macrocyclic lactones (MLs), 1064, 1102
- and ABC transporters, interactions between, 1114–1115
 - ecotoxicological impact, 1121
 - as ectoparasiticides, 1175–1177, 1175t
 - chemistry, 1175–1176
 - efficacy, 1176–1177
 - mechanism of action, 1176
 - pharmacokinetics, 1176
 - safety/toxicity, 1177
 - general pharmacology of, 1102–1104
 - mechanism of action, 1104–1106, 1105f
 - pharmacokinetic–
 - pharmacodynamic relationship, 1109–1111
 - pharmacokinetics of, 1106–1109
 - drug and host-related factors affecting, 1116–1120, 1118f, 1119f
 - exchange between bloodstream and target tissues, 1106–1108, 1106f, 1107f
 - hepatic metabolism, 1108–1109
 - preparations available, 1115–1116
 - resistance to, 1113–1114
 - safety and toxicity, 1120–1121
 - therapeutic uses, 1111
- dogs and cats, 1113
- horses, 1112
- ruminants, 1111–1112
- swine, 1112
- tissue residues and withdrawal times, 1120
- macrolide antibiotics, 912, 912t
- adverse effects and precautions, 920
 - antibacterial activity of, 915
 - azithromycin, 924–925
 - clarithromycin, 923
 - drug interactions, 920
 - erythromycin, 920–921
 - gamithromycin, 923
 - immunomodulatory effects, 916–918
 - interpretive criteria for, 916t
 - mechanism of action, 915
 - pharmacokinetic–
 - pharmacodynamic properties, 916–917, 917t
 - pharmacokinetics, 918–920, 919t
 - absorption and distribution, 918–920
 - metabolism and excretion, 920
 - resistance to, 915
 - source and chemistry, 912–915
 - spectrum of activity, 915–916, 916t
 - structure of, 913, 913f, 914f
 - tildipirosin, 923–924
 - tilmicosin, 922
 - tulathromycin, 922–923
 - tylosin, 921–922
- macula densa, anatomy of, 598f
- maduramicin, 1147f, 1148
- magnesium hydroxide, 1255, 1256
- Malassezia* dermatitis, terbinafine for, 1007
- male infertility, hCG for, 677–679
- mammalian target of rapamycin (mTOR), 1232
- mammals, drugs in, 1397
- farmed/domestic species, 1397–1398
 - small/pocket pets/rodents, 1397
 - zoo/marine mammals, 1398–1400
- mammary gland, oxytocin function in, 680
- Mannheimia hemolytica* pneumonia, 816
- mannitol
- absorption and elimination of, 603–604
 - for prophylaxis of acute renal failure, 604–605

Manual of Operative Veterinary

- Surgery*, 183
- manufacturing defect, 1451
- manufacturing process
- direct compression, 106
 - extrusion, 106
 - factors influencing product
 - dissolution, 106–107
 - roller compaction, 106
 - slugging, 106
 - tableting processes, 106
 - wet/dry granulation, 105–106
- marbofloxacin, 954t, 955f, 973
- marcfortine, 1069
- marketing exclusivity, for new animal drug, 1409
- maropitant, 1248–1249
- masitinib, 1215
- mass spectrometry (MS), 1442, 1443
- mast cells, 1304
- materia medica*, 3, 5
- mavacoxib, 470, 471f
- maximum residual limits for
 - veterinary drugs (MRLVD), 1426
- Maximum Residue Level (MRL), 1360
- MDR-1* deficient dogs, 179
- mebendazole, 1036f, 1049. *see also* benzimidazoles
- mecasermin, 664
- mechlorethamine, 1201, 1201f
- medetomidine, 345f, 347, 348t
- medical devices, 1407–1408
- medication control programs, 1439. *see also* performance animals, medication control programs in
- medication errors, 1451–1452
- mefenoxam, 1009–1010
- meglumine antimonate, 1136
- melarsomine, 1064
- melengestrol acetate (MGA), 683
- meloxicam, 471f
 - in food animal, 1368
- melphalan, 1202, 1202f
- menadiol, 637
- menadione, structure of, 633f
- meperidine, 176, 313
 - analgesic effects of, 312–313
- mepivacaine, 376t, 383
- 6-mercaptopurine (6-MP), 1235
- meropenem, 849
- mesalamine, 811, 1268, 1268f, 1268t
- mesna (2-mercaptoethanesulfonate), 1200, 1234
- metaanalysis, 1353
- metabolic acidosis, 574–576, 575f
- metabolic alkalosis, 576
- metabolic effects, of glucocorticoids, 742
- metabolism, drug, 32–33, 33t
 - aminoglycosides, 883
 - azathioprine, 1235, 1235f
 - benzimidazoles, 1038–1042
 - cephalosporins, 843
 - chloramphenicol, 905
 - clindamycin, 929
 - florfenicol, 910
 - fluoroquinolones, 966
 - macrolide antibiotics, 920
 - penicillins, 834
 - pharmacogenetics of, 1337–1339
 - sulfonamides, 804–805
 - tetracyclines, 864
- metabotropic receptors, 171
- metaproterenol, 1305
- metered-dose inhalers, 1306, 1312–1313, 1312t
 - in horses, use of, 1313
 - in small animals, use of, 1313
- metformin, 770
- methacholine, 156
- methantheline, 162
- methenamine
 - (hexamethylenetetramine), 938
- methicillin, 835
- methicillin-resistant *Staphylococcus aureus* (MRSA), 835
- methicillin-resistant *Staphylococcus pseudintermedius* (MRSP), 957
- methimazole (MMI), 715, 716–718, 716t
 - adverse effects of, 716–717
 - diagnostic scintigraphy, 718
 - monitoring of patients on, 718
 - pharmacokinetics and pharmacodynamics of, 716
 - transdermal, 717–718
- methohexital, 248, 249f, 249t, 250–251
 - dose of, 254t
 - effects on dogs, 254
 - generalized excitement and activation of epileptic foci, 251
 - regulatory information, 250t
- methoprene, 1166, 1170, 1183
- methotrexate (MTX), 1206–1207, 1207f, 1208f
- methoxyflurane, 228
 - advantages, 231
 - biotransformation, 231
 - pharmacokinetics, 231
 - renal failure and, 231
- rubber or plastic/gas partition
 - coefficient of, 219t
 - solubility of, 218t
 - undesirable effects of, 231
 - vapor pressure of, 228t
- methscopolamine, 1264, 1264t
- methylatropine, 162
- methylnaltrexone, 1254
- methylprednisolone, 740t
- methylprednisolone acetate, 1269
- methylthioinosine monophosphate (MeTIMP), 1235
- methylxanthines, 614, 1307–1308
 - adverse effects, 1309
 - antiinflammatory effects, 1308
 - clinical use, 1309–1310
 - drug interactions, 1309
 - formulations, 1308
 - pharmacological effects, 1308
- metioprime, pharmacokinetics of, 804t
- metoclopramide, 680, 1247, 1250
 - adverse effects, 1247
 - antiemetic effects, 1247
 - pharmacokinetics, 1247
- metomidate, 271f
 - chemistry, 271
 - dose, 272
 - drug availability, 272
 - history, 271
 - indications for, 271
 - mechanism of action, 271
 - pharmacokinetics, 271
 - physiology, 271–272
 - preparation, 271
 - regulatory information, 272
 - species differences, 272
- metoprolol, 146, 147, 546
- metronidazole, 1128, 1131, 1133–1134, 1262
 - benzoate, 1131
 - chemical structure of, 1134f
 - clinical use, 1133–1134
- metronidazole-responsive diarrhea, 1265–1266
- metronomic chemotherapy, 1193
- mexiletine, 549
- Meyer–Overton rule, 185
- Michaelis–Menten enzyme kinetics, 28
- Michaelis–Menten equation, 69
- miconazole, 1009
- microglia, 178
- Microzide, 667
- Midamor, 611
- midazolam, 404

1510 | Index

- midazolam maleate
 chemical name, 334
 dose, 334
 molecular formula, 334
 regulatory information, 334
- migration inhibition assay (LMIA), 1109
- milbemycin oxime, 1102, 1169t, 1177
- milbemycins, 1102, 1104, 1175. *see also* macrocyclic lactones (MLs)
- milk discard time, 1469, 1476
- milk letdown, oxytocin for, 681
- milrinone, 517
- mineralocorticoid, 740t
- mineralocorticoid receptor (MR), 71
- mineralocorticoid receptor antagonists, 612–614
 absorption and elimination of, 613
 chemistry/formulations of, 612–613
 mechanisms and sites of action, 613
 therapeutic uses, 613–614
 toxicity, adverse effects, contraindications, and drug interactions, 613
- mineralocorticoid receptor blockers, 520–522
 clinical uses, 521–522
- mineralocorticoids, 750–751
 history of, 750
 preparations and properties of, 751
 secretion and mechanism of action of, 750
 side effects of, 751
 structure of, 751f
 therapeutic use of, 751
- mineral oil, 1271
- minimum alveolar concentration (MAC), 222, 222t, 303
 cortical function and, 223
 volatile anesthetic concentrations and, 223
- minimum inhibitory concentration (MIC), 827
- minocycline, 178, 859f, 859t, 869
 pharmacokinetic parameters of, 863t
- minor food-producing animals, veterinary pharmaceuticals in, 1345
 approval process for use of, 1345–1346
 considerations and challenges, 1345
 FDA-approved drugs, 1346
 for aquaculture species, 1349t
 for cervids/other ruminants, 1348t
 for small ruminants, 1347t
- legislation and policies supporting availability of, 1346–1350
- Animal Medicinal Drug Use Clarification Act, 1346–1348
- Compliance Policy Guide (CPG), 1348–1349
- Minor Use and Minor Species Animal Health Act, 1349–1350
- programs supporting use of, 1350–1351
- Food Animal Residue Avoidance and Depletion Program, 1351
- Minor Use Animal Drug Program, 1350–1351
- withdrawal intervals, estimation of, 1351–1355
- allometric scaling, 1353–1354
- comparative pharmacokinetics, 1351–1353
- species grouping, 1354
- in vitro and molecular studies, 1354–1355
- Minor Use and Minor Species (MUMS) Animal Health Act, 1349–1350, 1401, 1422–1423
- conditional approval, 1350
- designation of drugs, 1350
- indexing, 1350
- Minor Use Animal Drug Program, 1350–1351
- Miostat[®], 157
- mirtazapine, 435, 1249–1250
- misoprostol, 1261–1262
- mitotane, 752–753
- mitoxantrone, 1205–1206, 1206f
- mivacurium, 198, 200
- MLs. *see* macrocyclic lactones
- The Modern Horse Doctor*, 183
- monensin, 1147f, 1148
- monepantel, 1071–1072
- Moniezia expansa*, 1046
- Monitored Adverse Reaction Committee (MARC) meeting, 1454
- monoamine oxidase inhibitors (MAOIs), 175, 435–436
- monoclonal antibodies (MAbs), 1214
- monoethylglycine xylylidide (MEGX), 381
- MonteCarlo simulations, 83f, 84
- montelukast, 1314
- morantel, 1058, 1059f, 1060
- morphine, 178, 312
 analgesic effects of, 312–313
 as antitussive, 1302
- mosapride, 1251
- motility modifiers, for diarrhea, 1263–1264
- Motilium, 680
- moxidectin, 1102, 1104, 1104f, 1107–1108, 1108f, 1111f, 1116, 1175, 1177
- moxifloxacin, 953, 973
- MSRT (morantel slow release trilamine bolus), 1060
- Mucinex[®], 1315
- mucosal protectants and adsorbents, 1262–1263
 bismuth subsalicylate, 1263
 kaolin–pectin formulations, 1262–1263
- multiple drug resistance (MDR), 12, 1196
- muscarinic receptor antagonists, 159–161
 antimuscarinic effects of, 161
 clinical uses, 161
 pharmacological effects, 160–161
- mustargen. *see* mechlorethamine
- mutation, 1333
- myasthenia gravis, 1237
- mycophenolate, 1237–1238
 adverse effects, 1238
 clinical use, 1237
 pharmacokinetics/
 pharmacodynamics, 1237
- mydriasis, 188
- mydriatics, 1330
- myocardial contractility, with digitalis and cardiac glycosides, 505
- myxedema coma, thyroid hormones for treatment of, 714–715

N

- naftifine, 1006
- nalbuphine, 308
- nalidixic acid, 1386
- N-alkane anesthetics, 226
- nalmefene, 308
- nalorphine, 308
- naloxegol, 1254
- naloxone, 308
- naltrexone, 308
- nandrolone, 685
- naphtalophos, 1061
- naphthalophos, 1061

- narasin, 1147f, 1148
 narcotics, 1430
 natamycin, 1010
 National Antimicrobial Resistance Monitoring System (NARMS), 958
 National Coordinating Council for Medication Error Reporting and Prevention (NCCMERP), 1451–1452
 National Formulary (NF), 96
 National Human Genome Research Institute, 1332
 National Pesticide Information Center (NPIC), 1453
 National Research Support Project #7 (NRSP-7). *see* Minor Use Animal Drug Program
 National Residue Program (NRP), 1470
Naunym-Schmiedeberg's Archives of Pharmacology, 4
N-butylscopolamine bromide (NBB), 161–162
N-butylscopolammonium bromide, 1264, 1310
 NCCMERP. *see* National Coordinating Council for Medication Error Reporting and Prevention
 nebulization, 1306
 nedocromil sodium, 1307
 nemadectins, 1175
 neomycin, 890
 structure of, 879f
 neonicotinoids, 1168
 dinotefuran, 1174
 imidacloprid, 1172–1173
 isoxazoline, 1174–1175
 nitenpyram, 1173
 spinosad, 1174
 neosporosis, drugs for, 1130t
 neostigmine, 158–159, 205, 1252–1253
 for reversal of neuromuscular blockade, 210
 nephron
 atomy of, 594f
 function of, 593–597
 ion and water movement, 596f
 structure of, 26–27, 27f
 Neptazane, 601
 netobimin, 1039, 1048
 neural NO synthase (nNOS), 121
 neuroendocrine effects, of cardiac glycosides and digitalis, 507
 neurokinin, 1245
 neurokinin-1 (NK-1), 1248
 neurokinin receptor (NK), 1302
 neuromuscular blocking (NMB)
 agents, 194
 action mechanism of, 194
 characteristics of, 199t
 clinical use of, 208–211
 competitive nondepolarizing agents, 195, 198–202, 199t
 asymmetric mixed-onium chlorofumarates, 201
 atracurium, 199–200
 doxacurium, 200
 mivacurium, 200
 pancuronium, 200
 rocuronium bromide, 201
 trisquaternary ether NMB agent, 201–202
 vecuronium, 200–201
 depolarizing agents, 195, 202–204
 phase I block, 202
 phase II block, 202
 development of, 194–195
 drug interactions, 208
 impulse transmission at somatic NMJ, 195
 pharmacological considerations, 198
 physiological and anatomic considerations, 195–196, 195f
 indications for, 194
 margin of safety of neuromuscular transmission, 209
 pharmacological effects of, 204
 autonomic effects, 206–207
 cardiovascular effects, 207–208
 central nervous system, 207
 histamine release, 207
 ocular effects, 208
 serum potassium, 208
 skeletal muscle, 204–206, 204f, 205f
 reversal of blockade, 209–210
 acetylcholinesterase inhibitors, 210
 sugammadex, 210–211
 sporadic use of, 194
 neuromuscular junction (NMJ), 194
 neuropeptide Y (NPY), 120
 neurosteroid anesthetics
 adverse effects/ contraindications, 269
 classification, 267
 dose, 269
 drug availability, 269
 history, 267
 indications, 268
 mechanism of action, 267
 metabolism, 269
 overdosage/acute toxicity, 269
 pharmacokinetics, 268, 268t
 physiological/pharmacodynamic effects, 268
 allergic reactions, 268
 analgesic effects, 268
 cardiovascular effects, 268
 CNS effects, 268
 following cesarean section, 268
 muscular effects, 268
 respiratory effects, 268
 regulatory information, 269
 species differences, 269
 neurotransmitters, 168, 170–171, 170f
 and receptors, 171–172
 agmatine, 177
 amines, 174–176
 amino acids, 172–174
 endocannabinoids, 177
 peptides, 176–177
 purines, 177
 neutral endopeptidase inhibitors, 615
 New Animal Drug Applications (NADAs), 1346, 1361, 1407, 1412–1419
n-3 fatty acids, for colitis, 1269–1270
N-halamines, 784
 nicarbazin, 1145–1146, 1145f
 niclofolan, 1087, 1088
 niclosamide, 1082, 1082f
 nicotine injections, 224
 nicotinic cholinergic receptor, 72, 194, 196–198, 196f
 NMB agents and, 197, 197f
 nicotinic receptors (nAChRs), 174
 nifurtimox, 1139–1140, 1140f
 nitarsonic, 1137
 nitazoxanide (NTZ), 1069, 1159
 nitenpyram, 1173
 efficacy, 1173
 pharmacokinetics, 1173
 safety/toxicity, 1173
 nitric oxide (NO), 121
 nitrobenzamides, 1144–1145, 1145f
 aklomid, 1145, 1145f
 dinitolmid, 1145, 1145f
 nitrofurans, 934–935
 as antiprotozoan drugs, 1139–1140
 in food-producing animals, 1470
 nitrogen, 389–390

1512 | Index

- nitrogen mustard, 1191, 1200–1202
 chlorambucil, 1201–1202, 1201f
 cyclophosphamide, 1200, 1200f
 ifosfamide, 1200–1201, 1200f
 mechlorethamine, 1201, 1201f
 melphalan, 1202, 1202f
- nitroglycerin, 524–526
- nitroimidazoles, 1128, 1129t, 1134f
 benznidazole, 1135
 metronidazole, 1128, 1131, 1133–1134
 ronidazole, 1135
 secnidazole, 1135
 tinidazole, 1134–1135
- nitroprusside, 524–526
- nitrosoureas, 1202
- nitrosteroids, 749
- nitrous oxide
 analgesic actions of, 224
 biotransformation, 231
 cardiovascular actions of, 232
 cerebral blood flow, in, 232
 CNS, effects of, 231–232
 kidney, effects of, 232
 liver, effects of, 232
 potency of, 231
 respiratory system, effects of, 232
 vapor pressure of, 228t
- nitrovasodilators, 524–526
 adverse effects, 526
 clinical uses, 525–526
 mechanism of action, 524
 pharmacokinetics, 524
 tolerance, 526
- nitroxylnil, 1087–1088, 1087f
 administration of, 1088
 chemical structure of, 1087f
 mechanism of action, 1088
 pharmacokinetic behavior, 1088
 side effects, 1088
- nizatidine, 1256–1257, 1256t
- Nizoral, 754
- NK-1 receptor antagonists, 1248–1249
 adverse effects, 1249
 clinical use, 1249
 pharmacokinetics, 1248–1249
- N*-methyl *d*-aspartate (NMDA receptor), 172, 178
- nociceptors, 168, 182
- nonadrenal disorder management, glucocorticoids for, 729
- nonadrenergic–noncholinergic (NANC) fibers, 121
- nonadrenergic–noncholinergic neurons, 121
- nonhuman primates, morphine effects on, 296
- nonlinear zero order kinetics, 29
- nonsteroidal antiinflammatory drugs (NSAIDs), 65, 606, 703
 additional actions of, 481
 chemical classification of classical, 470t
 SAID, 470–472
 eicosanoids and, 467–468
 in food animals, 1370
 and glucocorticoids, 735f, 748
 history of, 469–470
 for ocular inflammation, 1326, 1326t
 pharmacodynamics
 central sites and mechanisms of action of, 480–481, 482t
 efficacy, potency, and sensitivity of COX inhibition, 478–480
 inhibition of COX and 5-LO, 477–478, 478t
 pharmacokinetics of, 472t
 absorption, 472
 distribution, 472–473
 drug residues, 476–477
 excretion and metabolism (elimination), 473–476
 species differences in, 474, 475t
 terminal half-life of, 474t
 for respiratory diseases, 1313–1314
 selection of dose and dose regimen, 81
 therapeutic uses of
 acute pain and inflammation, 487–488, 488t
 antihemostatic actions of aspirin, 489
 antipyresis, 489
 calf and piglet scours, 491
 cancer, 489–490
 chronic pain, 488–489
 mastitis, metritis, and endotoxemia, 490
 neurodegenerative diseases, 491
 ophthalmic uses, 491
 respiratory diseases, 490–491
- toxicity of
 bone, tendon, and ligament healing, 486
 cardiovascular system and blood cells, 485–486
 gastrointestinal, 482–484
 hepatotoxicity, 485
 local irritancy, 484
 nervous system, 487
- renal, 484–485
 reproductive system, 487
 respiration, 487
 skin, 487
 soft tissue healing and repair, 486–487
- No Observable Effect Level (NOEL), 1359
- norepinephrine (NE), 136, 175, 421, 1304, 1304t
- novobiocin, 930–931
- noxious stimulus, 181
- Noyes–Whitney equation, 106
- NSAIDs. *see* nonsteroidal antiinflammatory drugs
- nuclear thyroid hormone receptors, 704–705
- nucleoside analogs
 acyclovir and valacyclovir, 1010–1012
 cidofovir, ganciclovir, and valganciclovir, 1013
 cytarabine and vidarabine, 1014
 idoxuridine and trifluridine, 1013–1014
 penciclovir and famciclovir, 1012–1013
 ribavirin, 1014
 zidovudine, PMEAs, and lamivudine, 1014–1015
- nucleoside reverse transcriptase inhibitor (NRTI), 1014
- nutraceuticals, 439
- nystatin, 1010
- O**
- occupancy theory, 74
- Occupational Safety and Health Administration (OSHA), 1199
- oclacitinib, 1233
 clinical use, 1233
 mechanism of action, 1233
 pharmacokinetics, 1233
 safety and adverse effects, 1233
- octreotide, 661–662
- ocular globe, 1321
- Office of Minor Use and Minor Species Animal Drug Development (OMUMS), 1422–1423
- Office of New Animal Drug Evaluation (ONADE), 1454
- oil/gas partition coefficient of anesthetics, 219
- ointments, 1322

- oleandomycin, 913
 oligodendrocytes, 178
 omega interferon, 1020
 omeprazole, 1258–1259, 1258t, 1262, 1433
 ondansetron, 176, 1247
 ophthalmic applications, of
 glucocorticoids, 749
 ophthalmic pharmacology, 1321
 anatomy and physiology related to, 1321
 corticosteroid formulations, 1325t
 drug levels in tissues, factors influencing
 administration factors, 1322–1323
 drug factors, 1322
 ocular factors, 1321–1322
 glaucoma and, 1323–1325
 infections and, 1326–1329
 inflammation and, 1325–1326
 lacrimogenics, 1329
 local anesthetics, 1330–1331
 mydriatics and cycloplegics, 1330
 topical administration, 1322, 1323t
 opiate antagonists, 1253–1254
 opioid peptides, 177
 opioids, 437
 advantage of, 281
 adverse effects of, 281
 agonists
 alfentanil, 303
 apomorphine, 304
 carfentanil, 303–304
 codeine, 298
 etorphine, 303–304
 fentanyl, 300–303
 heroin, 298–299
 hydrocodone, 297–298
 hydromorphone, 296–297
 meperidine (pethidine), 300
 methadone, 299–300
 morphine, 294–296
 oxycodone, 298
 oxymorphone, 297
 propoxyphene, 304
 remifentanil, 303
 sufentanil, 303
 antagonists
 central, 309
 diprenorphine, 309
 nalmeferone, 308
 naloxone, 308
 naltrexone, 308
 peripheral, 309
 chemical properties, 290t
 clinical pharmacology
 analgesia, 291
 as anesthetic, 291
 as antidiarrheal drug, 291
 antitussive use, 291
 effects on temperature regulation, 292
 in patients with head trauma, 292
 in treatment of congestive heart failure, 291
 contraindications, warnings, and drug interactions, 292–294
 for diarrhea, 1264–1265, 1264t
 dose, 312t
 emetic properties, 288–289
 in food-producing animals, 294
 history of, 281
 interactions between, 292
 with drug clearance, 293
 with other analgesics and antidepressants, 293–294
 in nonmammal species, 311–313, 312t
 partial and mixed, 304–308
 buprenorphine, 304–306
 butorphanol, 307
 nalbuphine, 308
 nalorphine, 308
 pentazocine, 308
 pharmacodynamics, 285–290
 antitussive effect, 288
 cardiovascular effects, 287–288
 central nervous system excitation, 286
 gastrointestinal effects, 288–289
 gastrointestinal motility, 289
 immune system effects, 290
 respiratory depression, 285
 supraspinal pathways, 285
 tolerance and dependence, 290
 urinary tract, 289
 pharmacokinetics of, 287t, 290–291
 physiology of, 282–285
 potency of, 296t
 as preanesthetics, 187, 1302
 receptor density in different species, 312t
 receptor types and their associated effects, 284t
 role in analgesia, 281, 285–286
 routes of administration
 epidural, 311
 peripheral, 311
 therapeutic uses in animals, 282t
 United States drug scheduling of, 283t
 orbifloxacin, 954t
 organophosphates, 1061–1062, 1170t, 1180–1182
 chemistry, 1181
 efficacy, 1181
 mechanism of action, 1181
 safety/toxicity, 1181–1182
 oritavancin, 936
 ormetoprim, 1153f, 1154
 pharmacokinetics of, 804t
 oseltamivir, 1015–1016
 adverse effects, 1016
 clinical use, 1016
 osmotic compensation, 604
 osmotic diuretics, 603–605
 absorption and elimination of, 603–604
 adverse effects of, 604
 chemistry/formulations of, 603
 contraindications of, 604
 drug interactions of, 604
 mechanisms and sites of action, 603
 therapeutic uses of, 604–605
 Ostwald ripening, 90
 ototoxicity, aminoglycosides and, 884
 outsourcing facility, 1431
 Ovagen, 678t
 Overnight Rapid Beef Identification Test (ORBIT), 1472
 over-the-counter (OTC) drugs, 1430
 ovulation induction, gonadorelin for, 676
 Ovuplant, 676
 oxantel, 1058, 1059
 oxazepam, behavioral responses of, 426–427
 oxazolidinones, 940
 adverse effects, 940
 clinical use, 940
 drug interactions, 940
 oxfendazole, 1036f, 1049. *see also*
 benzimidazoles
 oxibendazole, 1049
 oxidation, 92
 Oxject, 681
 oxolinic acid, 1385
 oxybarbiturates, 248
 oxyclozanide, 1089f, 1091, 1092f
 oxygen carrier, 585
 oxyglobin, 586–587
 oxymetazoline, 1315

1514 | Index

- oxytetracycline, 859f, 859t, 867–868, 1140, 1327
in aquatic animals, 1381, 1384, 1386–1397
pharmacokinetic parameters of, 862t
- oxytocin, 668, 678t, 680–681
adverse reactions and side effects, 681
clinical uses of, 681
function of, 680
mechanism of action, 681
structure of, 680
- P**
- pachycurares, 199
- paclitaxel, 1211, 1211f
- pain, 181
acute, 182
amantadine for, 1017
in animals, 181–182
chronic, 182–183
mechanisms of, 182–183, 182f
- Palladia, 773
- pancuronium, 197, 198, 200
characteristics of, 199t
- paraherquamide, 1069
- parasympathetic nervous system (PSNS), 113, 115f–116f, 116–119, 117t, 120–121, 151
ganglionic nicotinic receptors, 121
- parasympatholytics, for ocular disease, 1330
- parasympathomimetics, 151
for glaucoma, 1325
for ocular disease, 1329
- parathyroid hormone (PTH), 561
receptors, 596
- parecoxib, 470, 471f
- paromomycin, 891, 1138–1139, 1138f
- paroxetine, 433
- partition coefficients of API, 91
- parturition
prostaglandins analogs for, 681
reproductive hormonal drugs for, 686
- parvaquone, 1141f, 1143
- P450 assays, 1354
- patent term restoration, 1409
- Pausinystalia yohimbe*, 144
- pegvisomant, 662
- penciclovir, 1012–1013
adverse effects, 1013
clinical use, 1013
pharmacokinetics, 1012–1013
spectrum of activity, 1012
- penems. *see* carbapenems
- penetration-enhancing vehicles, 1434
- penicillin-binding proteins (PBPs), 826
- penicillin G, 1360
- penicillins, 11
adverse effects, 836
aminopenicillins, 829, 834–835
dosages for, 835t
elimination of, 835
formulations of, 835
antimicrobial activity, 829–830
antistaphylococcal, 829, 835
 β -lactamase inhibitors, 836–838
extended-spectrum, 829–830, 835–836
general pharmacology, 828–829
structure, 829, 829f
unitage, 828–829
natural, 829, 834
formulations, 833t, 834
penicillin G, 834
penicillin V, 834
pharmacokinetics, 830, 832t, 833–834, 833t
absorption, 830, 833
distribution, 833–834
elimination, 833
metabolism, 834
special species considerations, 836
susceptibility testing, 830, 831t
- pentamidine isethionate, 1157f, 1158
- Pentastarch (PEN), 582t
- pentavalent antimonials, 1135–1136, 1136f
meglumine antimonate, 1136
sodium stibogluconate, 1136, 1136f
- pentazocine, 308
- pentobarbital, 248, 249f, 249t, 250
adverse effects on fetus and neonates, 252
cardiovascular activity of, 250
delivery mode of, 250
dose of, 254t
duration of action of, 250
euthanasia solutions, 250
regulatory information, 250t
- pentoxifylline, 1307
- Pen Tsao*, 3
- Penzyme III, 1472
- peptides neurotransmitters, 176–177, 176t, 177t
- Pepto Bismol[®], 1263
- perfluorochemicals, 585–586
- performance animals, medication control programs in, 1439
- and controversies
anabolic steroids, 1445–1446
furosemide, 1444–1445
recombinant products, 1446
- drug testing process, 1440
detection, 1442
extraction, 1441
overview, 1442–1443
referee sample analysis, 1443–1444
sample type, 1440–1441
separation process, 1441–1442
- regulatory agencies and stakeholder organizations, 1439
- nonracing drug and medication rules, 1440
- racing animals, 1439–1440
- thresholds, reporting levels, and cutoffs, 1444, 1444t
- withdrawal times, factors affecting, 1444
- peripheral nociceptors, 168
- periventricular nucleus (PVN)
neurons, 731
- permeability coefficient, 10
- permethrin, 1169t, 1179
- pesticides, 1408
- pet food adverse events, reporting of, 1452
- Pet Food Early Warning and Surveillance System (PFEWSS), 1452
- PF1022A, 1070
- PG600, 678t
- P-glycoprotein (P-gp), 12, 179, 1196, 1334–1335
efflux pump, 994
macrocyclic lactones and, 1105–1106
in oral drug absorption, 1334
substrates, 1341t
- pharmaceutic principles
active pharmaceutical ingredient (API), characteristics of, 87–88, 88f
formulation challenges, 87
- pharmacodynamics (PD), 65
alfaxalone, 268
alpha-2-adrenergic antagonists, 353
benzodiazepines, 331–332
butyrophenone, 329
dissociative anesthetics, 260–262
dose and dosage regimen selection, 81–83
in vivo drug selectivity, 79f

- dose titration designs, 77–78, 78f
dose titration vs PK/PD modeling, 78–79, 78f, 79f
down-and up-regulation, 76
inhalation anesthetics, 222–232
neurosteroid anesthetics, 268
nonsteroidal antiinflammatory drugs, 480–481, 482t
opioids, 285–290
PK/PD model building, 79–81, 80f–81f
 fundamental differences between dose-ranging trial and, 79
 in graded concentration response relationship, 80–81
 Hill model, 80
 limitation of, 84
 quantal concentration–response relationship, 80
 rate of change of response over time, 80
 stimulation or inhibition function, 80
PK/PD predictive indices, 82
population, 76–77
population PK/PD, 83–84
types of drug targets, 65–67, 66f
pharmacogenetics, 1332, 1333
 in clinical practice, 1341–1342
 of drug distribution, 1335–1337, 1336f
 of drug excretion, 1339–1340
 P-gp mediated biliary excretion, 1339–1340
 solute carrier-mediated renal excretion, 1340
 of drug metabolism, 1337–1339
 canine, CYP polymorphisms in, 1338
 CYP polymorphisms in other species, 1338
 Phase II metabolic enzymes, 1338–1339
 of drug receptors, 1340
 future directions, 1342
 and idiosyncratic reactions, 1340
 of oral drug absorption, 1334–1335, 1335f
 and protein binding, 1340–1341
pharmacogenomics, 1332. *see also* pharmacogenetics
pharmacokinetics (PK), 65
 acyclovir, 1011
 afoxalaner, 1174
 alfaxalone, 268, 268t
 alpha-2-adrenergic antagonists, 352t
 alpha-2-adrenergic receptor agonists, 343, 344t
 of aminoglycosides, 882–884
 barbiturates, 252–253
 behavior drugs, 416–419
 benzodiazepines (BZDs), 333t
 bromide, 410
 butyrophenone, 329–330
 cephalosporins, 840–843, 841t
 chloramphenicol, 904–905, 905t, 906t
 cisapride, 1251–1252
 of clindamycin, 929t
 cyclosporine, 1230
 dapsone, 1239
 definition, 41
 diazepam, 402–403
 digitalis, 509–510
 dissociative anesthetics, 262
 dosage regimens, 57–62
 adjusting for disease, 60–62, 61f
 constant-dose, interval-extension method (IE), 61, 61f
 constant-interval, dose-reduction (DR), 61
 dosage rate, 59
 efficacy and safety, 60
 loading dose, 58
 maintenance dose, 58
 relative dosage interval, 59
 drug passage across membranes, 10–12
 enflurane, 231
 etomidate, 265–266
 famciclovir, 1012–1013
 fipronil, 1171
 florfenicol, 909–911, 910t
 fluconazole, 997
 flumazenil, 338
 fluoroquinolones, 958, 959t–964t, 965–987
 fluralaner, 1174–1175
 fundamental axioms of, 8–10
 gabapentin, 406
 griseofulvin, 988–989
 guaifenesin, 355
 half-life, 44
 halothane, 230
 imepitoin, 402
 imidacloprid, 1172
 interspecies extrapolations, 62–63, 62f
 itraconazole, 1001
 ketamine, 262
 ketoconazole, 994, 996
 lamivudine, 1015
 language of, 41–43
 levamisole, 1056–1057
 levetiracetam, 407
 lidocaine, 381
 macrolide antibiotics, 917t, 918–920, 919t
 methoxyflurane, 231
 metomidate, 271
 multicompartmental models, 52–53
 mycophenolate, 1237
 neurosteroid anesthetics, 268, 268t
 nitenpyram, 1173
 nitrovasodilators, 524
 noncompartmental models, 53–55
 nonlinear, 55–56
 nonsteroidal antiinflammatory drugs, 472–476, 472t
 oclacitinib, 1233
 one-compartment open model, 44–48, 45f
 absorption in, 46–48, 47f
 clearance, 45f
 C-T profile, 47–48
 equilibrium compartments, 44
 parameters of, 45–46, 46f
 semilogarithmic concentration-time profile for, 45f
 volume of distribution (Vd), 44–45
 opioids, 287t, 290–291
 penciclovir, 1012–1013
 penicillins, 830, 832t, 833–834, 833t
 phenobarbital, 253
 phenothiazines, 325
 phenytoin, 400
 physiological-based pharmacokinetic (PBPK) modeling, 57
 pimobendan, 516
 population, 56–57
 praziquantel, 1083–1085, 1084f
 primidone, 399
 propofol, 257
 and residues, 1473–1476
 rifampin/rifampicin, 932, 932t
 of sulfonamides, 800–805, 801t–804t
 terbinafine, 1006–1007
 tetrahydropyrimidines, 1059–1060
 theophylline, 1308, 1309t
 thiopental, 252–253
 tramadol, 310t, 311

- pharmacokinetics (PK) (*Continued*)
 - tricyclic antidepressants (TCAs), 429–430
 - two-compartment open model, 48–52
 - absorption in, 51
 - clearance, 51
 - data analysis and limitations, 51–52
 - volumes of distribution, 50–51
 - valacyclovir, 1011
 - voriconazole, 1003–1005
 - zidovudine, 1014–1015
 - zonisamide, 408–409
- pharmacology
 - definition of, 3
 - history of, 3–4
 - regulations and standards, 5–6
 - veterinary, 4–7
- pharmacopeia, 3
- pharmacovigilance, 1449–1453. *see also* Center for Veterinary Medicine (CVM)
- Pharmacy Compounding Accreditation Board (PCAB), 1435
- pharmacy, veterinary, 1427, 1428t
 - classification of drugs
 - compounded drugs, 1430
 - controlled substances, 1430
 - drug, definition of, 1429
 - legend (prescription) drugs, 1429–1430
 - over-the-counter (nonprescription) drugs, 1430
 - VFD drug, 1430
 - compounded drugs
 - current status of, 1430–1432
 - potential problems from, 1432–1434
 - transdermal medications for pets, 1434–1435
 - veterinarians and veterinary pharmacists, guidelines for, 1435
 - drug dispensing labeling requirements, 1436–1437
 - extralabel use
 - drugs prohibited for, 1429t
 - regulatory discretion for, 1427
 - requirements for, 1429t
 - legal extralabel use, need for, 1427–1429
 - prescribing controlled substances, 1436
 - inventory records, 1436
 - medical record, 1436
 - storage and security, 1436
 - prescription writing, 1437, 1437t
 - unapproved drugs available by importation, 1435–1436
- Phased Review process, 1421–1422
 - Administrative NADA, 1422
 - presubmission conference, 1422
 - protocol development meetings, 1422
 - standard operating procedures (SOPs), 1422
 - study documentation and submission, 1422
 - study protocols, 1422
 - submissions, 1422
- pheasants, amprolium for, 1144
- phenamidine isethionate, 1157f, 1158
- phencyclidine, 260f
- phenobarbital, 248, 249f, 249t, 250, 395–399
 - adverse effects
 - association with blood disorder, 398
 - on corticosteroid metabolism, 398
 - on fetus and neonates, 252
 - on hormone levels, 398
 - on liver, 397–398
 - clinical monitoring, 399
 - clinical use, 398–399
 - dose of, 254t
 - drug interactions, 397
 - mechanism of action, 396
 - pharmacokinetics of, 253, 396–397
 - regulatory information, 250t
- phenolphthalein, 1270
- phenothiazine, 1245, 1246t
- phenothiazines, 175, 179, 186–187, 324–328
 - acepromazine maleate, 326, 327f
 - analgesic activity of, 326
 - as antiemetic, 326
 - antihistamine properties of, 326
 - chemistry, 324
 - chlorpromazine hydrochloride, 327, 327f
 - contraindications, 328
 - drug interactions, 328
 - hematocrit of animals, effect of, 326
 - indications, 324
 - mechanism of action, 324
 - overdose/acute toxicity, 328
 - phototoxicity properties of, 326
 - physiological effects
 - cardiovascular effects, 325
 - CNS effects, 324–325
 - musculoskeletal effects, 325
 - pharmacokinetics and metabolism, 325
 - respiratory effects, 325
 - platelet aggregation, effect of, 325
 - promazine hydrochloride, 326–327, 327f
 - regulatory information, 328
 - species differences, 327–328
 - thermoregulation with, 325
 - veterinary approved products, 328
- phenothizaine, 1062
- phenothrin, 1179
- phenoxybenzamine, 143
- 2-phenoxyethanol, 392
- phentolamine, 143
- phenylbutazone, 11, 474t
- phenylephrine, 136
- phenylpropanolamine (PPA), 1315–1316
- phenytoin, 250, 400–401
 - clinical use, 400
 - mechanism of action, 400
 - pharmacokinetics, 400
 - therapeutic drug monitoring, 401
- phosmet dips, 1181
- phosphodiesterase enzyme, 1308
- phospholipase A₂ (PLA₂), inhibition of, 734
- photolysis, 92
- photophobia, 118
- pH partitioning phenomenon, 10–11, 11f
- PhRMa website, 1412
- physiologically based pharmacokinetic (PBPK) modeling, 57, 1353
- physostigmine, 158–159
- phytonadione, 637
- pigeons, ronidazole for, 1135
- pigs
 - acepromazine in, 328
 - antimicrobials for diarrhea in, 1266–1267
 - dissociative anesthetics in, 264
 - florfenicol for, 911
 - fluoroquinolones for, 973–974
 - macrocyclic lactones for, 1112
 - ponazuril for, 1151
 - propofol in, 258
 - toltrazuril for, 1150
 - trimethoprim–sulfadiazine for, 815
- pilocarpine, 157
 - for ocular disease, 1329
- pimecrolimus, 1232

- pimobendan, 513–516
adverse effects, 516
clinical application, 514–515
formulations and dosing, 516
mechanism of action, 515–516
pharmacokinetics, 516
- pinocytosis, 693
- piperacillin–tazobactam, 836, 838
- piperazine, 1062–1063, 1063f
dosages, 1062–1063
mode of action, 1062
safety and toxicity, 1063
- piperonyl butoxide, 1171
- piromidic acid, 1386
- piroxicam, 1213
- Pitocin, 678t, 681
- pituitary hormones, 649–668, 651t
anterior, 649–665, 650t
adrenocorticotropin, 651–655
corticotropin-releasing hormone, 649–651
glycoprotein hormones and associated releasing hormones, 655–661
melatonin, 655
somatomammotropins and regulatory hormones, 661–665
posterior, 665–668
antidiuretic hormone, 665–667
oxytocin, 668
- pivampicillin, 835
- planar chromatography, 1441
- plasma
cations and anions in, concentrations of, 557t
hypertonicity, 558
- plasma hormone binding, of thyroid hormones, 698
- plasma membrane transporters, thyroid hormones translocated by, 704
- plasma protein binding, 24–25
assessment of, 25
covalent binding, 24, 26
displacement with, 24–25
dissociation in, 24
hydrogen bonding, 25
noncovalent binding, 24
- plasma volume, in animals, 556t
- plasmin, 628
- pluronic lecithin organogel (PLO), 717, 1434
- p38 MAP kinase inhibitors, 178
- PMEA, 1014–1015
adverse effects, 1015
clinical use, 1015
- poikilothermic animals, 1354
- Poison Prevention Packaging Act, 1436–1437
- polyenes, for ocular infections, 1328
- polyether ionophores, 1146–1147, 1147f, 1368–1369
lasalocid, 1147–1148, 1147f
maduramicin, 1147f, 1148
monensin, 1147f, 1148
narasin, 1147f, 1148
salinomycin, 1149
semduramicin, 1147f, 1148–1149
- PolyHeme, 587
- polyhexamethylene biguanide (PHMB), 784
- polymorphisms, 89, 1333, 1337–1338
- polymyxins, 938–939
- ponazuril, 1150–1151
- population pharmacokinetics, 1352
- posaconazole, 1005–1006
- postantibiotic effect (PAE), 878
- Postapproval Experience (PAE) section, 1454
- Postapproval Monitoring Programs (PAMPs), 1455
- postsynaptic processes, 171
- potassium, 565–569
disorders of balance, 566–569
homeostasis, 565–566
renal regulation of excretion of, 566
- potassium clavulanate, 837
- potassium iodide, 716t, 1008, 1314
- potassium peroxymonosulfate (PPMS), 785
- potency
of drugs, 69–70, 69f, 70f
of inhaled anesthetic, 222
- potentiated sulfonamides, 813
sulfadimethoxine–ormetoprim, 816
trimethoprim–sulfachlorpyridazine, 815
trimethoprim–sulfadiazine, 813–815
trimethoprim–sulfamethoxazole, 815
- pradofloxacin, 953, 954t, 955, 955f
for dogs and cats, 970
- pranlukast, 1314
- praziquantel, 1082–1085
chemical structure of, 1082f
dosage of, 1083
and epsiprantel, 1085, 1086f
- febantel and, 1083
formulations, 1083
mode of action, 1083
pharmacokinetics of, 1083–1085, 1084f
- pyrantel, oxantel and, 1083
safety, 1085
- prazosin, 143, 157, 522
- preanesthetic medications, 186
 α_2 -adrenergic drugs, 187
dissociative drugs, 187
drug classes for, 186t
drug combinations, 187
hypnotic-sedatives, 187
opioids, 187
parasympatholytic (anticholinergic) drugs, 187–188
tranquilizer-sedatives, 186–187
- prednisolone, 740, 740t, 741f, 1214, 1269
for feline asthma, 1311
- prednisone, 740t, 741f, 1269
- pregabalin, 406–407
- premature ventricular contraction (PVCs), 84
- preprothytropin-releasing hormone (preproTRH), 655
- prescription, 1437
for controlled substances, 1437t
for noncontrolled substances, 1437t
writing of, 1437, 1437t
- prescription drugs, 1429–1430
- presynaptic processes, 168, 170–171, 170f
- Primer on the Autonomic Nervous System*, 113
- primidone, 399–400
adverse effects, 400
clinical efficacy, 399–400
clinical use, 400
pharmacokinetics, 399
therapeutic monitoring, 400
- probenecid, 834
- pro-benzimidazoles
administration routes, 1050
anthelmintic spectrum, 1047–1049
chemistry of, 1035–1037, 1036f
disposition kinetics and efficacy of, 1050–1053
drug transfer into target parasites, 1046–1047
febantel, 1048
formulations of, 1050, 1053
netobimin, 1048
pharmacodynamics, 1037

- pro-benzimidazoles (*Continued*)
 pharmacokinetics
 in nonruminant species,
 1044–1046
 in ruminant species, 1037–1044
 withdrawal times, safety, and
 toxicity, 1053–1054
- procainamide, 547
- procaine, 384
- procaine penicillin G, 834
- procarbazine (PCB), 1203–1204,
 1204f
- prochlorperazine, 1245, 1246t
- product defects, 1451
 reporting of, 1451
- production enhancement drugs, 1366t,
 1368–1369
- progesterone, 678t
- progestins, 678t, 683–684
- Proglycem, 773
- proinsulin, 763, 764f
- prokinetic drugs, 1250
 bethanechol, 1252
 cisapride, 1251–1252
 domperidone, 1251
 erythromycin, 1253
 H₂-receptor antagonists, 1253
 lidocaine, 1253
 metoclopramide, 1250
 neostigmine, 1252–1253
 opiate antagonists, 1253–1254
- prolactin (PRL), 664–665, 679–680
 drugs affects, 680
 mechanism of, 679
 regulation of, 679
 structure and function of, 679
 therapeutic uses, 680
- prolactin-inhibitory hormone, 651t
- prolactin-releasing hormone, 651t
- proliferative enteropathy, 1267
- promazine hydrochloride, 326–327,
 327f, 328
- promethazine, 1246, 1246t
- proopiomelanocortin (POMC), 176
- propantheline, 162, 1264, 1264t, 1268,
 1310
- propantheline bromide, 543–544
- proparacaine, 384
- propofol, 138, 188, 255–259, 259t
 adverse effects/contraindications,
 258
 chemistry, 255
 classification, 255–256
 compatibilities and
 incompatibilities, 259
 dose, 259
 induction dose and constant rate
 infusion dose, 259t
 drug availability, 259
 drug interactions, 259
 history, 255
 mechanism of, 256
 metabolism, 257–258
 overdose/acute toxicity, 259
 pharmacokinetics of, 257
 physiological effects
 antioxidant effects, 257
 cardiovascular effects, 256–257
 CNS effects, 256
 muscular effects, 257
 nausea and vomiting, 257
 respiratory effects, 257
 preparation of, 256
 regulatory information, 259
 species differences, 258–259
 structure, 255f
 syndrome, 258
 withdrawal times, 259
- propoxyphene, 304
- propranolol, 145, 146, 546
- propylthiouracil (PTU), 716, 716t
- Proscar, 678t, 685
- prostaglandin analogues, for
 glaucoma, 1324
- prostaglandin (PG)H synthase, 467
- prostaglandins, 678t
 analogs, 681–682
 adverse reactions, 682
 clinical uses of, 681–682
- protamine sulfate, 632
- proteomics, 1354, 1355
- prothrombin time (PT), 628
- proton pump inhibitors (PPIs),
 1258–1261, 1258t
 adverse effects, 1260–1261
 clinical use, 1259
 in dogs and cats, 1259–1260
 in horses, 1260
 drug interactions, 1261
 pharmacokinetics and metabolism,
 1259
- proximal convoluted tubule (PCT),
 594–595, 597–598, 597f
- pseudoephedrine, 1315–1316
- pseudomembranous colitis, 927, 929
- pseudopregnancy, reproductive
 hormonal drugs for, 686
- Publius Vegetius*, 3
- pulmonary edema, furosemide for,
 608–609
- purine analogues, for ocular
 infections, 1329
- purines, 177
- pyrantel, 1058–1061, 1059f. *see also*
 tetrahydropyrimidines
- pyrethrins and pyrethroids, 1170t,
 1178–1180
 chemistry, 1178
 efficacy, 1179–1180
 fifth-generation pyrethroids, 1179
 first-generation pyrethroids, 1179
 formulations, 1178
 fourth-generation pyrethroids, 1179
 mechanism of action, 1178–1179
 pharmacokinetics, 1178
 pyrethroid ether, 1179–1180
 safety/toxicity, 1180
 second-generation pyrethroids, 1179
 third-generation pyrethroids, 1179
- pyridinols, 1143
- pyridostigmine, 158–159
 for reversal of neuromuscular
 blockade, 210
- pyridoxal phosphate (PLP), 172
- pyrimethamine, 1153f, 1154–1155
- pyrimidine analogues, for ocular
 infections, 1328–1329
- pyriproxyfen, 1174, 1183
- Q**
- quaternary ammonium compounds
 (QACs), 781
- quinaldine sulfate, 392
- quinidine, 547–548
- quinolones, in aquatic animals,
 1385–1386
- R**
- rabacfosadine, 1215–1216
- rabbits
 alfaxalone and, 269
 diazepam for, 1150
 dissociative anesthetics in, 264
 lasalocid for, 1148
 morphine and, 296
 robenidine for, 1144
 sulfonamides for, 1151
- rabeprazole, 1259
- racing animals, medication rules for,
 1439–1440
- Racing Medication and Testing
 Consortium (RMTTC), 1440
- ractopamine, 1368
- radioactive iodine (¹³¹I) therapy, 719
- rafoxanide, 1089f, 1091, 1092f

- ranitidine, 1256–1257, 1256t
- Rational Questionnaire (RQ), 1453
- Rauwolfia* root, 144
- RBC volume, in animals, 556t
- receptor internalization, 171
- receptor reserve, 74
- receptors, 172, 173t, 174
 - neurotransmitters and, 171–172
 - agmatine, 177
 - amines, 174–176
 - amino acids, 172–174
 - endocannabinoids, 177
 - peptides, 176–177
 - purines, 177
- receptor tyrosine kinase (RTK) family, 72, 1214
- recombinant erythropoietin (rEPO), 1446
- recombinant growth hormone (rGH), 1446
- Red Book, 1470
- Reglan, 680
- regulation of animal drugs, 1407
 - FDA/CVM on, 1407
 - animal drugs, 1407
 - device, 1407–1408
 - history of, 1408–1409, 1409t
 - pesticides, 1408
 - veterinary biologics, 1408
 - Federal Food Drug and Cosmetic Act (FFDCA) on, 1407, 1408
 - amendments to, 1409–1411
 - international harmonization, 1425–1426
 - laws, regulations, and guidance, 1408
 - minor use/minor species, drugs for, 1422–1423
 - new animal drug, 1408, 1431–1432
 - challenges in development of, 1411–1412
 - premarket evaluation of, 1411–1412
 - New Animal Drug Applications (NADAs), 1407, 1412–1419
 - abbreviated, 1420–1421
 - components of, 1412–1419
 - Phased Review process, 1421–1422
 - over-the-counter (OTC) products, 1420
 - postapproval monitoring of drugs, 1423–1425
 - Adverse Drug Experience Reports, 1424–1425
 - Drug Experiencing Reports, 1423–1424
 - prescription (Rx) products, 1420
 - veterinary feed directive drugs (VFD), 1420
- Regumate, 678t, 683
- remifentanyl, 303
- renal elimination, 26–32
 - of aminoglycoside antibiotics, 31
 - biotransformation, 30
 - clearance, 30–31
 - calculating, 30–31
 - para-amino hippurate (PAH), 32
 - determinants of, 27–30
 - brush-border tubular membrane, 28, 28f
 - cellular structure of transport systems, 28, 28f
 - differences in urinary pH, 29
 - glomerular filtration barrier, 27–28, 28f
 - mechanism of nonionic passive tubular reabsorption, 29
 - organic anion and organic cation transporters, 28
 - mechanism of, 27–30
 - nephron, structure of, 26–27, 27f
 - physiology relevant to, 26–27
 - of pinocytosed drugs, 29
 - tubular secretion and reabsorption, 31–32
- renal epithelial sodium channel inhibitors, 611–612
- renal insufficiency, furosemide for, 608
- renal vasculature, anatomy of, 598f
- renin–angiotensin–aldosterone system (RAAS), 597–600, 599f
- repellents, 1184
- replacement therapy, glucocorticoids, 744–745
- Reportable Food Registry (RFR), 1452
- reproductive hormonal drugs, uses of, 686–687
 - for abortion, 686–687
 - for benign prostatic hypertrophy, 687
 - for cryptorchidism, 687
 - for parturition, 686
 - for pseudopregnancy, 686
 - for superovulation, 686
- reproductive hormones, 674–687, 675t
 - anabolic steroids, 684–685
 - androgens, 684
 - equine chorionic gonadotropin, 679
 - estrogens, 682–683
 - estrous cycle, 674–675
 - finasteride, 685
 - follicle-stimulating hormone, 679
 - gonadorelin, 676–677
 - gonadotropin-releasing hormone, 676
 - gonadotropins, 677–679
 - human chorionic gonadotropin, 677–679
 - overview, 674
 - oxytocin, 680–681
 - progestins, 683–684
 - prolactin, 679–680
 - prostaglandin analogs, 681–682
 - steroid hormones, 682–685
- reptiles
 - drugs for, 1396
 - fluoroquinolones for, 971
 - metronidazole for, 1134
- resiniferatoxin, 168
- resmethrin, 1179
- respiratory acidosis, 576–577, 576t
- respiratory alkalosis, 577, 577t
- respiratory stimulants, 1316
- Response Evaluation Criteria in Solid Tumors (RECIST), 1197
- retinoid X receptor (RXR), 704
- rheology, 92
- ribavirin, 1014
- ricobendazole, 1045, 1048
- rifampin/rifampicin, 931–934
 - adverse effects, 933
 - clinical use, 933–934
 - interactions, 932–933
 - mechanism of action and spectrum, 931–932
 - pharmacokinetics, 932, 932t
- rifaximin, 1265
- rimantadine, 1016–1017
- Risk Minimization Action Plans (RiskMAPs), 1455
- rivaroxaban, 636–637, 636t
- robenacoxib, 470, 471f
- robenidine, 1143–1144, 1143f
- rocuronium, 198
 - characteristics of, 199t
- rocuronium bromide (Zemuron), 201
- romifidine, 345f, 347, 347t
 - in preanesthetic period, 187
- ronidazole, 1135, 1266
 - chemical structure of, 1134f
 - clinical use, 1135
- ropivacaine (Naropin), 383–384
- roxarsone, 1137
- rumen flukes, 1085

- ruminants
 barbiturate and, 254–255
 fluoroquinolones for, 973
 macrocyclic lactones for, 1111–1112
 metoclopramide for, 1250
 morphine and, 296
 RXR. *see* retinoid X receptor (RXR)
- S**
 Safety Reporting Portal (SRP), 1452
 safety signal, 1453
 salicylanilides, 1087, 1088
 closantel, 1088–1091
 oxyclozanide, 1091
 rafxanide, 1091
 saline cathartics, 1270, 1270t
 saline expectorants, 1314
 saline, hypertonic, 790
 salinomycin, 1149
Salmonella, 791, 1266
 Sandostatin, 773
 sarcocystis, drugs for, 1131t
 saturated vapor pressure, 218
 scopolamine, 160, 1245–1246
 secnidazole, 1135
 sedation, 184
 sedatives
 alpha-2-adrenergic antagonists, 349–354
 alpha-2-adrenergic receptor agonists, 338–349
 benzodiazepine antagonists, 336–338
 benzodiazepine derivatives, 330–336
 butyrophenone, 328–330
 chloral hydrate, 357–358
 guaifenesin, 354–356
 phenothiazines, 324–328
 selamectin, 1102, 1103f, 1175, 1177
 selective glucocorticoid receptor agonists (SEGRAs), 733, 734f, 749
 selective glucocorticoid receptor modulators (SEGRMs), 733, 734f
 selective relaxant binding agent (SRBA), 210
 selective serotonin reuptake inhibitors (SSRIs), 176, 431–436, 433f
 adverse effects, 432–434
 nonbehavior modifying effects, 432
 selectivity of drug, 70–72
 selegiline, 176, 435–436
 semduramicin, 1147f, 1148–1149
 Sentinel Initiative, 1455–1456
 serotonin (5-HT), 421. *see* 5-hydroxytryptamine
 agonists and antagonists, 463
 metabolism, 460–461
 neuronal uptake of, 461–462
 pharmacological effects, 462–463
 physiological and pathological processes, 463
 side effects and interactions, 463
 sources, 460–461
 subtypes, 462
 serotonin antagonists, 1247
 serotonin syndrome, 176
 sertraline, 433–434
 seven transmembrane receptors (7TM receptors), 72
 sevoflurane, 224
 biotransformation, 229
 cardiovascular actions of, 230
 CNS, effect on, 229–230
 CO₂ absorbent stability, 229
 respiratory system, effect on, 230
 rubber or plastic/gas partition coefficient of, 219t
 solubility of, 218t
 vapor pressure of, 228t
 sheep
 alfaxalone effects on, 269
 decoquinatate for, 1142
 lasalocid for, 1148
 vitamin K₁ dose for, 638
 signal detection, at CVM, 1453
 sildenafil, 526–527
 silodosin, 143
 sinus tachycardia, antiarrhythmic agents for, 544–546
 sirolimus, 1232–1233
 skin, 1278
 anatomy and histology, 1278–1279, 1279f
 blood supply, 1280, 1281t
 dermis, 1279f, 1280
 epidermis, 1279–1280, 1279f
 avian, 1280
 as a barrier, 17–18, 18f
 biochemistry
 drug biotransformation, 1281–1282
 energy production and utilization, 1281
 lipid metabolism, 1282
 protein metabolism, 1282
 cells, 17–18
 cleansers, 789
 dermis and appendages, 18
 gross features of, 18, 18f
 layers, 17–18
 medicated applications, 1293
 dressings, 1294
 lotions, 1294
 ointments, 1293–1294
 pastes, 1294
 plasters, 1294
 poultices, 1294
 powders, 1294
 suspension, 1294
 percutaneous absorption
 electrically assisted transdermal drug delivery, 1289
 factors affecting, 1287
 penetration enhancers, 1287–1289
 principles of, 1283–1285, 1283f, 1284f
 pig, 1280–1281
 stratum corneum, 18–19
 topical vehicles, 1285–1287, 1286f, 1289
 adsorbents and protectives, 1289
 astringents, 1290
 caustics and escharotics, 1291
 demulcents, 1289–1290
 emollients, 1290, 1290t
 keratolytics, keratoplastics, and antiseborrheics, 1291–1293
 rubefacients, irritants, and vesicants, 1291
 skin elasticity, and dehydration, 561–562
 slugging, 106
 small intestinal bacterial overgrowth (SIBO), 1265
 SNARE proteins, 171
 soaker-type catheter, 370
 Society of Veterinary Hospital Pharmacists, 1435
 sodium cromoglycate. *see* cromolyn
 sodium–glucose cotransporters, 771
 sodium hypochlorite, 393, 783, 790
 sodium iodide, 1008
 sodium nitroprusside, 525
 sodium o-phenylphenol, 786
 sodium stibogluconate, 1136, 1136f
 “soft” steroids, 749–750
 solid-phase extraction (SPE), 1441
 solute carrier (SLCs) proteins, 179
 solute carrier (SLC) transporters, 1340
 somatostatin, 661, 662t, 772–773

- somatotropin (GH), 662–664
adverse effects of, 664
function of, 663
porcine, 663
secretion of, 662, 662t
structure of, 662
therapeutic use, 663–664
- somatotropin-inhibitory hormone, 651t
- somatotropin-releasing hormone, 651t
- sotalol, 546, 550
- spare receptors, 74
- spatial summation, 171
- species grouping, 1354
- specificity of drug, 70–72
- spectinomycin, 939–940
antimicrobial activity, 939
clinical use, 939–940
pharmacokinetics, 939
- spheroblasts, 826
- spinal and epidural anesthesia, 370–371
- spinosad, 1174
- spironolactone, 612–614
- splash blocks, 370
- Spot Test, 1472
- SRP. *see* Safety Reporting Portal
- stability of drug, 92
- stanazolol, 678t, 685
- Staphylococcus aureus*, 788
- static baths, 1377
- statistical tolerance limit procedure, 1471
- steady state blood concentrations, 31
- stereochemistry of the API, 93
- stereoisomers, 71
- sterilization, 782
- steroid base, 741–742
- steroid hormones, 674, 682–685
anabolic steroids, 684–685
estrogens, 682–683
finasteride, 685
mechanism of action of, 682
progestins, 683–684
testosterone, 684, 684f
- steroid implants, 1368
- steroidogenic acute regulatory (StAR) protein, 730, 730f
- steroid receptor isoforms, 735–736
- steroid synthesis inhibitors, 751–755
- Stewart's acid–base analysis, 572–573, 573t
- Stilboestrol, 683
- stimulant laxatives, 1270
- stimulation or inhibition function, 80
- St John's wort, 176
- stool softeners, 1271
- streptokinase, 641
- Streptomyces avermitilis*, 1102
- streptomycin, 879f
- stress supplementation, and
glucocorticoids, 747–748
- strong ion difference (SID), 572–573
- Stuart–Prower factor, 627t
- substance P, 177
- succinylcholine, 197, 202–204
cardiovascular effects of, 207
characteristics of, 199t
neuromuscular blocking effect of, 205–206, 206f
side effects from, 203
- sucralfate, 1257–1258
clinical use, 1258
drug interactions, 1258
structure, 1257f
- Sucromate, 676
- sufentanil, 303
- sugammadex, for neuromuscular
blockade reversal, 210–211
- subactam–ampicillin, 838
- sulfabromomethazine, 812
- sulfachlorpyridazine, 812–813
- sulfadiazine, 797f, 797t, 811–812, 1151, 1152f
pharmacokinetics of, 802t
- sulfadimethoxine, 797f, 797t, 807–808, 1151, 1152f
clinical use of, 808
formulations, 808
pharmacokinetics of, 807–808
- sulfadimethoxine–ormetoprim, 816
in aquatic animals, 1384–1385, 1387–1388
- sulfadimethoxine–sulfamethoxazole, 813
- sulfadimidine. *see* sulfamethazine
- sulfadoxine, 797f, 797t, 1151, 1152f
- sulfaethoxyipyridazine, 812
- sulfaguanidine, 797f, 1151, 1152f
- sulfamerazine, 811
pharmacokinetics of, 811
- sulfamethazine, 797f, 808–810, 1151, 1152f
pharmacokinetics of, 801t
- sulfamethoxazole, 797f, 797t, 1151, 1152f
pharmacokinetics of, 802t
- sulfanilamide, 796
- sulfanitran, 1151, 1152f
- Sulfa-on-Site (SOS) test, 1472
- sulfaquinolaxaline, 797f, 797t, 810–811, 1151, 1152f
and hypoprothrombinemia, 806
- sulfasalazine, 811
for inflammatory bowel diseases, 1267–1268, 1268f
- sulfathiazole, 811
pharmacokinetics of, 811
- sulfisoxazole, 812
- sulfonamides, 796
adverse effects, 805
acetylator status and, 806–807
blood clotting disorders, 806
blood dyscrasias, 806
carcinogenesis, 807
crystalluria, 805
diarrhea, 807
hepatic necrosis, 806
hypersensitivity, 805–806
keratoconjunctivitis sicca, 805
potassium regulation, 807
skin reactions, 806
thyroid metabolism disorders, 806
- as antiprotozoan drugs, 1151, 1152f
pharmacokinetics of, 800–805, 801t–804t
distribution, 800, 802, 804
excretion, 805
metabolism, 804–805
oral absorption, 800
- pharmacology of, 796–800
clinical uses and microbial
susceptibility, 798–799
drug resistance, 799–800
interactions affecting
antimicrobial activity, 799
mechanism of action, 798, 798f
susceptibility testing, 799
- potentiated, 813
- sulfadimethoxine–ormetoprim, 816
- trimethoprim–
sulfachlorpyridazine, 815
- trimethoprim–sulfadiazine, 813–815
- trimethoprim–sulfamethoxazole, 815
- properties of, 797t
- residues in food animals, 816–817
- structure of, 797f
- in veterinary medicine, 807–813
sulfabromomethazine, 812
sulfachlorpyridazine, 812–813
sulfadiazine, 811–812

- sulfonamides (*Continued*)
- sulfadimethoxine, 807–808
 - sulfaethoxyypyridazine, 812
 - sulfamerazine, 811
 - sulfamethazine, 808–810
 - sulfaquinoxaline, 810–811
 - sulfasalazine, 811
 - sulfathiazole, 811
 - sulfisoxazole, 812
- sulfonylurea glipizide, 769f
- sulfonylureas, 768–770, 769f, 769t
- superovulation, reproductive
- hormonal drugs for, 686
- surface disinfection, 782
- surfactant, 94–95
- surfactants, 1271
- Swab Test on Premises (STOP), 1472
- swine
- etomidate in, 267
 - morphine in, 296
 - thiopental in, 255
 - xylazine in, 345
- sympathetic nerve discharge (SND), 113
- sympathetic nervous system (SNS), 113, 117t, 131, 600
- anatomy of, 119–120
 - “fight-or-flight” response, 114
 - preganglionic and postganglionic anatomical relationships of nerves, 120f
 - SNS-induced physiological responses, 113–115
- sympathomimetics, 131–132
- chemical structures of, 132f
 - dobutamine, 513
 - dopamine, 513
 - for ocular disease, 1330
- synaptic vesicles, 170
- synaptosomal nerve-associated proteins (SNAPs), 122
- synergists, 1183–1184
- Synergize™, 785
- synthetic L-thyroxine. *see* levothyroxine
- synthetic prostaglandins, 1261–1262
- synthetic vitamin K, structure of, 633f
- Syntocinon, 678t, 681
- systemic inflammatory response syndrome (SIRS), 583–584
- T**
- tableting processes, 106
- tachyarrhythmias, antiarrhythmic agents for, 544–550
- tachykinins, 177
- tachyphylaxis, 76
- tacrolimus, 1232
- tamsulosin, 143
- tapeworm infections, 1081. *see also* anticestodal drugs; benzimidazoles
- targeted therapies, 1191
- TBG. *see* thyroxine-binding protein
- TCBZ. *see* triclabendazole
- tedizolid, 940
- teeth discoloration, tetracyclines and, 865
- Tegretol, 667
- telavancin, 936
- telazol, 187, 263–264
- dose, 263
 - species differences, 263–264
- temodar. *see* temozolomide
- temozolomide, 1203, 1203f
- temperature-sensitive thermogels, 1460
- temporal summation, 171
- teratogen, 1471
- terazosin, 143
- terbinafine, 1006–1007
- adverse effects, 1007
 - clinical use, 1007
 - pharmacokinetics, 1006–1007
 - spectrum of activity, 1006
- terbutaline, 1305
- testosterone, 684, 684f
- tetanus toxin, 171
- tetracaine (Amethocaine), 384
- tetracycline antibiotics, 858, 859f, 859t, 867
- adverse effects
 - allergy, 865
 - esophageal lesions, 865
 - gastrointestinal microflora changes, 865
 - hepatic disease, 865
 - interactions, 865
 - IV administration, risks from, 865–866
 - outdated products and, 865
 - photosensitivity, 865
 - problems in young animals, 865
 - renal tubular necrosis, 865
 - antimicrobial spectrum and clinical uses, 864–865
 - as antiprotozoan drugs, 1140
 - chemical and physical properties of, 859t
 - chlortetracycline, 866–867
 - dosages, 866t
 - doxycycline, 868–869
 - formulations of, 864t
 - indications for, 858
 - mechanism of action, 858
 - minocycline, 859f, 859t, 869
 - nonantimicrobial uses of, 869–870
 - angular limb deformities in foals, 870
 - arthritis, 870
 - dermatology, 869–870
 - for ocular infections, 1327
 - oxytetracycline, 859f, 859t, 867–868
 - pharmacokinetic parameters of, 862t
 - pharmacokinetic–pharmacodynamic properties, 860
 - absorption, 860–861, 861t
 - distribution, 861–864
 - excretion and elimination, 864
 - metabolism, 864
 - protein binding, 860t
 - resistance to, 859
 - structure of, 858, 859f
 - susceptibility testing, 859–860
 - breakpoints for, 860t
 - tetracycline, 859f, 859t, 867
- tetrahydropyrimidines, 1058–1061
- anthelmintic spectrum, 1060–1061
 - chemistry, 1058–1059, 1059f
 - dosages, 1060
 - formulations, 1060
 - mode of action, 1059
 - pharmacokinetics, 1059–1060
 - routes of administration, 1060
 - safety and toxicity, 1061
- tetramisole, 1054
- tetroxoprim, 804t
- theileriosis, 1143
- drugs for, 1130t
- theophylline, 1307–1310, 1308t, 1309t. *see also* methylxanthines
- therapeutic drug monitoring, 77
- therapeutic index, 77, 1191
- therapeutic window, 72, 77
- thermal degradation, 92
- thiabendazole, 1048, 1054
- thiacetarsamide sodium, 1064
- thiamine analogues, 1144
- thiamphenicol, 908–909
- thiamylal, 249t, 250
- thiazide, 610–611
- thiazidelike, 610–611
- thiazolidinediones, 770

- thin layer chromatography (TLC), 1441
- thiobarbiturates, 188, 248, 252, 253, 254, 291, 301, 390
- thiopental, 248, 249–250, 249f, 249t
cardiovascular effects, 251
dose of, 254t
pharmacokinetics of, 252–253
pH of, 253
regulatory information, 250t
- thiophanate, 1039
- thiopurine methyltransferase (TPMT), 1235–1237, 1339
- thiostrepton, 931
- thioureylenes/thionamides, 715–719, 715f
medical options to, 718–719
- thrombin inhibitors, 635–636
- thrombocytopenia, sulfonamides and, 806
- thromboelastography (TEG) test, 629
- thyroglobulin (Tg), 693
- thyroid
antithyroid drugs, 715–719, 715f, 716t
factors altering function of
illness and malnutrition effect, 699–701
imaging of, 720
physiology of, 691–699
hypothalamic-pituitary-thyroid axis, 694–695, 695f
iodine metabolism, 691–693
metabolic clearance rate, 699
plasma hormone binding of
thyroid hormone, 698
thyroid hormone metabolism, 695–698, 696f, 697f
thyroid hormone secretion, 693–694
thyroid hormone synthesis, 692f, 693
tissue thyroid hormone uptake, 698–699
- thyroid hormones, 691–719
analogs, relative nuclear binding affinity of, 703t
antithyroid drugs, 715–719, 715f, 716t
cellular localization of, 697f
hyperthyroidism, 691
hypothyroidism, 691
mechanism of action of
clinical effect correlation with cellular actions, 703–704
cytosolic binding proteins, 704
extranuclear actions, 705
nuclear thyroid hormone receptors, 704–705
plasma membrane transporters, 704
metabolism of, 695–698, 696f, 697f
clearance rate, 699, 700t
compartmental model of, 699f
drug effect on, 701–703
extrathyroidal factors affects, 699–703
illness and malnutrition effect, 699–701
pathways of, 696f
monitoring therapy with, 713–714
myxedema coma treatment, 714–715
overdose effect of, 713
peripheral action of, 696f
physiologic and pharmacologic effects of, 705–708, 706t
calorigenesis and thermoregulation, 705
cardiovascular effects, 707
dermatological effects, 706
dermatologic effects, 706
endocrine effects, 708
gastrointestinal effects, 707
growth and maturation effects, 705–706
hematologic effects, 708
immunologic effects, 708
lipid and carbohydrate metabolism, 706
neuromuscular effects, 707
reproductive effects, 707
plasma hormone binding of, 698
preparations of, 708–715
crude products, 708
synthetic L-thyroxine, 708–712
synthetic L-triiodothyronine, 712–713
secretion of, 693–694
synthesis of, 692f, 693
therapeutic failure, 714
therapeutic trial for hypothyroidism, 713
thyroid physiology, 691–699
uptake of, 698–699
- thyroid peroxidase (TPO), 693
- thyroid-response element (TRE), 704
- thyroid scintigraphy, 718
- thyroid-stimulating hormone (TSH), 651t, 657–661, 692f, 694–695
alpha and beta subunits of, 658
binding of, 658
chemistry of, 657
concentration of, effects of drugs on, 660–661
glycosylation patterns, 660
mechanism of action, 658
preparation of, 658–659
protocols for, 659t
stimulation test, 659–660
structural homology, 660
- thyrotropin-releasing hormone (TRH), 655–657
diagnosis of hypothyroidism
in cats, 657
in dogs, 656–657
in horse, 657
stimulation test, 656–657
protocols for, 657t
- thyroxine-binding prealbumin (TBPA), 698
- thyroxine-binding protein (TBG), 698
- ticarcillin, 836
- ticarcillin–clavulanate, 836, 838
- ticlopidine, 640
- tigecycline, 858, 859
- tigers, dissociative anesthetics, effects of, 263
- tiletamine, 187, 260, 260f
adverse effects/contraindications, 263
- tilmicosin, 912t, 922
chemical structures of, 914f
pharmacokinetics of, 917t
- timolol maleate, 148
- tincture of iodine, 783
- tinidazole, 1134–1135, 1266
chemical structure of, 1134f
clinical use, 1134–1135
- tissue residue depletion studies, 1420–1421
- tissue solubility of anesthetics, 219
- tissue-type plasminogen activator (t-PA), 641
- tobramycin, 890
structure of, 879f
- toceranib, 1197, 1214–1215, 1214f
- toceranib phosphate, 773
- α-tocopherol polyethylene glycol 1000 succinate (TPGS), 96
- tolazoline, 144, 351–353, 351f, 353t, 354
- tolerance, 76, 1470–1471
- tolfenamic acid, 471f
- toltrazuril, 1149f, 1150

- topical anesthesia, 370
total body water (TBW), 556, 556t
total intravenous anesthesia (TIVA)
 techniques, 247
Toxicologie Generale, 4
toxoplasmosis, drugs for, 1130t
TPO. *see* thyroid peroxidase
tramadol, 176, 309–311, 310t, 312,
 438–439
 as antitussive, 1304
 drug availability, 311
 efficacy of, 310
 mode of administration, 309
 pharmacokinetics and metabolism
 of, 311
 uses, 309
tranquilizers, as preanesthetic drug,
 186–187
transduction, 168
transient receptor potential vallinoid
 (TRPV) family of receptors, 168
transmissible spongiform
 encephalopathies (TSE), 96
transpeptidation reaction, 826
transthyretin (TTR), 698, 704
Transylol, 642
trazodone, 434–435
trenbolone, 1368
trenbolone acetate, 685
triamcinolone, 740t, 741f
triamterene, 611–612
triazine derivatives, 1149, 1149f
 diclazuril, 1149–1150, 1149f
 ponazuril, 1150–1151
 toltrazuril, 1149f, 1150
tribromoethanol, 272f
 adverse effects, 272
 chemistry, 272
 dose, 272–273
 drug availability, 273
 history, 272
 mechanism of action, 272
 physiology, 272
tricaine methanesulfonate, 273f, 392,
 1396
 adverse effects, 273
 chemistry, 273
 drug availability, 273
 history, 273
 mechanism of action, 273
 physiology of, 273
 withdrawal information, 273
trichlorfon, 1061
trichomoniasis, drugs for, 1129t
triclabendazole, 1093–1097
 chemical structure and metabolic
 pathways, 1094f
 combined formulations, 1096
 in lactating animals, 1096–1097
 pharmacokinetics of, 1094–1095,
 1095f
 resistance to, 1096, 1096f
 sulfoxide metabolite of, 1094, 1095
triclosan, 786
tricyclic antidepressants (TCAs),
 428–431, 429f
 adverse effects, 430–431
 pharmacokinetic properties,
 429–430
trifluoroacetic acid, 230
trifluridine, 1013–1014
trilostane, 752f, 753
trimethoprim, 1152–1154, 1153f
 pharmacokinetics of, 803t
trimethoprim–sulfachlorpyridazine,
 815
trimethoprim–sulfadiazine, 813–815
 for bacterial skin infections, 814
 for cattles, 815
 clinical uses, 814
 for dogs and cats, 814–815
 dosage, 814
 formulations, 813
 for horses, 814
 for pigs, 815
 for urinary tract infections, 814
trimethoprim–sulfamethoxazole, 815
trimethoprim–sulfonamides, 798–799
Trusopt, 601
trypanosomiasis, drugs for, 1129t
TTR. *see* transthyretin
tubular secretory pathways, 31–32
tubulin, 1037
tulathromycin, 912t, 922–923
 chemical structures of, 914f
 pharmacokinetics of, 917t
turkeys
 amprolium for, 1144
 diclazuril for, 1150
 dinitolmide for, 1145
 halofuginone for, 1146
 lasalocid for, 1148
 monensin for, 1148
 ormetoprim for, 1154
 sulfonamides for, 1151
two-state model of drug action, 75–76,
 75f
tylosin, 912t, 921–922
 chemical structures of, 913f
 pharmacokinetic parameters of, 919t
tylosin-responsive diarrhea, 1265
tyrosine kinase inhibitors, 1214–1215
 masitinib, 1215
 toceranib, 1214–1215, 1214f
- ## U
- UDP-glucuronyl transferase (UGT)
 enzymes, 1338
ulceration, gastrointestinal, 1254–1262
ulcerative colitis, in dogs, 1266
unfractionated heparin (UFH), 629
unitary theory of narcosis, 185
United States Department of
 Agriculture (USDA), 1350, 1470,
 1471
United States Equestrian Federation
 (USEF), 1440, 1444
United States Pharmacopeia (USP), 4,
 5, 1431, 1435, 1451
up-regulation, 76
ureidopenicillins, 836
urethane, 271f
 carcinogenicity, 271
 chemistry, 271
 dose, 271
 drug availability, 271
 history, 270
 mechanism of action, 271
 metabolism, 271
 physiological effects, 271
 regulatory information, 271
urokinase, 641
ursodeoxycholic acid, 1271
US Controlled Substances Act, 1970,
 247
US Department of Agriculture,
 1408
USEF. *see* United States Equestrian
 Federation
uterine contractions, prostaglandins
 analogs and, 681
uterine infections, prostaglandins
 analogs for, 682
uterus, oxytocin function in, 680
- ## V
- valacyclovir, 1010–1012
 adverse effects, 1012
 clinical use, 1011–1012
 pharmacokinetics, 1011
 spectrum of activity, 1011
valganciclovir, 1013
valproic acid, 401
vancomycin, 936–937, 1265
 administration guidelines, 937

- adverse effects, 937
clinical use, 937
- vapor pressure, of anesthetic, 218
- vasopressin, 614–615
effects of drugs and electrolytes, 559f
- Vasopstrict, 666
- vecuronium, 197, 200–201
characteristics of, 199t
- ventricular tachycardia,
antiarrhythmic agents for, 546–550
- vesicular glutamate transporters (VGLUTs), 172
- vesicular monoamine transporter (VMAT), 175
- The Veterinarian's Vade Mecum*, 5
- veterinary biologics, 1408
- Veterinary Co-operative Oncology Group Common Terminology Criteria for Adverse Events (VCOG-CTCAE), 1191–1192
- Veterinary Drug Information Monographs, 1466
- veterinary feed additives, 1461–1463, 1463f
- veterinary feed directive (VFD), 1349, 1411, 1420, 1430, 1461
- Veterinary International Committee on Harmonization (VICH), 1365
- Veterinary Material Medica and Therapeutics*, 5
- Veterinary Medical Dictionary for Drug Regulatory Authorities (VeDDRA), 1453
- veterinary pharmacology, 4–7
- Veterinary Services, 1408
- Veterinary Susceptibility Testing Subcommittee (VAST) of Clinical and Laboratory Standards Institute (CLSI), 6
- Vetoryl, 753
- Vetstarch, 582t
- VICH (International Cooperation on Harmonization of Technical Requirements for Registration of Veterinary Medicinal Products), 1425
- vidarabine, 1014
- vinblastine (VBL), 1210–1211, 1210f
- vinca alkaloids, 1210–1211, 1210f
extravasation, 1199
- vincristine (VCR), 1210–1211, 1210f
- Vinstrol-V, 678t
- virginiamycin, 935–936
- Virus Serum Toxin Act, 1408
- visceral targets, 152f
- vitamin K₁, 637–638
- vitamin K₂, 637
- vitamin K₃, 637
- vitreous humor (VH), 1321
- volatage-gated Na⁺ channels, 66
- volatile inhalation anesthetics
effects on arterial oxygen tension (P_aO₂), 224, 225f
myocardial contractility and, 226
- vomiting center, 178
- vomiting, neurotransmitters involved in, 1245, 1246t. *see also* antiemetic drugs
- von Willebrand factor (vWF), 626
- voriconazole, 993t, 1003–1005
adverse effects, 1005
clinical use, 1005
pharmacokinetics, 1003–1005
structure of, 1003, 1004f
- W**
- warfarin, 632–638
adverse effects of, 635
agents to reverse, 637–638
clinical use, administration, and monitoring, 634–635
mechanism of action, 633
pharmacological properties of, 633t, 634
precautions in using, 635
structure of, 633f
thrombin inhibitors, 635–636
vitamin-K cycle and, 634f
- waterborne treatments, 1377–1378
- water, sodium, and chloride, 558–565
disorders of balance, 561–565
homeostasis, 558–559, 559f
renal regulation of excretion of, 559–561, 560f
- wet/dry granulation, 105–106
- white petrolatum, 1271
- Winstrol-V, 685
- withdrawal intervals, estimation of
allometric scaling, 1353–1354
comparative pharmacokinetics, 1351–1353
- species grouping, 1354
- in vitro and molecular studies, 1354–1355
- withdrawal time, 1469, 1470, 1471, 1475
definition of, 1443
factors affecting, 1443
- Wolff–Chaikoff effect, 693
- World Health Organization (WHO), 1426, 1449, 1476
- X**
- xanthines. *see* methylxanthines
- xenobiotics, 1400
- xenon
analgesic actions of, 224
solubility of, 218t
- xylazine hydrochloride, 343–346, 345f
- xylazine, in preanesthetic period, 187
- xylitol, 96
- xylometazoline, 1315
- Y**
- yohimbine, 144, 350–351, 351f, 351t
- Z**
- zafirlukast, 1314
- zidovudine, 1014–1015
adverse effects, 1015
clinical use, 1015
pharmacokinetics, 1014–1015
- zileuton, 1314
- zilpaterol, 1306, 1368
- Zolatel[®], 259
- zolazepam, 262, 263
chemical name, 335
molecular formula, 335
regulatory information, 335
- zolpidem, 427–428
- zonisamide, 408–409
adverse effects, 406
clinical use, 409
pharmacokinetics, 408–409
- zoological pharmacology, 1395
allometry in, 1400–1401
invertebrates, 1395–1396
vertebrates
avian, 1397
mammalian, 1397–1400
reptile and amphibian, 1396

